10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number 1-5975

HUMANA INC.

(Exact name of registrant as specified in its charter)

Delaware	61-0647538
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

500 West Main Street

Louisville, Kentucky 40202

(Address of principal executive offices, including zip code)

(502) 580-1000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, $0.16 2/3 par value	HUM	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ☐    No  ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

Class of Common Stock	Outstanding at September 30, 2023
$0.16 2/3 par value	123,110,720 shares

Humana Inc.

FORM 10-Q

SEPTEMBER 30, 2023

INDEX

		Page
Part I: Financial Information
Item 1.	Financial Statements
	Condensed Consolidated Balance Sheets (Unaudited) at September 30, 2023 and December 31, 2022	3
	Condensed Consolidated Statements of Income (Unaudited) for the three and nine months ended September 30, 2023 and 2022	4
	Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the three and nine months ended September 30, 2023 and 2022	5
	Condensed Consolidated Statements of Stockholders' Equity (Unaudited) for the three and nine months ended September 30, 2023 and 2022	6
	Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2023 and 2022	8
	Notes to Condensed Consolidated Financial Statements (Unaudited)	10
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	36
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	54
Item 4.	Controls and Procedures	54
Part II: Other Information
Item 1.	Legal Proceedings	55
Item 1A.	Risk Factors	55
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	55
Item 3.	Defaults Upon Senior Securities	55
Item 4.	Mine Safety Disclosures	55
Item 5.	Other Information	56
Item 6.	Exhibits	57
	Signatures	58
	Certifications

Humana Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

	September 30, 2023		December 31, 2022
	(in millions, except share amounts)
ASSETS
Current assets:
Cash and cash equivalents	$	15,148	$	5,061
Investment securities	15,145		13,881
Receivables, net of allowances of $73 in 2023     and $70 in 2022	1,824		1,674
Other current assets	6,136		5,567
Total current assets	38,253		26,183
Property and equipment, net	3,342		3,221
Long-term investment securities	370		380
Equity method investments	762		749
Goodwill	9,540		9,142
Other long-term assets	3,638		3,380
Total assets	$	55,905	$	43,055
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Benefits payable	$	10,196	$	9,264
Trade accounts payable and accrued expenses	7,600		5,238
Book overdraft	246		298
Unearned revenues	7,536		286
Short-term debt	2,245		2,092
Total current liabilities	27,823		17,178
Long-term debt	9,483		9,034
Other long-term liabilities	1,595		1,473
Total liabilities	38,901		27,685
Stockholders’ equity:
Preferred stock, $1 par; 10,000,000 shares authorized; none issued	—		—
Common stock, $0.16 2/3 par; 300,000,000 shares authorized;   198,690,082 shares issued at September 30, 2023 and 198,666,598 shares issued at December 31, 2022	33		33
Capital in excess of par value	3,362		3,246
Retained earnings	28,191		25,492
Accumulated other comprehensive loss	(1,503)		(1,304)
Treasury stock, at cost, 75,579,362 shares at September 30, 2023 and     73,691,955 shares at December 31, 2022	(13,134)		(12,156)
Total stockholders' equity	16,949		15,311
Noncontrolling interests	55		59
Total equity	17,004		15,370
Total liabilities and equity	$	55,905	$	43,055

See accompanying notes to condensed consolidated financial statements.

3

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

	Three months ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(in millions, except per share results)
Revenues:
Premiums	$	25,099	$	21,468	$	76,144	$	66,437
Services	1,016		1,159		2,993		3,772
Investment income	308		172		775		222
Total revenues	26,423		22,799		79,912		70,431
Operating expenses:
Benefits	21,745		18,384		65,612		57,108
Operating costs	3,271		3,061		9,361		9,120
Depreciation and amortization	201		182		578		527
Total operating expenses	25,217		21,627		75,551		66,755
Income from operations	1,206		1,172		4,361		3,676
Gain on sale of Gentiva Hospice	—		(240)		—		(240)
Interest expense	114		102		347		293
Other (income) expense, net	(6)		13		40		(16)
Income before income taxes and equity in net losses	1,098		1,297		3,974		3,639
Provision for income taxes	256		107		911		820
Equity in net (losses) earnings	(12)		3		(39)		1
Net income	$	830	$	1,193	$	3,024	$	2,820
Net loss attributable to noncontrolling interests	2		2		6		1
Net income attributable to Humana	$	832	$	1,195	$	3,030	$	2,821
Basic earnings per common share	$	6.74	$	9.45	$	24.37	$	22.27
Diluted earnings per common share	$	6.71	$	9.39	$	24.26	$	22.16

See accompanying notes to condensed consolidated financial statements.

4

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

	Three months ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(in millions)
Net income attributable to Humana	$	832	$	1,195	$	3,030	$	2,821
Other comprehensive income (loss):
Change in gross unrealized investment losses	(365)		(590)		(314)		(1,982)
Effect of income taxes	85		135		73		455
Total change in unrealized investment losses, net of tax	(280)		(455)		(241)		(1,527)
Reclassification adjustment for net realized losses	3		50		56		23
Effect of income taxes	—		(11)		(14)		(5)
Total reclassification adjustment, net of tax	3		39		42		18
Other comprehensive loss, net of tax	(277)		(416)		(199)		(1,509)
Comprehensive income attributable to Humana	$	555	$	779	$	2,831	$	1,312

See accompanying notes to condensed consolidated financial statements.

5

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

	Common Stock			Capital In Excess of Par Value		Retained Earnings		Accumulated Other Comprehensive Loss		Treasury Stock		Total Stockholders' Equity		Noncontrolling Interests		Total Equity
	Issued Shares	Amount
	(dollars in millions, share amounts in thousands)
Three months ended September 30, 2023
Balances, June 30, 2023	198,690	$	33	$	3,313	$	27,468	$	(1,226)	$	(12,754)	$	16,834	$	57	$	16,891
Net income						832						832		(2)		830
Other comprehensive loss								(277)				(277)				(277)
Common stock repurchases				—						(383)		(383)				(383)
Dividends and dividend    equivalents				—		(109)						(109)				(109)
Stock-based compensation				53								53				53
Restricted stock unit vesting	—	—		(3)						3		—				—
Stock option exercises	—	—		(1)						—		(1)				(1)
Balances, September 30, 2023	198,690	$	33	$	3,362	$	28,191	$	(1,503)	$	(13,134)	$	16,949	$	55	$	17,004
Three months ended September 30, 2022
Balances, June 30, 2022	198,667	$	33	$	3,153	$	24,511	$	(1,051)	$	(11,156)	$	15,490	$	20	$	15,510
Net income						1,195						1,195		(2)		1,193
Distribution from noncontrolling interest holders, net														3		3
Sale of Gentiva Hospice														(11)		(11)
Acquisition														53		53
Other comprehensive loss								(416)				(416)				(416)
Common stock repurchases				—						(4)		(4)				(4)
Dividends and dividend    equivalents				—		(100)						(100)				(100)
Stock-based compensation				80								80				80
Restricted stock unit vesting	—	—		(3)						3		—				—
Stock option exercises	—	—		4						5		9				9
Balances, September 30, 2022	198,667	$	33	$	3,234	$	25,606	$	(1,467)	$	(11,152)	$	16,254	$	63	$	16,317

See accompanying notes to condensed consolidated financial statements.

6

	Common Stock			Capital In Excess of Par Value		Retained Earnings		Accumulated Other Comprehensive (Loss) income		Treasury Stock		Total Stockholders' Equity		Noncontrolling Interests		Total Equity
	Issued Shares	Amount
	(dollars in millions, share amounts in thousands)
Nine months ended September 30, 2023
Balances, December 31, 2022	198,667	$	33	$	3,246	$	25,492	$	(1,304)	$	(12,156)	$	15,311	$	59	$	15,370
Net income						3,030						3,030		(6)		3,024
Distribution from noncontrolling interest holders, net												—		7		7
Acquisition												—		(5)		(5)
Other comprehensive loss								(199)				(199)				(199)
Common stock repurchases				—						(1,011)		(1,011)				(1,011)
Dividends and dividend    equivalents				—		(331)						(331)				(331)
Stock-based compensation				142								142				142
Restricted stock unit vesting	23	—		(30)						30		—				—
Stock option exercises	—	—		4						3		7				7
Balances, September 30, 2023	198,690	$	33	$	3,362	$	28,191	$	(1,503)	$	(13,134)	$	16,949	$	55	$	17,004
Nine months ended September 30, 2022
Balances, December 31, 2021	198,649	$	33	$	3,082	$	23,086	$	42	$	(10,163)	$	16,080	$	23	$	16,103
Net income						2,821						2,821		(1)		2,820
Distribution to noncontrolling interest holders, net												—		(1)		(1)
Sale of Gentiva Hospice												—		(11)		(11)
Acquisition												—		53		53
Other comprehensive loss								(1,509)				(1,509)				(1,509)
Common stock repurchases				—						(1,032)		(1,032)				(1,032)
Dividends and dividend    equivalents				—		(301)						(301)				(301)
Stock-based compensation				173								173				173
Restricted stock unit vesting	18	—		(31)						31		—				—
Stock option exercises	—	—		10						12		22				22
Balances, September 30, 2022	198,667	$	33	$	3,234	$	25,606	$	(1,467)	$	(11,152)	$	16,254	$	63	$	16,317

    

7

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the nine months ended September 30,
	2023		2022
	(in millions)
Cash flows from operating activities
Net income	$	3,024	$	2,820
Adjustments to reconcile net income to net cash provided by     operating activities:
Gain on sale of Gentiva Hospice	—		(240)
Loss on investment securities, net	49		136
Equity in net losses (earnings)	39		(1)
Stock-based compensation	142		173
Depreciation	628		555
Amortization	51		73
Impairment of property and equipment	31		144
Deferred income taxes	—		(33)
Changes in operating assets and liabilities, net of effect of     businesses acquired and disposed:
Receivables	(126)		11
Other assets	(935)		(465)
Benefits payable	870		948
Other liabilities	39		(195)
Unearned revenues	7,250		5,758
Other	53		30
Net cash provided by operating activities	11,115		9,714
Cash flows from investing activities
Proceeds from sale of Gentiva Hospice, net	—		2,708
Acquisitions, net of cash and cash equivalents acquired	(223)		(293)
Purchases of property and equipment, net	(721)		(862)
Purchases of investment securities	(3,366)		(4,740)
Proceeds from maturities of investment securities	885		1,214
Proceeds from sales of investment securities	815		1,979
Net cash (used in) provided by investing activities	(2,610)		6
Cash flows from financing activities
Receipts from contract deposits, net	2,481		3,787
Proceeds from issuance of senior notes, net	1,215		744
Repayments of senior notes	(1,719)		—
Proceeds from issuance (repayments) of commercial paper, net	1,618		(660)
Repayment of term loan	(500)		(2,000)
Debt issue costs	(4)		(2)
Change in book overdraft	(52)		(89)
Common stock repurchases	(1,002)		(1,032)
Dividends paid	(320)		(291)
Other	(135)		(13)
Net cash provided by financing activities	1,582		444
Increase in cash and cash equivalents	10,087		10,164
Cash and cash equivalents at beginning of period	5,061		3,394
Cash and cash equivalents at end of period	$	15,148	$	13,558

8

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS—(Continued)

(Unaudited)

	For the nine months ended September 30,
	2023		2022
	(in millions)
Supplemental cash flow disclosures:
Interest payments	$	317	$	256
Income tax payments, net	$	957	$	751
Details of businesses acquired in purchase transactions:
Fair value of assets acquired, net of cash and cash equivalents acquired	$	454	$	411
Less: Fair value of liabilities assumed	(236)		(65)
Less: Noncontrolling interests acquired	5		(53)
Cash paid for acquired businesses, net of cash and cash equivalents acquired	$	223	$	293

See accompanying notes to condensed consolidated financial statements.

9

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. BASIS OF PRESENTATION AND SIGNIFICANT EVENTS

The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2022, that was filed with the Securities and Exchange Commission, or the SEC, on February 16, 2023. We refer to this Form 10-K as the “2022 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.

The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.

Employer Group Commercial Medical Products Business Exit

In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.

Value Creation Initiatives

During 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities beginning in 2023, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, during the three and nine months ended September 30, 2022, we recorded charges of $82 million and $285 million, respectively. For the three and nine months ended September 30, 2022, these charges primarily relate to $4 million and $144 million, respectively, in asset impairments, including software and abandonment, and $44 million and $65 million, respectively, of severance charges in connection with workforce optimization. The remainder of the charges primarily relate to external consulting fees. During the three months ended September 30, 2023, we recorded charges of $52 million primarily in asset impairments relating to software and abandonment. In connection with these initiatives, we expect to incur additional charges through the end of 2024. These charges are recorded at the corporate level and not allocated to the segments.

10

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

COVID-19

The emergence and spread of the novel coronavirus, or COVID-19, beginning in the first quarter of 2020 has impacted our business. Initially during periods of increased incidences of COVID-19, a reduction in non-COVID-19 hospital admissions for non-emergent and elective medical care have resulted in lower overall healthcare system utilization. At the same time, COVID-19 treatment and testing costs increased utilization. During 2022, we experienced lower overall utilization of the healthcare system than anticipated, as the reduction in COVID-19 utilization following the increased incidence associated with the Omicron variant outpaced the increase in non-COVID-19 utilization. The significant disruption in utilization during 2020 also impacted our ability to implement clinical initiatives to manage health care costs and chronic conditions of our members, and appropriately document their risk profiles, and, as such, significantly affected our 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2021 as a result of the COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and shifting the timing of claim payments and provider capitation surplus payments, impacted our claim reserve development and operating cash flows for 2021.

The COVID-19 National Emergency declared in 2020 was terminated on April 10, 2023 and the Public Health Emergency expired on May 11, 2023.

Revenue Recognition

Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

At September 30, 2023, accounts receivable related to services were $322 million. For the three and nine months ended September 30, 2023, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the condensed consolidated balance sheet at September 30, 2023.

For the three and nine months ended September 30, 2023, services revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. Further, services revenue expected to be recognized in any future year related to remaining performance obligations was not material.

2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The new guidance relates to accounting for long-duration contracts of insurers which revises key elements of the measurement models and disclosure requirements for long-duration contracts issued by insurers, including the amortization of deferred contract acquisition costs and the measurement of liabilities for future policy benefits using current, rather than locked-in, assumptions. The new guidance, limited to our Medicare Supplement product which represents less than 1% of consolidated premiums and services revenue, became effective for us beginning January 1, 2023 and is to be applied to contracts in force on the basis of their

11

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

existing carrying value amounts at the beginning of the earliest period presented. The adoption of the new standard in 2023 did not have a material impact on our consolidated results of operations, financial position or cash flows.

There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.

3. ACQUISITIONS AND DIVESTITURES

On August 11, 2022, we completed the sale of a 60% interest in Gentiva (formerly Kindred) Hospice to Clayton, Dubilier & Rice, or CD&R, for cash proceeds of approximately $2.7 billion, net of cash disposed, including debt repayments from Gentiva Hospice to Humana of $1.9 billion. In connection with the sale we recognized a pre-tax gain, net of transaction costs, of $240 million. For the three and nine months ended September 30, 2022, the accompanying condensed consolidated statement of income includes revenues related to Gentiva Hospice of $177 million and $958 million, respectively, and pretax earnings of $24 million and $150 million, respectively.

During 2023 and 2022, we acquired various health and wellness related businesses which, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows. The results of operations and financial condition of these businesses acquired in 2023 and 2022 have been included in our condensed consolidated statements of income and condensed consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in 2023 and 2022 were not material to our results of operations. For asset acquisitions, the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the year of acquisition, were not material for disclosure purposes.

12

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

4. INVESTMENT SECURITIES

Investment securities classified as current and long-term were as follows at September 30, 2023 and December 31, 2022, respectively:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
	(in millions)
September 30, 2023
U.S. Treasury and other U.S. government     corporations and agencies:
U.S. Treasury and agency obligations	$	2,043	$	—	$	(105)	$	1,938
Mortgage-backed securities	3,890		—		(637)		3,253
Tax-exempt municipal securities	848		—		(50)		798
Mortgage-backed securities:
Residential	497		—		(85)		412
Commercial	1,475		—		(155)		1,320
Asset-backed securities	1,849		—		(65)		1,784
Corporate debt securities	6,864		14		(868)		6,010
Total debt securities	$	17,466	$	14	$	(1,965)	15,515
Common stock							—
Total investment securities							$	15,515
December 31, 2022
U.S. Treasury and other U.S. government     corporations and agencies:
U.S. Treasury and agency obligations	$	1,093	$	1	$	(55)	$	1,039
Mortgage-backed securities	3,697		4		(471)		3,230
Tax-exempt municipal securities	765		—		(37)		728
Mortgage-backed securities:
Residential	477		—		(76)		401
Commercial	1,554		—		(155)		1,399
Asset-backed securities	1,809		1		(79)		1,731
Corporate debt securities	6,551		3		(828)		5,726
Total debt securities	$	15,946	$	9	$	(1,701)	14,254
Common stock							7
Total investment securities							$	14,261

13

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

We held certain corporate debt securities of Gentiva Hospice at September 30, 2023 with amortized cost and fair value of approximately $281 million and $295 million, respectively.

Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at September 30, 2023 and December 31, 2022, respectively:

	Less than 12 months				12 months or more				Total
	Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses
	(in millions)
September 30, 2023
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	1,483	$	(51)	$	407	$	(54)	$	1,890	$	(105)
Mortgage-backed securities	1,084		(66)		2,169		(571)		3,253		(637)
Tax-exempt municipal securities	278		(6)		515		(44)		793		(50)
Mortgage-backed securities:
Residential	48		(1)		363		(84)		411		(85)
Commercial	15		—		1,304		(155)		1,319		(155)
Asset-backed securities	343		(6)		1,430		(59)		1,773		(65)
Corporate debt securities	961		(35)		4,648		(833)		5,609		(868)
Total debt securities	$	4,212	$	(165)	$	10,836	$	(1,800)	$	15,048	$	(1,965)
December 31, 2022
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	512	$	(5)	$	397	$	(50)	$	909	$	(55)
Mortgage-backed securities	1,231		(104)		1,683		(367)		2,914		(471)
Tax-exempt municipal securities	64		(2)		615		(36)		679		(38)
Mortgage-backed securities:
Residential	124		(16)		274		(60)		398		(76)
Commercial	243		(13)		1,157		(142)		1,400		(155)
Asset-backed securities	620		(32)		1,011		(46)		1,631		(78)
Corporate debt securities	1,625		(98)		3,825		(730)		5,450		(828)
Total debt securities	$	4,419	$	(270)	$	8,962	$	(1,431)	$	13,381	$	(1,701)

Approximately 98% of our debt securities were investment-grade quality, with a weighted average credit rating of AA by Standard & Poor's Rating Service, or S&P, at September 30, 2023. Most of the debt securities that were below investment-grade were rated BB-, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding approximately 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.

Our unrealized losses from all debt securities were generated from approximately 1,790 positions out of a total of approximately 2,070 positions at September 30, 2023. All issuers of debt securities we own that were trading at an unrealized loss at September 30, 2023 remain current on all contractual payments. After taking into account these

14

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time these debt securities were purchased. At September 30, 2023, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position for the three and nine months ended September 30, 2023 or 2022.

The detail of gains (losses) related to investment securities and included within investment income was as follows for the three and nine months ended September 30, 2023 and 2022:

	Three months ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(in millions)				(in millions)
Gross gains on investment securities	$	—	$	2	$	15	$	41
Gross losses on investment securities	(4)		(52)		(65)		(58)
Gross gains on equity securities	—		51		1		51
Gross losses on equity securities	—		—		—		(170)
Net recognized (losses) gains on investment securities	$	(4)	$	1	$	(49)	$	(136)

The gains and losses related to equity securities for the three and nine months ended September 30, 2023 and 2022 was as follows:

	Three months ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(in millions)				(in millions)
Net gains (losses) recognized on equity securities during the period	$	—	$	51	$	1	$	(119)
Less: Net gains (losses) recognized on equity securities sold during the period	—		47		—		(105)
Unrealized gains (losses) recognized on equity securities still held at the end of the period	$	—	$	4	$	1	$	(14)

The contractual maturities of debt securities available for sale at September 30, 2023, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

	Amortized Cost		Fair Value
	(in millions)
Due within one year	$	659	$	654
Due after one year through five years	4,850		4,565
Due after five years through ten years	3,017		2,573
Due after ten years	1,229		954
Mortgage and asset-backed securities	7,711		6,769
Total debt securities	$	17,466	$	15,515

For additional information regarding our investment securities, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

15

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

5. FAIR VALUE

Financial Assets

The following table summarizes our fair value measurements at September 30, 2023 and December 31, 2022, respectively, for financial assets measured at fair value on a recurring basis:

	Fair Value Measurements Using
	Fair Value		Quoted Prices in Active Markets (Level 1)		Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
	(in millions)
September 30, 2023
Cash equivalents	$	15,035	$	15,035	$	—	$	—
Debt securities:
U.S. Treasury and other U.S. government     corporations and agencies:
U.S. Treasury and agency obligations	1,938		—		1,938		—
Mortgage-backed securities	3,253		—		3,253		—
Tax-exempt municipal securities	798		—		798		—
Mortgage-backed securities:
Residential	412		—		412		—
Commercial	1,320		—		1,320		—
Asset-backed securities	1,784		—		1,784		—
Corporate debt securities	6,010		—		5,905		105
Total debt securities	15,515		—		15,410		105
Total invested assets	$	30,550	$	15,035	$	15,410	$	105
December 31, 2022
Cash equivalents	$	4,832	$	4,832	$	—	$	—
Debt securities:
U.S. Treasury and other U.S. government     corporations and agencies:
U.S. Treasury and agency obligations	1,039		—		1,039		—
Mortgage-backed securities	3,230		—		3,230		—
Tax-exempt municipal securities	728		—		728		—
Mortgage-backed securities:
Residential	401		—		401		—
Commercial	1,399		—		1,399		—
Asset-backed securities	1,731		—		1,731		—
Corporate debt securities	5,726		—		5,625		101
Total debt securities	14,254		—		14,153		101
Common stock	7		7		—		—
Total invested assets	$	19,093	$	4,839	$	14,153	$	101

16

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

Our Level 3 assets had a fair value of $105 million at September 30, 2023, or 0.3% of our total invested assets. During the nine months ended September 30, 2023 and 2022, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:

	For the nine months ended September 30, 2023		For the nine months ended September 30, 2022
	Private Placements
	(in millions)
Beginning balance at January 1	$	101	$	68
Total gains or losses:
Realized in earnings	—		—
Unrealized in other comprehensive income	(1)		—
Purchases	13		(12)
Sales	—		44
Maturities	(4)		—
Transfer out	(4)
Balance at September 30	$	105	$	100

Interest Rate Swaps

During the third quarter of 2023, we entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on our $750 million of 5.875% senior notes and our $750 million of 5.500% senior notes from fixed rates to variable rates to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities. Our swap agreements, which are considered derivative instruments, exchange the fixed interest rate under our 5.875% and 5.500% senior notes for a variable interest rate based on SOFR. Interest rate swaps with notional amounts of $650 million, maturing September 1, 2032, and $250 million, maturing March 15, 2033, were outstanding on our 5.875% and 5.500% senior notes, respectively, at September 30, 2023. These swap agreements were qualified and designated as a fair value hedge. The swap liability, included within other long-term liabilities on our condensed consolidated balance sheet, was not material at September 30, 2023. We include the gain or loss on the swap agreements in interest expense on our condensed consolidated income statement, the same line item as the offsetting loss or gain on the related senior notes. The gain or loss due to hedge ineffectiveness was not material for the three and nine months ended September 30, 2023.

Financial Liabilities

Our debt is recorded at carrying value in our consolidated balance sheets. The carrying value of our senior notes debt outstanding, net of unamortized debt issuance costs, was $9.5 billion at September 30, 2023 and $10.0 billion at December 31, 2022. The fair value of our senior notes debt was $8.7 billion at September 30, 2023 and $9.4 billion at December 31, 2022. The fair value of our senior notes debt is determined based on Level 2 inputs, including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities. Carrying value approximates fair value for our term loans and commercial paper borrowings. The commercial paper borrowings were $2.2 billion at September 30, 2023. The term loans and commercial paper borrowings were $1.1 billion at December 31, 2022.

Put and Call Options Measured at Fair Value

Our put and call options associated with our equity method investments are measured at fair value each period using a Monte Carlo simulation.

The put and call options fair values associated with our Primary Care Organization strategic partnership with Welsh, Carson, Anderson & Stowe, or WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte

17

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $410 million and $12 million, respectively, at September 30, 2023. The put and call options fair values, derived from the Monte Carlo simulation, were $267 million and $10 million, respectively, at December 31, 2022. The put liability and call asset are included within other long-term liabilities and other long-term assets, respectively, within our condensed consolidated balance sheets.

The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, annualized volatility and credit spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term revenue, to measure underlying cash flows, weighted average cost of capital and long term growth rate. The table below presents the assumptions used for each reporting period.

	September 30, 2023		December 31, 2022
Annualized volatility	16.6% - 19.6%		16.7% - 20.8%
Credit spread	0.9% - 1.4%		1.3% - 1.5%
Revenue exit multiple	1.5x - 2.5x		1.5x - 2.5x
Weighted average cost of capital	12.0% - 13.0%		11.5% - 12.5%
Long term growth rate	3.0	%	3.0	%

The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.

Other Assets and Liabilities Measured at Fair Value

Certain assets and liabilities are measured at fair value on a non-recurring basis subject to fair value adjustment only in certain circumstances. As disclosed in Note 3, we acquired various health and wellness related businesses during 2023. The net assets acquired and resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs. The net tangible assets including receivables and accrued liabilities were recorded at their carrying value which approximated their fair value due to their short term nature. The fair value of goodwill and other intangible assets were internally estimated based primarily on the income approach. The income approach estimates fair value based on the present value of cash flow that the assets could be expected to generate in the future. We developed internal estimates for expected cash flows in the present value calculation using inputs and significant assumptions that include historical revenues and earnings, revenue growth rates, the amount and timing of future cash flows, discount rates, contributory asset charges and future tax rates, among others. The excess purchase price over the fair value of assets and liabilities acquired is recorded as goodwill.

As disclosed in Note 3, we completed the sale of Gentiva Hospice on August 11, 2022. The carrying value of the assets and liabilities of Gentiva Hospice disposed approximates fair value. The amount of goodwill included in the carrying value is based on the relative fair value of the Home Solutions reporting unit included within the CenterWell segment.

Other than the assets and liabilities acquired during 2023, there were no other material assets or liabilities measured at fair value on a recurring or nonrecurring basis during 2023.

For additional information regarding our fair value measurements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

18

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

6. MEDICARE PART D

We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with the Centers for Medicare and Medicaid Services, or CMS. The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at September 30, 2023 and December 31, 2022. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

	September 30, 2023				December 31, 2022
	Risk Corridor Settlement		CMS Subsidies/ Discounts		Risk Corridor Settlement		CMS Subsidies/ Discounts
	(in millions)
Other current assets	$	131	$	517	$	240	$	696
Trade accounts payable and accrued expenses	(150)		(3,566)		(166)		(1,236)
Net current (liability) asset	(19)		(3,049)		74		(540)
Other long-term assets	235		—		19		—
Other long-term liabilities	(123)		—		(78)		—
Net long-term asset (liability)	112		—		(59)		—
Total net asset (liability)	$	93	$	(3,049)	$	15	$	(540)

7. GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the carrying amount of goodwill for our reportable segments for the nine months ended September 30, 2023 were as follows:

	Insurance		CenterWell		Total
	(in millions)
Balance at January 1, 2023	$	2,472	$	6,670	$	9,142
Acquisitions	191		207		398
Balance at September 30, 2023	$	2,663	$	6,877	$	9,540

19

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at September 30, 2023 and December 31, 2022:

		September 30, 2023						December 31, 2022
	Weighted Average Life	Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net
		($ in millions)
Other intangible assets:
Certificates of need	Indefinite	$	1,132	$	—	$	1,132	$	1,132	$	—	$	1,132
Medicare licenses	Indefinite	302		—		302		286		—		286
Customer contracts/     relationships	9.4 years	955		708		247		929		673		256
Trade names and     technology	6.7 years	139		106		33		142		107		35
Provider contracts	11.6 years	73		64		9		73		63		10
Noncompetes and     other	8.4 years	84		42		42		86		40		46
Total other intangible     assets	9.2 years	$	2,685	$	920	$	1,765	$	2,648	$	883	$	1,765

    For the three months ended September 30, 2023 and 2022, amortization expense for other intangible assets was approximately $17 million and $25 million, respectively. For the nine months ended September 30, 2023 and 2022, amortization expense for other intangible assets was approximately $51 million and $61 million, respectively. The following table presents our estimate of amortization expense remaining for 2023 and each of the next five succeeding years at September 30, 2023:

	(in millions)
For the years ending December 31,
2023	$	15
2024	60
2025	58
2026	44
2027	34
2028	29

For additional information regarding our goodwill and intangible assets, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

20

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

8. BENEFITS PAYABLE

On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the nine months ended September 30, 2023 and 2022:

	For the nine months ended September 30,
	2023		2022
	(in millions)
Balances, beginning of period	$	9,264	$	8,289
Acquisitions	62		—
Incurred related to:
Current year	66,370		57,512
Prior years	(758)		(404)
Total incurred	65,612		57,108
Paid related to:
Current year	(56,700)		(48,835)
Prior years	(8,042)		(7,325)
Total paid	(64,742)		(56,160)
Balances, end of period	$	10,196	$	9,237

The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net incurred claims amounts. At September 30, 2023, benefits payable included IBNR of approximately $6.4 billion, primarily associated with claims incurred in 2023.

Amounts incurred related to prior periods vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development).

Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

21

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

9. EARNINGS PER COMMON SHARE COMPUTATION

Detail supporting the computation of basic and diluted earnings per common share was as follows for the three and nine months ended September 30, 2023 and 2022:

	Three months ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders	$	832	$	1,195	$	3,030	$	2,821
Weighted average outstanding shares of common stock     used to compute basic earnings per common share	123,426		126,572		124,335		126,678
Dilutive effect of:
Employee stock options	26		61		31		50
Restricted stock	531		723		519		577
Shares used to compute diluted earnings per common share	123,983		127,356		124,885		127,305
Basic earnings per common share	$	6.74	$	9.45	$	24.37	$	22.27
Diluted earnings per common share	$	6.71	$	9.39	$	24.26	$	22.16
Number of antidilutive stock options and restricted stock     excluded from computation	137		78		251		267

For additional information regarding earnings per common share, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

10. STOCKHOLDERS’ EQUITY

Dividends

The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2023 under our Board approved quarterly cash dividend policy:

Record Date	Payment Date	Amount per Share		Total Amount
				(in millions)
12/30/2022	1/27/2023	$	0.7875	$	98
03/31/2023	04/28/2023	$	0.8850	$	111
06/30/2023	07/28/2023	$	0.8850	$	110
9/29/2023	10/27/2023	$	0.8850	$	109

In October 2023, the Board declared a cash dividend of $0.885 per share payable on January 26, 2024 to stockholders of record as of the close of business on December 29, 2023. Declaration and payment of future quarterly dividends are at the discretion of our Board and may be adjusted as business needs or market conditions change.

Stock Repurchases

Our Board of Directors may authorize the purchase of our common stock shares. Under the share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as

22

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

amended, or in privately-negotiated transactions, including pursuant to accelerated share repurchase agreements with investment banks, subject to certain regulatory restrictions on volume, pricing, and timing.

On February 15, 2023, the Board of Directors replaced the previous share repurchase authorization of up to $3 billion (of which approximately $1 billion remained unused) with a new authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2026. During the nine months ended September 30, 2023, we repurchased 2.0 million shares in open market transactions for $980 million at an average price of $478.20 under the current share repurchase authorization. During the nine months ended September 30, 2022, we did not repurchase shares in open market transactions.

Our remaining repurchase authorization was $1.9 billion as of October 31, 2023.

In connection with employee stock plans, we acquired 0.06 million common shares for $31 million and 0.07 million common shares for $32 million during the nine months ended September 30, 2023 and 2022, respectively.

For additional information regarding our stockholders' equity, refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

11. INCOME TAXES

The effective income tax rate was 23.5% and 23.1% for the three and nine months ended September 30, 2023, respectively, and 8.2% and 22.5% for the three and nine months ended September 30, 2022, respectively. The year-over-year increase in the effective income tax rate is primarily due to the August 2022 disposition of our 60% interest in Gentiva Hospice, which resulted in an increase to our tax basis in both the shares sold and the shares retained, thereby reducing the effective income tax rate for the three and nine months ended September 30, 2022.

For additional information regarding income taxes, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

23

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

12.  DEBT

The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(in millions)
Short-term debt:
Commercial paper	$	2,245	$	595
Senior notes:
$1.5 billion, 0.650% due August 3, 2023	—		1,497
Total senior notes	—		1,497
Total short-term debt	$	2,245	$	2,092
Long-term debt:
Senior notes:
$600 million, 3.850% due October 1, 2024	$	572	$	599
$600 million, 4.500% due April 1, 2025	598		597
$500 million, 5.700% due March 13, 2026	497		—
$750 million, 1.350% due February 3, 2027	688		745
$600 million, 3.950% due March 15, 2027	537		597
$500 million, 5.750% due March 1, 2028	495		494
$750 million, 3.700% due March 23, 2029	689		743
$500 million, 3.125% due August 15, 2029	458		496
$500 million, 4.875% due April 1, 2030	496		495
$750 million, 2.150% due February 3, 2032	743		743
$750 million, 5.875% due March 1, 2033	715		739
$250 million, 8.150% due June 15, 2038	261		261
$400 million, 4.625% due December 1, 2042	396		396
$750 million, 4.950% due October 1, 2044	740		740
$400 million, 4.800% due March 15, 2047	396		396
$500 million, 3.950% due August 15, 2049	493		493
$750 million, 5.500% due March 15, 2053	709		—
Total senior notes	9,483		8,534
Term loans:
Delayed draw term loan, due May 28, 2024	—		500
Total term loans	—		500
Total long-term debt	$	9,483	$	9,034

Senior Notes

In March 2023, we issued $500 million of 5.700% unsecured senior notes due March 13, 2026 and $750 million of 5.500% unsecured senior notes due March 15, 2053. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.2 billion. We used the net proceeds to repay outstanding amounts under our $500 million Delayed Draw Term Loan. The remaining net proceeds will be used for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.

In August 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $750 million aggregate principal amount of 1.350% senior notes maturing in February 2027, our $600 million aggregate principal amount of 3.950% senior notes maturing in March 2027, our $750 million aggregate principal amount of 3.700%

24

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

senior notes maturing in March 2029, and our $500 million aggregate principal amount of 3.125% senior notes maturing in August 2029 during the period beginning on August 7, 2023 and ending on November 15, 2023. For the three months ended September 30, 2023, we repurchased $213 million principal amount of these senior notes for approximately $196 million cash.

In March 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $1.5 billion aggregate principal amount of 0.650% senior notes maturing in August 2023 and our $600 million aggregate principal amount of 3.850% senior notes maturing in October 2024 during the period beginning on March 13, 2023 and ending on July 21, 2023. For the nine months ended September 30, 2023, we repurchased $361 million principal amount of these senior notes for approximately $358 million cash. In August 2023, we repaid the remaining $1.2 billion aggregate principal amount of our 0.650% senior notes due on their maturity date of August 3, 2023.

During the third quarter of 2023, we entered into interest rate swap agreements to exchange the fixed interest rate under our 5.875% and 5.500% senior notes for a variable interest rate based on SOFR, as further described in Note 5. As a result, the carrying value of these senior notes has been adjusted to reflect changes in value caused by an increase or decrease in interest rates. The cumulative, aggregate adjustment to the carrying value of the 5.875% and 5.500% senior notes was $26 million and $5 million, respectively, at September 30, 2023.

For additional information regarding our Senior Notes, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Revolving Credit Agreements

In June 2023, we entered into an amended and restated 5-year, $2.5 billion unsecured revolving credit agreement (replacing the 5-year, $2.5 billion unsecured revolving credit agreement entered in June 2021) and entered into a 364-day $1.5 billion unsecured revolving credit agreement (replacing the 364-day $1.5 billion unsecured revolving credit agreement entered in June 2022, which expired in accordance with its terms).

Under the credit agreements, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at Term SOFR or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based Term SOFR, at our option.

The SOFR spread, currently 103.5 basis points under the 5-year revolving credit agreement and 105.5 basis points under the 364-day revolving credit agreement, varies depending on our credit ratings ranging from 92.0 to 130.0 basis points under the 5-year revolving credit agreement and from 94.0 to 135.0 basis points under the 364-day revolving credit agreement. We also pay an annual facility fee regardless of utilization. This facility fee, currently 9.0 basis points, under the 5-year revolving credit agreement and 7.0 basis points under the 364-day revolving agreement, varies depending on our credit ratings ranging from 8.0 to 20.0 basis points under the 5-year revolving credit agreement and from 6.0 to 15.0 basis points under the 364-day revolving credit agreement.

Our credit agreements contain customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 60%, as well as customary events of default. We are in compliance with this financial covenant, with actual debt to capitalization of 41.1% as measured in accordance with the revolving credit agreements as of September 30, 2023.

25

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

At September 30, 2023, we had no borrowings and approximately $18 million of letters of credit outstanding under the revolving credit agreements. Accordingly, as of September 30, 2023, we had $2.482 billion of remaining borrowing capacity under the 5-year revolving credit agreement and $1.5 billion of remaining borrowing capacity under the 364-day revolving credit agreement (which excludes the uncommitted $750 million of incremental loan facilities), none of which would be restricted by our financial covenant compliance requirement.

For additional information regarding our Revolving Credit Agreements, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Commercial Paper

Under our commercial paper program we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any time. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the nine months ended September 30, 2023 was $2.3 billion, with $2.2 billion outstanding at September 30, 2023 compared to $0.6 billion outstanding at December 31, 2022. The outstanding commercial paper at September 30, 2023 had a weighted average annual interest rate of 5.58%.

For additional information regarding our Commercial Paper refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Other Short-term Borrowings

We are a member, through one subsidiary, of the Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At September 30, 2023 we had no outstanding short-term FHLB borrowings.

13. COMMITMENTS, GUARANTEES AND CONTINGENCIES

Government Contracts

Our Medicare products, which accounted for approximately 83% of our total premiums and services revenue for the nine months ended September 30, 2023, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2023, and all of our product offerings filed with CMS for 2023 have been approved.

CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997, or BBA, and the Benefits Improvement and Protection Act of 2000, or BIPA, generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service, or FFS, program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS

26

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model.

CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, perform audits of various companies’ risk adjustment diagnosis data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices that influence the calculation of health status-related premium payments to MA plans.

In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract’s entire health status-related risk adjusted premium amount for the year under audit. In doing so, CMS recognized “that the documentation standard used in RADV audits to determine a contract’s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).” To correct for this difference, CMS stated that it would apply a “Fee-for-Service Adjuster (FFS Adjuster)” as “an offset to the preliminary recovery amount.” This adjuster would be “calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.” CMS stated that this methodology would apply to audits beginning with PY 2011. Humana relied on CMS’s 2012 guidance in submitting MA bids to CMS. Humana also launched a “Self-Audits” program in 2013 that applied CMS’s 2012 RADV audit methodology and included an estimated FFS Adjuster. Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS.

In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit methodology, including elimination of the FFS Adjuster. CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011. On January 30, 2023, CMS published a final rule related to the RADV audit methodology (Final RADV Rule). The Final RADV Rule confirmed CMS’s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS’s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed. However, CMS’s Final RADV Rule does not adopt a specific sampling, extrapolation or audit methodology. CMS instead stated its general plan to rely on “any statistically valid method . . . that is determined to be well-suited to a particular audit.”

We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (“APA”). CMS failed to meet its legal obligations in the federal rulemaking process to give a reasoned justification for the rule or provide a meaningful opportunity for public comment. They also chose to apply the rule retroactively rather than prospectively, as required by law. Humana’s actuarially certified bids through PY 2023 preserved Humana’s position that CMS should apply an FFS Adjuster in any RADV audit that CMS intends to extrapolate. We expect CMS to apply the Final RADV Rule, including the first application of extrapolated audit results to determine audit settlements without a FFS Adjuster, to CMS and HHS-OIG RADV audits conducted for PY 2018 and subsequent years. The Final RADV Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.

In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows.

On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members. It is critical that MA plans

27

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.

Our state-based Medicaid business, which accounted for approximately 7% of our total premiums and services revenue for the nine months ended September 30, 2023 primarily consisted of serving members enrolled in Medicaid, and in certain circumstances members who qualify for both Medicaid and Medicare, under contracts with various states.

At September 30, 2023, our Military business, which accounted for approximately 1% of our total premiums and services revenue for the nine months ended September 30, 2023, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract comprises 32 states and approximately 6 million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract, which was originally set to expire on December 31, 2022, was subsequently extended by the DoD and is currently scheduled to expire on December 31, 2023, unless further extended.

In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the TRICARE East Region by the Defense Health Agency of the DoD. The contract is expected to go into effect in 2024. Until then the T2017 contract remains in place. Under the terms of the award, our service area covers approximately 4.6 million beneficiaries in a region consisting of 24 states and Washington, D.C. The length of the contract is one base year with eight annual option periods, which, if all options are exercised, would result in a total contract length of nine years.

The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.

Legal Proceedings and Certain Regulatory Matters

As previously disclosed, the Civil Division of the United States Department of Justice provided us with an information request in December 2014, concerning our Medicare Part C risk adjustment practices. The request relates to our oversight and submission of risk adjustment data generated by providers in our Medicare Advantage network, as well as to our business and compliance practices related to risk adjustment data generated by our providers and by us, including medical record reviews conducted as part of our data and payment accuracy compliance efforts, the use of health and well-being assessments, and our fraud detection efforts. We believe that this request for information is in connection with a wider review of Medicare Risk Adjustment generally that includes a number of Medicare Advantage plans, providers and vendors. We cooperated with the Department of Justice, and we have not heard from the Department of Justice on this matter since 2020.

As previously disclosed, on January 19, 2016, an individual filed a qui tam suit captioned United States of America ex rel. Steven Scott v. Humana Inc., currently pending in United States District Court, Western District of Kentucky, Louisville division. The complaint alleges certain civil violations by us in connection with the actuarial equivalence of the plan benefits under Humana’s Basic PDP plan, a prescription drug plan offered by us under Medicare Part D. The action seeks damages and penalties on behalf of the United States under the False Claims Act. The court ordered the qui tam action unsealed on September 13, 2017, so that the relator could proceed, following notice from the U.S. Government that it was not intervening at that time. On March 31, 2022, the Court denied the parties' Motions for Summary Judgement. We take seriously our obligations to comply with applicable CMS requirements and actuarial standards of practice, and continue to vigorously defend against these allegations. As of September 30, 2023, we have accrued certain anticipated expenses in connection with this matter.

28

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. There is no assurance that we will prevail in the lawsuit. See “Government Contracts” in this footnote to the unaudited Consolidated Financial Statements of this Form 10-Q for additional information regarding this matter.

Other Lawsuits and Regulatory Matters

Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider contracting, risk adjustment, competitive practices, commission payments, privacy issues, utilization management practices, pharmacy benefits, access to care, sales practices, and provision of care by our healthcare services businesses, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.

We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. Under state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do.

As a government contractor, we may also be subject to false claims litigation, such as qui tam lawsuits brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government or related overpayments from the government, including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of nonperformance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.

A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.

We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is

29

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.

The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.

14. SEGMENT INFORMATION

During December 2022, we realigned our businesses into two distinct segments: Insurance and CenterWell. The Insurance segment includes the businesses that were previously included in the Retail and Group and Specialty segments, as well as the Pharmacy Benefit Manager, or PBM, business which was previously included in the Healthcare Services segment. The CenterWell segment (formerly Healthcare Services) represents our payor-agnostic healthcare services offerings, including pharmacy dispensing services, primary care, and home services. In addition to the new segment classifications being utilized to assess performance and allocate resources, we believe this simpler structure will create greater collaboration across the Insurance and CenterWell businesses and will accelerate work that is underway to centralize and integrate operations within the organization. Prior period segment financial information has been recast to conform to the 2023 presentation.

Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources.

The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our Military business, primarily our T-2017 East Region contract, as well as the operations of our PBM business.

The CenterWell segment includes our pharmacy, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.

Our CenterWell intersegment revenues primarily relate to the operations of CenterWell Pharmacy (our mail- order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics.

In addition, our CenterWell intersegment revenues include revenues earned by certain owned providers derived from certain value-based arrangements with our health plans. Under these value-based arrangements, our owned providers enter into agreements with our health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our members. In exchange, the owned provider receives a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our members. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.

30

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

We present our condensed consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $5.7 billion and $5.4 billion for the three months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023 and 2022 these amounts were $14.7 billion and $14.2 billion, respectively. In addition, depreciation and amortization expense associated with certain businesses delivering benefits to our members, primarily associated with our primary care and pharmacy operations, are included with benefits expense. The amount of this expense was $35 million and $30 million for the three months ended September 30, 2023 and 2022, respectively, and $102 million and $89 million for the nine months ended September 30, 2023 and 2022, respectively.

Other than those described previously, the accounting policies of each segment are the same. For additional information regarding our accounting policies refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home services, to our Insurance segment customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below.

Our segment results were as follows for the three and nine months ended September 30, 2023 and 2022:

31

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Three months ended September 30, 2023	(in millions)
External revenues
Premiums:
Individual Medicare Advantage	$	19,637	$	—	$	—	$	19,637
Group Medicare Advantage	1,695		—		—		1,695
Medicare stand-alone PDP	493		—		—		493
Total Medicare	21,825		—		—		21,825
Commercial fully-insured	842		—		—		842
Specialty benefits	252		—		—		252
Medicare Supplement	185		—		—		185
State-based contracts and other	1,995		—		—		1,995
Total premiums	25,099		—		—		25,099
Services revenue:
Home solutions	—		342		—		342
Primary care	—		214		—		214
Commercial ASO	55		—		—		55
Military and other	202		—		—		202
Pharmacy solutions	—		203		—		203
Total services revenue	257		759		—		1,016
Total external revenues	25,356		759		—		26,115
Intersegment revenues
Services	1		1,307		(1,308)		—
Products	—		2,594		(2,594)		—
Total intersegment revenues	1		3,901		(3,902)		—
Investment income	154		—		154		308
Total revenues	25,511		4,660		(3,748)		26,423
Operating expenses:
Benefits	21,976		—		(231)		21,745
Operating costs	2,634		4,207		(3,570)		3,271
Depreciation and amortization	179		53		(31)		201
Total operating expenses	24,789		4,260		(3,832)		25,217
Income from operations	722		400		84		1,206
Interest expense	—		1		113		114
Other income, net	—		—		(6)		(6)
Income (loss) before income taxes and equity in net earnings	722		399		(23)		1,098
Equity in net losses	—		(12)		—		(12)
Segment earnings (loss)	$	722	$	387	$	(23)	$	1,086
Net loss (income) attributable to noncontrolling interests	3		(1)		—		2
Segment earnings (loss) attributable to Humana	$	725	$	386	$	(23)	$	1,088

32

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Three months ended September 30, 2022	(in millions)
External revenues
Premiums:
Individual Medicare Advantage	$	16,007	$	—	$	—	$	16,007
Group Medicare Advantage	1,792		—		—		1,792
Medicare stand-alone PDP	534		—		—		534
Total Medicare	18,333		—		—		18,333
Commercial fully-insured	1,075		—		—		1,075
Specialty benefits	262		—		—		262
Medicare Supplement	188		—		—		188
State-based contracts and other	1,610		—		—		1,610
Total premiums	21,468		—		—		21,468
Services revenue:
Home solutions	—		519		—		519
Primary care	—		159		—		159
Commercial ASO	73		—		—		73
Military and other	137		—		—		137
Pharmacy solutions	—		271		—		271
Total services revenue	210		949		—		1,159
Total external revenues	21,678		949		—		22,627
Intersegment revenues
Services	14		863		(877)		—
Products	—		2,459		(2,459)		—
Total intersegment revenues	14		3,322		(3,336)		—
Investment income	51		3		118		172
Total revenues	21,743		4,274		(3,218)		22,799
Operating expenses:
Benefits	18,413		—		(29)		18,384
Operating costs	2,294		3,929		(3,162)		3,061
Depreciation and amortization	163		45		(26)		182
Total operating expenses	20,870		3,974		(3,217)		21,627
Income (loss) from operations	873		300		(1)		1,172
Gain on sale of Gentiva Hospice	—		(240)		—		(240)
Interest expense	—		—		102		102
Other expense, net	—		—		13		13
Income (loss) before income taxes and equity in net earnings	873		540		(116)		1,297
Equity in net earnings (losses)	8		(5)		—		3
Segment earnings (loss)	$	881	$	535	$	(116)	$	1,300
Net loss attributable to noncontrolling interests	2		—		—		2
Segment earnings (loss) attributable to Humana	$	883	$	535	$	(116)	$	1,302

33

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Nine months ended September 30, 2023	(in millions)
External revenues
Premiums:
Individual Medicare Advantage	$	59,195	$	—	$	—	$	59,195
Group Medicare Advantage	5,192		—		—		5,192
Medicare stand-alone PDP	1,677		—		—		1,677
Total Medicare	66,064		—		—		66,064
Commercial fully-insured	2,810		—		—		2,810
Specialty benefits	758		—		—		758
Medicare Supplement	546		—		—		546
State-based contracts and other	5,966		—		—		5,966
Total premiums	76,144		—		—		76,144
Services revenue:
Home solutions	—		997		—		997
Primary care	—		605		—		605
Commercial ASO	190		—		—		190
Military and other	540		—		—		540
Pharmacy solutions	—		661		—		661
Total services revenue	730		2,263		—		2,993
Total external revenues	76,874		2,263		—		79,137
Intersegment revenues
Services	30		3,584		(3,614)		—
Products	—		7,848		(7,848)		—
Total intersegment revenues	30		11,432		(11,462)		—
Investment income	385		—		390		775
Total revenues	77,289		13,695		(11,072)		79,912
Operating expenses:
Benefits	66,096		—		(484)		65,612
Operating costs	7,597		12,526		(10,762)		9,361
Depreciation and amortization	516		152		(90)		578
Total operating expenses	74,209		12,678		(11,336)		75,551
Income from operations	3,080		1,017		264		4,361
Interest expense	—		2		345		347
Other expense, net	—		—		40		40
Income (loss) before income taxes and equity in net losses	3,080		1,015		(121)		3,974
Equity in net losses	(2)		(37)		—		(39)
Segment earnings (loss)	$	3,078	$	978	$	(121)	$	3,935
Net loss (income) attributable to noncontrolling interests	7		(1)		—		6
Segment earnings (loss) attributable to Humana	$	3,085	$	977	$	(121)	$	3,941

34

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Nine months ended September 30, 2022	(in millions)
External Revenues
Premiums:
Individual Medicare Advantage	$	49,751	$	—	$	—	$	49,751
Group Medicare Advantage	5,524		—		—		5,524
Medicare stand-alone PDP	1,779		—		—		1,779
Total Medicare	57,054		—		—		57,054
Commercial fully-insured	3,324		—		—		3,324
Specialty benefits	784		—		—		784
Medicare Supplement	555		—		—		555
State-based contracts and other	4,720		—		—		4,720
Total premiums	66,437		—		—		66,437
Services revenue:
Home solutions	—		1,997		—		1,997
Primary care	—		409		—		409
Commercial ASO	225		—		—		225
Military and other	395		—		—		395
Pharmacy solutions	—		746		—		746
Total services revenue	620		3,152		—		3,772
Total external revenues	67,057		3,152		—		70,209
Intersegment revenues
Services	42		2,614		(2,656)		—
Products	—		7,394		(7,394)		—
Total intersegment revenues	42		10,008		(10,050)		—
Investment income	143		6		73		222
Total revenues	67,242		13,166		(9,977)		70,431
Operating expenses:
Benefits	57,311		—		(203)		57,108
Operating costs	6,486		12,002		(9,368)		9,120
Depreciation and amortization	469		136		(78)		527
Total operating expenses	64,266		12,138		(9,649)		66,755
Income (loss) from operations	2,976		1,028		(328)		3,676
Gain on sale of Gentiva Hospice	—		(240)		—		(240)
Interest expense	—		—		293		293
Other income, net	—		—		(16)		(16)
Income (loss) before income taxes and equity in net losses	2,976		1,268		(605)		3,639
Equity in net earnings (losses)	16		(15)		—		1
Segment earnings (loss)	$	2,992	$	1,253	$	(605)	$	3,640
Net loss (income) attributable to noncontrolling interests	2		(1)		—		1
Segment earnings (loss) attributable to Humana	$	2,994	$	1,252	$	(605)	$	3,641

35

Humana Inc.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The condensed consolidated financial statements of Humana Inc. in this document present the Company’s financial position, results of operations and cash flows, and should be read in conjunction with the following discussion and analysis. References to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries. This discussion includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in filings with the Securities and Exchange Commission, or SEC, in our press releases, investor presentations, and in oral statements made by or with the approval of one of our executive officers, the words or phrases like “believes,” “expects,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward–looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including, among other things, information set forth in Item 1A. – Risk Factors in our 2022 Form 10-K, as modified by any changes to those risk factors included in this document and in other reports we filed subsequent to February 16, 2023, in each case incorporated by reference herein. In making these statements, we are not undertaking to address or update such forward-looking statements in future filings or communications regarding our business or results. In light of these risks, uncertainties and assumptions, the forward–looking events discussed in this document might not occur. There may also be other risks that we are unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.

Executive Overview

General

Humana Inc., headquartered in Louisville, Kentucky, is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large.

Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking

total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs, excluding depreciation and amortization, as a percentage of total revenue less investment income, represents a statistic used to measure administrative spending efficiency.

Employer Group Commercial Medical Products Business Exit

In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.

Sale of Hospice and Personal Care Divisions

On August 11, 2022, we completed the sale of a 60% interest in Gentiva Hospice to Clayton, Dubilier & Rice, or CD&R, for cash proceeds of approximately $2.7 billion, net of cash disposed, including debt repayments from Gentiva Hospice to Humana of $1.9 billion. In connection with the sale we recognized a pre-tax gain, net of transaction costs, of $240 million.

COVID-19

The emergence and spread of the novel coronavirus, or COVID-19, beginning in the first quarter of 2020 has impacted our business. Initially during periods of increased incidences of COVID-19, a reduction in non-COVID-19 hospital admissions for non-emergent and elective medical care have resulted in lower overall healthcare system

36

utilization. At the same time, COVID-19 treatment and testing costs increased utilization. During 2022, we experienced lower overall utilization of the healthcare system than anticipated, as the reduction in COVID-19 utilization following the increased incidence associated with the Omicron variant outpaced the increase in non-COVID-19 utilization. The significant disruption in utilization during 2020 also impacted our ability to implement clinical initiatives to manage health care costs and chronic conditions of our members, and appropriately document their risk profiles, and, as such, significantly affected our 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2021 as a result of the COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and shifting the timing of claim payments and provider capitation surplus payments, impacted our claim reserve development and operating cash flows for 2021.

The COVID-19 National Emergency declared in 2020 was terminated on April 10, 2023 and the Public Health Emergency expired on May 11, 2023.

Value Creation Initiatives

During 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities beginning in 2023, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, during the three and nine months ended September 30, 2022, we recorded charges of $82 million and $285 million, respectively. For the three and nine months ended September 30, 2022, these charges primarily relate to $4 million and $144 million, respectively, in asset impairments, including software and abandonment, and $44 million and $65 million, respectively, of severance charges in connection with workforce optimization. The remainder of the charges primarily relate to external consulting fees. During the three months ended September 30, 2023, we recorded charges of $52 million primarily in asset impairments relating to software and abandonment. In connection with these initiatives, we expect to incur additional charges through the end of 2024. These charges are recorded at the corporate level and not allocated to the segments.

Business Segments

During December 2022, we realigned our businesses into two distinct segments: Insurance and CenterWell. The Insurance segment includes the businesses that were previously included in the Retail and Group and Specialty segments, as well as the Pharmacy Benefit Manager, or PBM, business which was previously included in the Healthcare Services segment. The CenterWell segment (formerly Healthcare Services) represents our payor-agnostic healthcare services offerings, including pharmacy dispensing services, primary care, and home services. In addition to the new segment classifications being utilized to assess performance and allocate resources, we believe this simpler structure will create greater collaboration across the Insurance and CenterWell businesses and will accelerate work that is underway to centralize and integrate operations within the organization. Prior period segment financial information has been recast to conform to the 2023 presentation. For a recast of prior period segment financial information, refer to Note 14 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources.

The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our Military business, primarily our T-2017 East Region contract, as well as the operations of our PBM business.

37

The CenterWell segment includes our pharmacy, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.

The results of each segment are measured by income (loss) from operations. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home services, to our Insurance segment customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations.

Seasonality

COVID-19 disrupted the pattern of our quarterly earnings and operating cash flows largely due to the temporary deferral of non-essential care which resulted in reductions in non-COVID-19 hospital admissions and lower overall healthcare system utilization during higher levels of COVID-19 hospital admissions. At the same time, during periods of increased incidences of COVID-19, COVID-19 treatment and testing costs increased. Similar impacts and seasonal disruptions from either higher or lower utilization are expected to persist as we recover from the COVID-19 global health crisis.

One of the product offerings of our Insurance segment is Medicare stand-alone prescription drug plans, or PDP, under the Medicare Part D program. Our quarterly Insurance segment earnings and operating cash flows are impacted by the Medicare Part D benefit design and changes in the composition of our membership. The Medicare Part D benefit design results in coverage that varies as a member’s cumulative out-of-pocket costs pass through successive stages of a member’s plan period, which begins annually on January 1 for renewals. These plan designs generally result in us sharing a greater portion of the responsibility for total prescription drug costs in the early stages and less in the latter stages. As a result, the PDP benefit ratio generally decreases as the year progresses. In addition, the number of low income senior members as well as year-over-year changes in the mix of membership in our stand-alone PDP products affects the quarterly benefit ratio pattern.

The Insurance segment also experiences seasonality in the commercial fully-insured product offering. The effect on the Insurance segment benefit ratio is opposite of the Medicare stand-alone PDP impact, with the benefit ratio increasing as fully-insured members progress through their annual deductible and maximum out-of-pocket expenses. The Employer Group Commercial Fully-Insured business increased the Insurance segment benefit ratio by 20 basis points and increased the Insurance segment benefit ratio by 30 basis points for the three months ended September 30, 2023 and 2022, respectively. The Employer Group Commercial Fully-Insured business did not impact the Insurance segment benefit ratio for the nine months ended September 30, 2023 and increased the Insurance segment benefit ratio by 10 basis points for the nine months ended 2022.

The Insurance segment also experiences seasonality in the operating cost ratio as a result of costs incurred in the second half of the year associated with the Medicare marketing season. The Insurance segment may experience adverse impacts in the operating cost ratio as a result of our Employer Group Commercial Medical Products exit phased over the 18-24 months following our February 2023 announcement. The Employer Group Commercial Fully-Insured business increased the Insurance segment operating cost ratio by 40 basis points and increased the Insurance segment operating cost ratio by 50 basis points for the three months ended September 30, 2023 and 2022, respectively. The Employer Group Commercial Fully-Insured business increased the Insurance segment operating

38

cost ratio by 40 basis points and increased the Insurance segment operating cost ratio by 50 basis points for the nine months ended September 30, 2023 and 2022, respectively.

2023 Highlights

•Our strategy offers our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused, provided by both employed physicians and physicians with network contract arrangements. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. We believe this strategy is positioning us for long-term growth in both membership and earnings. We offer providers a continuum of opportunities to increase the integration of care and offer assistance to providers in transitioning from a fee-for-service to a value-based arrangement. These include performance bonuses, shared savings and shared risk relationships. At September 30, 2023, approximately 3,727,500 members, or 69%, of our individual Medicare Advantage members were in value-based relationships under our integrated care delivery model, as compared to 3,145,200 members, or 69%, at September 30, 2022.

•Net income attributable to Humana was $0.8 billion, or $6.71 per diluted common share, and $1.2 billion, or $9.39 per diluted common share, for the three months ended September 30, 2023 and 2022, respectively. Net income attributable to Humana was $3.0 billion, or $24.26 per diluted common share, and $2.8 billion, or $22.16 per diluted common share, for the nine months ended September 30, 2023 and 2022, respectively. These comparisons were significantly impacted by put/call valuation adjustments associated with non-consolidating minority interest investments, transaction and integration costs, charges associated with value creation initiatives, the change in the fair value of publicly-traded equity securities, the gain on sale of Gentiva Hospice and accrual related to certain anticipated litigation expenses. The impact of these adjustments to our consolidated income before income taxes and equity in net earnings and diluted earnings per common share was as follows for the 2023 and 2022 quarter and period:

39

	For the three months ended September 30,				For the nine months ended September 30,
	2023		2022		2023		2022
Consolidated income before income taxes and equity in net earnings:
Gain on sale of Gentiva Hospice	$	—	$	(240)	$	—	$	(240)
Put/call valuation adjustments associated with our non consolidating minority interest investments	35		13		141		(16)
Transaction and integration costs	—		17		(47)		70
Change in the fair value of publicly-traded equity securities	—		(51)		(1)		119
Value creation initiatives	52		82		52		285
Accrual related to certain anticipated litigation expenses	15		—		105		—
Total	$	102	$	(179)	$	250	$	218
	For the three months ended September 30,				For the nine months ended September 30,
	2023		2022		2023		2022
Diluted earnings per common share:
Gain on sale of Gentiva Hospice	$	—	$	(1.89)	$	—	$	(1.89)
Put/call valuation adjustments associated with our non consolidating minority interest investments	0.28		0.10		1.13		(0.13)
Transaction and integration costs	—		0.13		(0.38)		0.55
Change in the fair value of publicly-traded equity securities	—		(0.40)		(0.01)		0.94
Value creation initiatives	0.42		0.65		0.42		2.24
Accrual related to certain anticipated litigation expenses	0.12		—		0.84		—
Net tax impact of transactions	(0.18)		(1.25)		$	(0.57)	$	(0.66)
Total	$	0.64	$	(2.66)	$	1.43	$	1.05

40

Health Care Reform

We are and will continue to be regularly subject to new laws and regulations, changes to existing laws and regulations, and judicial determinations that impact the interpretation and applicability of those laws and regulations. The Health Care Reform Law, the Families First Act, the CARES Act, and the Inflation Reduction Act, and related regulations, are examples of laws which have enacted significant reforms to various aspects of the U.S. health insurance industry, including, among others, mandated coverage requirements, mandated benefits and guarantee issuance associated with commercial medical insurance, rebates to policyholders based on minimum benefit ratios, adjustments to Medicare Advantage premiums, the establishment of federally facilitated or state-based exchanges coupled with programs designed to spread risk among insurers, and the introduction of plan designs based on set actuarial values, and changes to the Part D prescription drug benefit design.

It is reasonably possible that these laws and regulations, as well as other current or future legislative, judicial or regulatory changes including restrictions on our ability to manage our provider network or otherwise operate our business, or restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, increases in member benefits or changes to member eligibility criteria without corresponding increases in premium payments to us, or increases in regulation of our prescription drug benefit businesses, in the aggregate may have a material adverse effect on our results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting our ability to expand into new markets, increasing our medical and operating costs, further lowering our Medicare payment rates and increasing our expenses associated with assessments); our financial position (including our ability to maintain the value of our goodwill); and our cash flows.

We intend for the discussion of our financial condition and results of operations that follows to assist in the understanding of our financial statements and related changes in certain key items in those financial statements from year to year, including the primary factors that accounted for those changes. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home services, to our Insurance segment customers and are described in Note 14 to the condensed consolidated financial statements included in this report.

41

Comparison of Results of Operations for 2023 and 2022

The following discussion primarily details our results of operations for the three months ended September 30, 2023, or the 2023 quarter, the three months ended September 30, 2022, or the 2022 quarter, the nine months ended September 30, 2023, or the 2023 period, and the nine months ended September 30, 2022, or the 2022 period.

Consolidated

													Change
	Three months ended September 30,						Nine Months Ended September 30,						Three months ended September 30, 2023 vs 2022				Nine Months Ended September 30, 2023 vs 2022
	2023			2022			2023			2022			$		%		$		%
	($ in millions, except per common share results)
Revenues:
Insurance premiums	$	25,099		$	21,468		$	76,144		$	66,437		$	3,631	16.9	%	$	9,707	14.6	%
Services:
Insurance	257			210			730			620			47		22.4	%	110		17.7	%
CenterWell	759			949			2,263			3,152			(190)		(20.0)	%	(889)		(28.2)	%
Total services revenue	1,016			1,159			2,993			3,772			(143)		(12.3)	%	(779)		(20.7)	%
Investment income	308			172			775			222			136		79.1	%	553		249.1	%
Total revenues	26,423			22,799			79,912			70,431			3,624		15.9	%	9,481		13.5	%
Operating expenses:
Benefits	21,745			18,384			65,612			57,108			3,361		18.3	%	8,504		14.9	%
Operating costs	3,271			3,061			9,361			9,120			210		6.9	%	241		2.6	%
Depreciation and amortization	201			182			578			527			19		10.4	%	51		9.7	%
Total operating expenses	25,217			21,627			75,551			66,755			3,590		16.6	%	8,796		13.2	%
Income from operations	1,206			1,172			4,361			3,676			34		2.9	%	685		18.6	%
Gain on sale of Gentiva Hospice	—			(240)			—			(240)			(240)		(100.0)	%	(240)		(100.0)	%
Interest expense	114			102			347			293			12		11.8	%	54		18.4	%
Other (income) expense, net	(6)			13			40			(16)			19		146.2	%	56		350.0	%
Income before income taxes and equity in net earnings	1,098			1,297			3,974			3,639			(199)		(15.3)	%	335		9.2	%
Provision for income taxes	256			107			911			820			149		139.3	%	91		11.1	%
Equity in net (losses) earnings	(12)			3			(39)			1			15		500.0	%	40		nm
Net income	$	830		$	1,193		$	3,024		$	2,820		$	(363)	(30.4)	%	$	204	7.2	%
Diluted earnings per common share	$	6.71		$	9.39		$	24.26		$	22.16		$	(2.68)	(28.5)	%	$	2.10	9.5	%
Benefit ratio (a)	86.6		%	85.6		%	86.2		%	86.0		%			1.0	%			0.2	%
Operating cost ratio (b)	12.5		%	13.5		%	11.8		%	13.0		%			(1.0)	%			(1.2)	%
Effective tax rate	23.5		%	8.2		%	23.1		%	22.5		%			15.3	%			0.6	%

(a)Represents benefits expense as a percentage of premiums revenue.

(b)Represents operating costs as a percentage of total revenues less investment income.

nm - not meaningful

42

Premiums Revenue

Consolidated premiums revenue increased $3.6 billion, or 16.9%, from $21.5 billion in the 2022 quarter to $25.1 billion in the 2023 quarter and increased $9.7 billion, or 14.6%, from $66.4 billion in the 2022 period to $76.1 billion in the 2023 period primarily due to individual Medicare Advantage and state-based contracts membership growth and higher per member individual Medicare Advantage premiums. These factors were partially offset by the year-over-year decline in membership associated with group commercial medical, group Medicare Advantage and stand-alone PDP products. In addition, the period was negatively impacted by the phase-out of COVID-19 sequestration relief in 2022.

Services Revenue

Consolidated services revenue decreased $0.1 billion, or 12.3%, from $1.2 billion in the 2022 quarter to $1.0 billion in the 2023 quarter and decreased $0.8 billion, or 20.7%, from $3.8 billion in the 2022 period to $3.0 billion in the 2023 period primarily due to the divestiture of the 60% ownership of Gentiva Hospice in August 2022.

Investment Income

Investment income increased $136 million, or 79.1%, from $172 million in the 2022 quarter to $308 million in the 2023 quarter primarily due to an increase in interest income on our debt securities partially offset by the net favorable mark to market impact of our publicly traded equity securities investments during the 2022 quarter. Investment income increased $553 million, or 249.1%, from $222 million in the 2022 period to $775 million in the 2023 period primarily due to an increase in interest income on our debt securities as well as the net unfavorable mark to market impact of our publicly traded equity securities during the 2022 period.

Benefit Expense    

Consolidated benefits expense increased $3.4 billion, or 18.3%, from $18.4 billion in the 2022 quarter to $21.7 billion in the 2023 quarter and increased $8.5 billion, or 14.9%, from $57.1 billion in the 2022 period to $65.6 billion in the 2023 period. The consolidated benefit ratio increased 100 basis points from 85.6% for the 2022 quarter to 86.6% for the 2023 quarter and increased 20 basis points from 86.0% for the 2022 period to 86.2% for the 2023 period primarily due to investments in the benefit design of our Medicare Advantage products for 2023, the continuation of elevated Medicare Advantage utilization trends initially discussed in the second quarter of 2023, combined with higher COVID-19 admissions in the 2023 quarter, without the offsetting impact of lower non-COVID care, as well as the impact of continued individual Medicare Advantage growth following the previous Annual Election Period, or AEP, including a high proportion of age-ins, which typically have a higher benefits expense ratio initially than the average new member. These increases were partially offset by increased individual Medicare Advantage premiums and decreased average unit costs given the additional 20% payment on COVID-19 admissions during the Public Health Emergency, which expired on May 11, 2023. In addition, the period was favorably impacted by higher favorable prior-period medical claims reserve development. Further, the 2023 quarter and period ratios continue to reflect a shift in line of business mix, with growth in individual Medicare Advantage and state-based contracts and other membership, which can carry a higher benefits expense ratio.

Consolidated benefits expense included $4 million of favorable prior-period medical claims reserve development in the 2023 quarter and $7 million of favorable prior-period medical claims development in the 2022 quarter. Consolidated benefits expense included $758 million of favorable prior-period medical claims reserve development in the 2023 period and $404 million of favorable prior-period medical claims reserve development in the 2022 period. Prior-period medical claims reserve development did not impact the Insurance segment benefit ratio in the 2023 quarter or the 2022 quarter. Prior-period medical claims reserve development decreased the consolidated benefit ratio by approximately 100 basis points in the 2023 period and decreased the consolidated benefit ratio by approximately 60 basis points in the 2022 period.

43

Operating Costs

Our segments incur both direct and shared indirect operating costs. We allocate the indirect costs shared by the segments primarily as a function of revenues. As a result, the profitability of each segment is interdependent.

Consolidated operating costs increased $0.2 billion, or 6.9%, from $3.1 billion in the 2022 quarter to $3.3 billion in the 2023 quarter and increased $0.2 billion, or 2.6%, from $9.1 billion in the 2022 period to $9.4 billion in the 2023 period. The consolidated operating cost ratio decreased 100 basis points from 13.5% for the 2022 quarter to 12.5% for the 2023 quarter and decreased 120 basis points from 13.0% for the 2022 period to 11.8% for the 2023 period primarily due to the divestiture of the 60% ownership of Gentiva Hospice in August 2022, which carried a significantly higher operating cost ratio compared to the historical consolidated operating cost ratio, scale efficiencies associated with growth in individual Medicare Advantage membership, as well as administrative cost efficiencies that resulted as part of the our value creation initiatives, combined with a lesser impact from accelerated charges related to value-creation initiatives in 2023 compared to 2022. These factors were partially offset by an increase in commissions for brokers related to the individual Medicare Advantage membership growth in 2023 and an accrual related to certain anticipated litigation expenses in the 2023 quarter and period. In addition, the 2023 period was negatively impacted by the phase-out of COVID-19 sequestration relief in 2022.

Depreciation and Amortization

Depreciation and amortization increased $19 million, or 10.4%, from $182 million in the 2022 quarter to $201 million in the 2023 quarter and increased $51 million, or 9.7%, from $527 million in the 2022 period to $578 million in the 2023 period primarily due to capital expenditures.

Interest Expense

Interest expense increased $12 million, or 11.8%, from $102 million in the 2022 quarter to $114 million in the 2023 quarter and increased $54 million, or 18.4%, from $293 million in the 2022 period to $347 million in the 2023 period due to higher rates on higher average debt balances.

Income Taxes

The effective income tax rate was 23.5% and 8.2% for the three months ended September 30, 2023, and 2022, respectively, and 23.1% and 22.5% for the nine months ended September 30, 2023 and 2022, respectively. The year-over-year increase in the effective income tax rate is primarily due to the August 2022 disposition of our 60% interest in Gentiva Hospice, which resulted in an increase to our tax basis in both the shares sold and the shares retained, thereby reducing the effective income tax rate for the three and nine months ended September 30, 2022.

44

Insurance Segment

	September 30,		Change
	2023	2022	Members	%
Membership:
Individual Medicare Advantage	5,374,400	4,564,200	810,200	17.8	%
Group Medicare Advantage	510,300	564,600	(54,300)	(9.6)	%
Medicare stand-alone PDP	2,885,800	3,569,100	(683,300)	(19.1)	%
Total Medicare	8,770,500	8,697,900	72,600	0.8	%
Medicare Supplement	299,400	316,500	(17,100)	(5.4)	%
Commercial fully-insured	409,300	574,500	(165,200)	(28.8)	%
State-based contracts and other	1,264,600	1,098,900	165,700	15.1	%
Military	5,935,400	5,977,900	(42,500)	(0.7)	%
Commercial ASO	284,300	438,600	(154,300)	(35.2)	%
Total Medical Membership	16,963,500	17,104,300	(140,800)	(0.8)	%
Total Specialty Membership (a)	4,964,300	5,210,100	(245,800)	(4.7)	%

(a) We provide a full range of insured specialty products including dental, vision, and life insurance benefits marketed to individuals and groups. Members included in these products may not be unique to each product since members have the ability to enroll in a medical product and one or more specialty products.

													Change
	Three months ended September 30,						Nine Months Ended September 30,						Three months ended September 30, 2023 vs 2022				Nine Months Ended September 30, 2023 vs 2022
	2023			2022			2023			2022			$		%		$		%
	($ in millions)
Premiums and Services Revenue:
Premiums:
Individual Medicare Advantage	$	19,637		$	16,007		$	59,195		$	49,751		$	3,630	22.7	%	$	9,444	19.0	%
Group Medicare Advantage	1,695			1,792			5,192			5,524			(97)		(5.4)	%	(332)		(6.0)	%
Medicare stand-alone PDP	493			534			1,677			1,779			(41)		(7.7)	%	(102)		(5.7)	%
Total Medicare	21,825			18,333			66,064			57,054			3,492		19.0	%	9,010		15.8	%
Commercial fully-insured	842			1,075			2,810			3,324			(233)		(21.7)	%	(514)		(15.5)	%
Specialty benefits	252			262			758			784			(10)		(3.8)	%	(26)		(3.3)	%
Medicare Supplement	185			188			546			555			(3)		(1.6)	%	(9)		(1.6)	%
State-based contracts and other	1,995			1,610			5,966			4,720			385		23.9	%	1,246		26.4	%
Total premiums revenue	25,099			21,468			76,144			66,437			3,631		16.9	%	9,707		14.6	%
Commercial ASO	55			73			190			225			(18)		(24.7)	%	(35)		(15.6)	%
Military and other	202			137			540			395			65		47.4	%	145		36.7	%
Services revenue	257			210			730			620			47		22.4	%	110		17.7	%
Total premiums and services revenue	$	25,356		$	21,678		$	76,874		$	67,057		$	3,678	17.0	%	$	9,817	14.6	%
Income from operations	$	722		$	873		$	3,080		$	2,976		$	(151)	(17.3)	%	$	104	3.5	%
Benefit ratio	87.6		%	85.8		%	86.8		%	86.3		%			1.8	%			0.5	%
Operating cost ratio	10.4		%	10.6		%	9.9		%	9.7		%			(0.2)	%			0.2	%

45

Income from operations

Insurance segment income from operations decreased $0.2 billion, or 17.3%, from $0.9 billion in the 2022 quarter to $0.7 billion in the 2023 quarter primarily due to the same factors impacting the segment's higher benefit ratio offset by the segment's lower operating cost ratio as more fully described below. Insurance segment income from operations increased $0.1 billion, or 3.5%, from $3.0 billion in the 2022 period to $3.1 billion in the 2023 period primarily due to growth in individual Medicare Advantage membership in 2023.

Enrollment

Individual Medicare Advantage membership increased 810,200 members, or 17.8%, from September 30, 2022 to September 30, 2023 primarily due to membership additions associated with the previous AEP and continued growth in 2023. The year-over-year growth was further impacted by continued enrollment resulting from special elections, age-ins, and Dual Eligible Special Need Plans, or D-SNP, membership. Individual Medicare Advantage membership includes 868,000 D-SNP members as of September 30, 2023, a net increase of 201,000 members, or 30.1%, from 667,000 members as of September 30, 2022.

Group Medicare Advantage membership decreased 54,300 members, or 9.6%, from September 30, 2022 to September 30, 2023 reflecting the net loss of certain large accounts partially offset by continued growth in small group accounts.

Medicare stand-alone PDP membership decreased 683,300 members, or 19.1%, from September 30, 2022 to September 30, 2023 primarily due to continued intensified competition for Medicare stand-alone PDP offerings.

State-based contracts and other membership increased 165,700 members, or 15.1%, from September 30, 2022 to September 30, 2023 reflecting the impact of membership additions associated with the implementation of the Louisiana and Ohio contracts effective January 2023 and February 2023, respectively, partially offset by ending the suspension of state eligibility redetermination efforts previously enacted as part of the Public Health Emergency.

Commercial fully-insured medical membership decreased 165,200 members, or 28.8%, from September 30, 2022 to September 30, 2023 and commercial ASO medical membership decreased 154,300 members, or 35.2%, from September 30, 2022 to September 30, 2023. These decreases reflect our planned exit of the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.

Military membership decreased 42,500 members, or 0.7%, from September 30, 2022 to September 30, 2023. Membership includes military service members, retirees, and their families to whom we are providing healthcare services under the current TRICARE East Region contract.

Specialty membership decreased 245,800 members, or 4.7%, from September 30, 2022 to September 30, 2023 reflecting the decline in membership associated with our Optional Supplemental Benefit products as a result of enhanced mandatory dental and vision supplemental benefits on Medicare Advantage plans. In addition, the decline reflects loss of dental and vision individuals due to terminations as well as loss of dental and vision groups cross-sold with commercial medical products.

Premiums Revenue

Insurance segment premiums revenue increased $3.6 billion, or 16.9%, from $21.5 billion in the 2022 quarter to $25.1 billion in the 2023 quarter and increased $9.7 billion, or 14.6%, from $66.4 billion in the 2022 period to $76.1 billion in the 2023 period primarily due to individual Medicare Advantage and state-based contracts membership growth and higher per member individual Medicare Advantage premiums. These factors were partially offset by the year-over-year decline in membership associated with group commercial medical, group Medicare Advantage and stand-alone PDP products. In addition, the period was negatively impacted by the phase-out of COVID-19 sequestration relief in 2022.

46

Services Revenue

Insurance segment services revenue increased $47 million, or 22.4%, from $210 million in the 2022 quarter to $257 million in the 2023 quarter and increased $110 million, or 17.7%, from $620 million in the 2022 period to $730 million in the 2023 period.

Benefits Expense

The Insurance segment benefit ratio increased 180 basis points from 85.8% for the 2022 quarter to 87.6% for the 2023 quarter and increased 50 basis points from 86.3% for the 2022 period to 86.8% for the 2023 period primarily due to investments in the benefit design of our Medicare Advantage products for 2023, the continuation of elevated Medicare Advantage utilization trends initially discussed in the second quarter of 2023, combined with higher COVID-19 admissions in the 2023 quarter, without the offsetting impact of lower non-COVID care, as well as the impact of continued individual Medicare Advantage growth following the previous Annual Election Period, or AEP, including a high proportion of age-ins, which typically have a higher benefits expense ratio initially than the average new member. These increases were partially offset by increased individual Medicare Advantage premiums and decreased average unit costs given the additional 20% payment on COVID-19 admissions during the Public Health Emergency, which expired on May 11, 2023. In addition, the period was favorably impacted by higher favorable prior-period medical claims reserve development. Further, the 2023 quarter and period ratios continue to reflect a shift in line of business mix, with growth in individual Medicare Advantage and state-based contracts and other membership, which can carry a higher benefits expense ratio.

The Insurance segment benefits expense included $4 million of favorable prior-period medical claims reserve development in the 2023 quarter and $7 million of favorable prior-period medical claims reserve development in the 2022 quarter. The Insurance segment benefit expense included $758 million of favorable prior-period medical claims reserve development in the 2023 period and $404 million of favorable prior-period medical claims reserve development in the 2022 period. Prior-period medical claims reserve development did not impact the Insurance segment benefit ratio in the 2023 quarter or the 2022 quarter. Prior-period medical claims reserve development decreased the Insurance segment benefit ratio by approximately 100 basis points in the 2023 period and decreased the Insurance segment benefit ratio by approximately 60 basis points in the 2022 period.

Operating Costs

The Insurance segment operating cost ratio decreased 20 basis points from 10.6% for the 2022 quarter to 10.4% for the 2023 quarter primarily due to scale efficiencies associated with growth in the individual Medicare Advantage membership and administrative cost efficiencies as a result of our value creation initiatives. These factors were partially offset by an increase in commissions for brokers related to the individual Medicare Advantage membership growth in 2023 and an accrual related to certain anticipated litigation expenses in the 2023 quarter. The Insurance segment operating cost ratio increased 20 basis points from 9.7% for the 2022 period to 9.9% for the 2023 period primarily due to the net unfavorable impact of the 2023 quarter operating cost ratio factors. In addition, the period was negatively impacted by the phase-out of COVID-19 sequestration relief in 2022.

47

CenterWell Segment

													Change
	Three months ended September 30,						Nine Months Ended September 30,						Three months ended September 30, 2023 vs 2022				Nine Months Ended September 30, 2023 vs 2022
	2023			2022			2023			2022			$		%		$		%
	($ in millions)
Revenues:
Services:
Home solutions	$	342		$	519		$	997		$	1,997		$	(177)	(34.1)	%	$	(1,000)	(50.1)	%
Pharmacy solutions	203			271			661			746			(68)		(25.1)	%	(85)		(11.4)	%
Primary care	214			159			605			409			55		34.6	%	196		47.9	%
Total services revenue	759			949			2,263			3,152			(190)		(20.0)	%	(889)		(28.2)	%
Intersegment revenues:
Home solutions	453			126			1,088			352			327		259.5	%	736		209.1	%
Pharmacy solutions	2,594			2,459			7,848			7,394			135		5.5	%	454		6.1	%
Primary care	854			737			2,496			2,262			117		15.9	%	234		10.3	%
Total intersegment revenues	3,901			3,322			11,432			10,008			579		17.4	%	1,424		14.2	%
Total services and intersegment revenues	$	4,660		$	4,271		$	13,695		$	13,160		$	389	9.1	%	$	535	4.1	%
Income from operations	$	400		$	300		$	1,017		$	1,028		$	100	33.3	%	$	(11)	(1.1)	%
Operating cost ratio	90.3		%	92.0		%	91.5		%	91.2		%			(1.7)	%			0.3	%

Income from operations

CenterWell income from operations increased $0.1 billion, or 33.3%, from $0.3 billion in the 2022 quarter to $0.4 billion in the 2023 quarter and decreased $0.01 billion, or 1.1%, from $1.03 billion in the 2022 period to $1.02 billion in the 2023 period primarily due to the same factors impacting the segment's operating cost ratio as more fully described below.

Services Revenue

CenterWell services revenue decreased $0.2 billion, or 20.0%, from $0.9 billion in the 2022 quarter to $0.8 billion in the 2023 quarter and decreased $0.9 billion, or 28.2%, from $3.2 billion in the 2022 period to $2.3 billion in the 2023 period primarily due to the divestiture of the 60% ownership of Gentiva Hospice in August 2022.

Intersegment Revenues

CenterWell intersegment revenues increased $0.6 billion, or 17.4%, from $3.3 billion in the 2022 quarter to $3.9 billion in the 2023 quarter and increased $1.4 billion, or 14.2%, from $10.0 billion in the 2022 period to $11.4 billion in the 2023 period primarily due to individual Medicare Advantage membership growth, which led to higher pharmacy revenues, higher revenues associated with growth in the primary care business, and greater revenues associated with the home solutions business as a result of the expansion of the value-based care home model in 2023 compared to 2022.

48

Operating Costs

The CenterWell segment operating cost ratio decreased 170 basis points from 92.0% for the 2022 quarter to 90.3% for the 2023 quarter primarily due to an improving ratio in the primary care business driven by year-over-year medical costs favorability and administrative cost efficiencies related to the pharmacy solutions business. These factors were partially offset by the divestiture of the 60% ownership of Gentiva Hospice in August 2022, which carried a lower operating cost ratio compared to other businesses within the segment, the expansion of the value-based care model within the home solutions business, which carries a higher operating cost ratio compared to the core fee-for-service business, along with growth in Medicare Advantage episodes in the core fee-for-service business, as well as continued investments within the home solutions business to abate the pressures of the current nursing labor environment. The CenterWell segment operating cost ratio increased 30 basis points from 91.2% for the 2022 period to 91.5% for the 2023 period primarily due the unfavorable impact of the 2023 quarter operating cost ratio factors.

Liquidity

Historically, our primary sources of cash have included receipts of premiums, services revenue, and investment and other income, as well as proceeds from the sale or maturity of our investment securities, and borrowings. Our primary uses of cash historically have included disbursements for claims payments, operating costs, interest on borrowings, taxes, purchases of investment securities, acquisitions, capital expenditures, repayments on borrowings, dividends, and share repurchases. As premiums generally are collected in advance of claim payments by a period of up to several months, our business normally should produce positive cash flows during periods of increasing premiums and enrollment. Conversely, cash flows would be negatively impacted during periods of decreasing premiums and enrollment. From period to period, our cash flows may also be affected by the timing of working capital items including premiums receivable, benefits payable, and other receivables and payables. Our cash flows are impacted by the timing of payments to and receipts from CMS associated with Medicare Part D subsidies for which we do not assume risk. The use of cash flows may be limited by regulatory requirements of state departments of insurance (or comparable state regulators) which require, among other items, that our regulated subsidiaries maintain minimum levels of capital and seek approval before paying dividends from the subsidiaries to the parent. Our use of cash flows derived from our non-insurance subsidiaries, such as in our CenterWell segment, is generally not restricted by state departments of insurance (or comparable state regulators).

For additional information regarding our liquidity risk, refer to Part I, Item 1A, "Risk Factors" in our 2022 Form 10-K and Part II, Item 1A, "Risk Factors" of this Form 10-Q.

Cash and cash equivalents increased to approximately $15.1 billion at September 30, 2023 from $5.1 billion at December 31, 2022. The change in cash and cash equivalents for the nine months ended September 30, 2023 and 2022 is summarized as follows:

	Nine Months Ended
	2023		2022
	(in millions)
Net cash provided by operating activities	$	11,115	$	9,714
Net cash (used in) provided by investing activities	(2,610)		6
Net cash provided by financing activities	1,582		444
Increase in cash and cash equivalents	$	10,087	$	10,164

Cash Flow from Operating Activities

Cash flows provided by operations of $11.1 billion in the 2023 period increased $1.4 billion from cash flows provided by operations of $9.7 billion in the 2022 period. Our operating cash flows for the 2023 period and the 2022 period were significantly impacted by the early receipt of the Medicare premium remittance of $7.1 billion in September 2023 and $5.8 billion in September 2022, because the payment date for October 2023 and 2022, respectively, fell on a weekend. Generally, when the first day of a month falls on a weekend or holiday, with the

49

exception of January 1 (New Year's Day), we receive this payment at the end of the previous month. This also resulted in an increase to unearned revenues in our condensed consolidated balance sheet at September 30, 2023 and 2022. Our operating cash flows for the 2023 period also reflect higher earnings compared to the 2022 period.

The most significant drivers of changes in our working capital are typically the timing of payments of benefits expense and receipts for premiums. Benefits expense includes claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care and other supplemental benefits provided on or prior to the balance sheet date. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

The detail of total net receivables at September 30, 2023 and December 31, 2022 and reconciliation to cash flow for the nine months ended September 30, 2023 and 2022 was as follows:

	September 30, 2023		December 31, 2022		2023 Period Change		2022 Period Change
	(in millions)
Medicare	$	1,293	$	1,260	$	33	$	4
Commercial and other	479		383		96		(225)
Military	125		101		24		4
Allowances	(73)		(70)		(3)		12
Total net receivables	$	1,824	$	1,674	$	150	$	(205)
Reconciliation to cash flow statement:
Receivables from acquisition					(24)		—
Receivables disposed					—		194
Change in receivables per cash flow statement					$	126	$	(11)

The changes in Medicare receivables for both the 2023 period and the 2022 period reflect individual Medicare Advantage membership growth and the typical pattern caused by the timing of accruals and related collections associated with the CMS risk-adjustment model. Significant collections occur with the mid-year and final settlements with CMS in the second and third quarter.

Cash Flow from Investing Activities

During the 2023 period and 2022 period, we acquired various businesses for approximately $223 million and $293 million, net of cash and cash equivalents received, respectively.

During the 2022 period, we completed the sale of a 60% interest of Gentiva Hospice to CD&R for cash proceeds of approximately $2.7 billion, net of cash disposed, including debt repayments from KAH Hospice to Humana of $1.9 billion. In connection with the sale we recognized a pre-tax gain, net of transaction costs, of $240 million which is reported as a gain on sale of KAH Hospice in the accompanying condensed consolidated statements of income for the three and nine months ended September 30, 2022.

Our ongoing capital expenditures primarily relate to our information technology initiatives, support of services in our primary care operations including medical and administrative facility improvements necessary for activities such as the provision of care to members, claims processing, billing and collections, wellness solutions, care coordination, regulatory compliance and customer service. Total capital expenditures, excluding acquisitions, were $721 million in the 2023 period and $862 million in the 2022 period.

Net purchases of investment securities were $1.7 billion and $1.5 billion in the 2023 and 2022 periods, respectively.

50

Cash Flow from Financing Activities

Receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk were higher than claim payments by $2.5 billion and $3.7 billion in the 2023 and 2022 periods, respectively.

Under our administrative services only TRICARE contracts, health care costs payments for which we do not assume risk exceeded reimbursements from the federal government by $28 million in the 2023 period and reimbursements from the federal government exceeded health care costs payments for which we do not assume risk by $60 million in the 2022 period.

In August 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $750 million aggregate principal amount of 1.350% senior notes maturing in February 2027, our $600 million aggregate principal amount of 3.950% senior notes maturing in March 2027, our $750 million aggregate principal amount of 3.700% senior notes maturing in March 2029, and our $500 million aggregate principal amount of 3.125% senior notes maturing in August 2029 during the period beginning on August 7, 2023 and ending on November 15, 2023. For the three months ended September 30, 2023, we repurchased $213 million principal amount of these senior notes for approximately $196 million cash.

In March 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $1.5 billion aggregate principal amount of 0.650% senior notes maturing in August 2023 and our $600 million aggregate principal amount of 3.850% senior notes maturing in October 2024 during the period beginning on March 13, 2023 and ending on July 21, 2023. For the nine months ended September 30, 2023, we repurchased $361 million principal amount of these senior notes for approximately $358 million cash. In August 2023, we repaid the remaining $1.2 billion aggregate principal amount of our 0.650% senior notes due on their maturity date of August 3, 2023.

In March 2023, we issued $500 million of 5.700% unsecured senior notes due March 13, 2026 and $750 million of 5.500% unsecured senior notes due March 15, 2053. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.2 billion. We used the net proceeds to repay outstanding amounts under our $500 million Delayed Draw Term Loan. The remaining net proceeds will be used for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.

In August 2022, we repaid the $2.0 billion October 2021 Term Loan Agreement without a prepayment penalty due.

In March 2022, we issued $750 million of 3.700% unsecured senior notes due March 23, 2029. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $744 million.

Net proceeds from the issuance of commercial paper were $1.6 billion in the 2023 period and net repayments from the issuance of commercial paper were $660 million in the 2022 period. The maximum principal amount outstanding at any one time during the 2023 period was $2.3 billion.

We repurchased common shares for $980 million and $1.0 billion in the 2023 period and 2022 period, respectively, under share repurchase plans authorized by the Board of Directors. We also acquired common shares in connection with employee stock plans for $31 million and $32 million in the 2023 period and 2022 period, respectively.

We paid dividends to stockholders of $320 million during the 2023 period and $291 million during the 2022 period.

Future Sources and Uses of Liquidity

Dividends

For additional information regarding our dividends to stockholders, refer to Note 10 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

51

Stock Repurchases

For additional information regarding stock repurchases, refer to Note 10 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

Debt

For additional information regarding debt, including our senior notes, term loans, revolving credit agreements, commercial paper program and other short-term borrowings, refer to Note 12 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

Divestiture

On August 11, 2022, we completed the sale of a 60% interest in Gentiva Hospice to CD&R, for cash proceeds of approximately $2.7 billion, net of cash disposed, including debt repayments from Gentiva Hospice to Humana of $1.9 billion. In connection with the sale we recognized a pre-tax gain, net of transaction costs, of $240 million.

For additional information regarding the divestiture, refer to Note 3 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

Liquidity Requirements

We believe our cash balances, investment securities, operating cash flows, and funds available under our credit agreement and our commercial paper program or from other public or private financing sources, taken together, provide adequate resources to fund ongoing operating and regulatory requirements, acquisitions, future expansion opportunities, and capital expenditures for at least the next twelve months, as well as to refinance or repay debt, and repurchase shares.

Adverse changes in our credit rating may increase the rate of interest we pay and may impact the amount of credit available to us in the future. Our investment-grade credit rating at September 30, 2023 was BBB+ according to Standard & Poor’s Rating Services, or S&P, and Baa2 according to Moody’s Investors Services, Inc., or Moody’s. A downgrade by S&P to BB+ or by Moody’s to Ba1 triggers an interest rate increase of 25 basis points with respect to $250 million of our senior notes. Successive one notch downgrades increase the interest rate an additional 25 basis points, or annual interest expense by $1 million, up to a maximum 100 basis points, or annual interest expense by $3 million.

In addition, we operate as a holding company in a highly regulated industry. Humana Inc., our parent company, is dependent upon dividends and administrative expense reimbursements from our subsidiaries, most of which are subject to regulatory restrictions. We continue to maintain significant levels of aggregate excess statutory capital and surplus in our state-regulated operating subsidiaries. Cash, cash equivalents, and short-term investments at the parent company were $518 million at September 30, 2023 compared to $934 million at December 31, 2022. This decrease primarily reflects common stock repurchases, repayment of the Delayed Draw Term Loan and senior notes, capital expenditures, repayment of borrowings under the commercial paper program, capital contributions to certain subsidiaries, cash dividends to shareholders and acquisitions partially offset by net proceeds from the issuance of senior notes and commercial paper, the sale of investment securities, dividends from insurance subsidiaries and cash from certain non-insurance subsidiaries within our CenterWell segment. Our use of operating cash derived from our non-insurance subsidiaries, such as our CenterWell segment, is generally not restricted by departments of insurance (or comparable state regulators).

Regulatory Requirements

Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity’s level of statutory income and statutory capital and surplus. If the dividend, together with other dividends paid within the preceding twelve months,

52

exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an extraordinary dividend requiring prior regulatory approval. In most states, prior notification is provided before paying a dividend even if approval is not required.

Although minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements vary significantly at the state level. Based on the most recently filed statutory financial statements as of June 30, 2023, our state regulated subsidiaries had aggregate statutory capital and surplus of approximately $12.1 billion, which exceeded aggregate minimum regulatory requirements of $9.1 billion. The amount of ordinary dividends paid to our parent company was approximately $661 million during the nine months ended September 30, 2023. The amount, timing and mix of ordinary and extraordinary dividend payments will vary due to state regulatory requirements, the level of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix.

53

Item 3.    Quantitative and Qualitative Disclosures about Market Risk

Our earnings and financial position are exposed to financial market risk, including those resulting from changes in interest rates.

Interest rate risk also represents a market risk factor affecting our consolidated financial position due to our significant investment portfolio, consisting primarily of fixed maturity securities of investment-grade quality with a weighted average S&P credit rating of AA at September 30, 2023. Our net unrealized position increased $259 million from a net unrealized loss position of $1.7 billion at December 31, 2022 to a net unrealized loss position of $2.0 billion at September 30, 2023. At September 30, 2023, we had gross unrealized losses of $2.0 billion on our investment portfolio primarily due to an increase in market interest rates since the time the securities were purchased. There were no material credit allowances during the nine months ended September 30, 2023. While we believe that these securities in an unrealized loss will recover in value over time and we currently do not have the intent to sell such securities, given the current market conditions and the significant judgments involved, there is a continuing risk that future declines in fair value may occur and material realized losses from sales or credit allowances may be recorded in future periods.

Duration is the time-weighted average of the present value of the bond portfolio’s cash flow. Duration is indicative of the relationship between changes in fair value and changes in interest rates, providing a general indication of the sensitivity of the fair values of our fixed maturity securities to changes in interest rates. However, actual fair values may differ significantly from estimates based on duration. The average duration of our investment portfolio, including cash and cash equivalents, was approximately 2.9 years as of September 30, 2023 and December 31, 2022. Based on the duration, including cash equivalents, a 1% increase in interest rates would generally decrease the fair value of our securities by approximately $654 million at September 30, 2023.

Item 4.    Controls and Procedures

Under the supervision and with the participation of our Chief Executive Officer, or CEO, our Chief Financial Officer, or CFO, and our Principal Accounting Officer, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures for the quarter ended September 30, 2023.

Based on our evaluation, our CEO, CFO, and our Principal Accounting Officer concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information the Company is required to disclose in its reports under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, including, without limitation, ensuring that such information is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

54

Part II. Other Information

Item 1.     Legal Proceedings

For additional information regarding legal proceedings pending against us and certain other pending or threatened litigation, investigations or other matters, refer to “Legal Proceedings and Certain Regulatory Matters” in Note 13 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

Item 1A. Risk Factors

There have been no changes to the risk factors included in our 2022 Form 10-K.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

(a)None.

(b)N/A

(c)The following table provides information about our purchases of equity securities that are registered by us pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, during the three months ended September 30, 2023:

Period	Total Number of Shares Purchased (1)(2)	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)(2)	Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (1) (2)
July 2023	368,823	$	442.65	368,823	$	2,241,914,412
August 2023	287,179	484.30		287,179	2,102,834,796
September 2023	154,886	473.51		154,886	2,029,494,351
Total	810,888	$	—	810,888

(1)On February 15, 2023, the Board of Directors replaced the previous share repurchase authorization of up to $3 billion (of which approximately $1 billion remained unused) with a new authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2026. Our remaining repurchase authorization was $1.9 billion as of October 31, 2023.

(2)Excludes 61,733 shares repurchased in connection with employee stock plans.

Item 3.     Defaults Upon Senior Securities

None.

Item 4.     Mine Safety Disclosures

Not applicable.

55

Item 5.     Other Information

a.None.

b.None.

c.During the three months ended September 30, 2023, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

56

Item 6:     Exhibits

3(i)	Restated Certificate of Incorporation of Humana Inc. filed with the Secretary of State of Delaware on November 9, 1989, as restated to incorporate the amendment of January 9, 1992, and the correction of March 23, 1992 (incorporated herein by reference to Exhibit 4(i) to Humana Inc.’s Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (Reg. No. 33-49305) filed February 2, 1994).
3(ii)	Humana Inc. Amended and Restated By-laws, effective as of December 8, 2022 (incorporated herein by reference to Exhibit 3(b) to Humana Inc.’s Current Report on Form 8-K filed on December 8, 2022).
31.1	Principal Executive Officer certification pursuant to Section 302 of Sarbanes–Oxley Act of 2002.
31.2	Principal Financial Officer certification pursuant to Section 302 of Sarbanes–Oxley Act of 2002.
32	Principal Executive Officer and Principal Financial Officer certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	The following materials from Humana Inc.'s Quarterly Report on Form 10-Q formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets at September 30, 2023 and December 31, 2022; (ii) the Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2023 and 2022; (iii) the Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2023 and 2022; (iv) the Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2023 and 2022; (v) the Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022; and (vi) Notes to Condensed Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104	Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.

57

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			HUMANA INC.
			(Registrant)
Date:	November 1, 2023	By:	/s/ JOHN-PAUL W. FELTER
			John-Paul W. Felter
			Senior Vice President, Chief Accounting Officer and Controller (Principal Accounting Officer)

58

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002

I, Bruce D. Broussard, principal executive officer of Humana Inc., certify that:

1. I have reviewed this Report of Humana Inc. (the "Company") on Form 10-Q for the period ending September 30, 2023;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	November 1, 2023
Signature:	/s/ Bruce D. Broussard
	Bruce D. Broussard Principal Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002

I, Susan M. Diamond, principal financial officer of Humana Inc., certify that:

1. I have reviewed this Report of Humana Inc. (the "Company") on Form 10-Q for the period ending September 30, 2023;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	November 1, 2023
Signature:	/s/ Susan M. Diamond
	Susan M. Diamond Principal Financial Officer

EX-32

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Report of Humana Inc. (the "Company") on Form 10-Q for the period ending September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned hereby certifies, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, in their capacity as an officer of Humana Inc., that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Bruce D. Broussard

Bruce D. Broussard
Principal Executive Officer

November 1, 2023

/s/ Susan M. Diamond

Susan M. Diamond
Principal Financial Officer

November 1, 2023

A signed original of this written statement required by Section 906 has been provided to Humana Inc. and will be retained by Humana Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Cover	9 Months Ended
	Sep. 30, 2023 shares
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	1-5975
Entity Registrant Name	HUMANA INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	61-0647538
Entity Address, Address Line One	500 West Main Street
Entity Address, City or Town	Louisville
Entity Address, State or Province	KY
Entity Address, Postal Zip Code	40202
City Area Code	502
Local Phone Number	580-1000
Title of 12(b) Security	Common stock, $0.16 2/3 par value
Trading Symbol	HUM
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	123,110,720
Entity Central Index Key	0000049071
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 15,148	$ 5,061
Investment securities	15,145	13,881
Receivables, net of allowances of $73 in 2023 and $70 in 2022	1,824	1,674
Other current assets	6,136	5,567
Total current assets	38,253	26,183
Property and equipment, net	3,342	3,221
Long-term investment securities	370	380
Equity method investments	762	749
Goodwill	9,540	9,142
Other long-term assets	3,638	3,380
Total assets	55,905	43,055
Current liabilities:
Benefits payable	10,196	9,264
Trade accounts payable and accrued expenses	7,600	5,238
Book overdraft	246	298
Unearned revenues	7,536	286
Short-term debt	2,245	2,092
Total current liabilities	27,823	17,178
Long-term debt	9,483	9,034
Other long-term liabilities	1,595	1,473
Total liabilities	38,901	27,685
Stockholders’ equity:
Preferred stock, $1 par; 10,000,000 shares authorized; none issued	0	0
Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,690,082 shares issued at September 30, 2023 and 198,666,598 shares issued at December 31, 2022	33	33
Capital in excess of par value	3,362	3,246
Retained earnings	28,191	25,492
Accumulated other comprehensive loss	(1,503)	(1,304)
Treasury stock, at cost, 75,579,362 shares at September 30, 2023 and 73,691,955 shares at December 31, 2022	(13,134)	(12,156)
Total stockholders' equity	16,949	15,311
Noncontrolling interests	55	59
Total equity	17,004	15,370
Total liabilities and equity	$ 55,905	$ 43,055

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Receivables, net of allowances	$ 73	$ 70
Preferred stock, par (in dollars per share)	$ 1	$ 1
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par (in dollars per share)	$ 0.1667	$ 0.1667
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	198,690,082	198,666,598
Treasury stock, shares (in shares)	75,579,362	73,691,955

XML

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Health Care [Member]	Health Care [Member]	Health Care [Member]	Health Care [Member]
Revenues:
Premiums	$ 25,099	$ 21,468	$ 76,144	$ 66,437
Services	1,016	1,159	2,993	3,772
Investment income	308	172	775	222
Total revenues	26,423	22,799	79,912	70,431
Operating expenses:
Benefits	21,745	18,384	65,612	57,108
Operating costs	3,271	3,061	9,361	9,120
Depreciation and amortization	201	182	578	527
Total operating expenses	25,217	21,627	75,551	66,755
Income (loss) from operations	1,206	1,172	4,361	3,676
Gain on sale of Gentiva Hospice	0	(240)	0	(240)
Interest expense	114	102	347	293
Other (income) expense, net	(6)	13	40	(16)
Income (loss) before income taxes and equity in net losses	1,098	1,297	3,974	3,639
Provision for income taxes	256	107	911	820
Equity in net (losses) earnings	(12)	3	(39)	1
Net income	830	1,193	3,024	2,820
Net loss attributable to noncontrolling interests	2	2	6	1
Net income attributable to Humana	$ 832	$ 1,195	$ 3,030	$ 2,821
Basic earnings per common share (in dollars per share)	$ 6.74	$ 9.45	$ 24.37	$ 22.27
Diluted earnings per common share (in dollars per share)	$ 6.71	$ 9.39	$ 24.26	$ 22.16

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net income attributable to Humana	$ 832	$ 1,195	$ 3,030	$ 2,821
Other comprehensive income (loss):
Change in gross unrealized investment losses	(365)	(590)	(314)	(1,982)
Effect of income taxes	85	135	73	455
Total change in unrealized investment losses, net of tax	(280)	(455)	(241)	(1,527)
Reclassification adjustment for net realized losses	3	50	56	23
Effect of income taxes	0	(11)	(14)	(5)
Total reclassification adjustment, net of tax	3	39	42	18
Other comprehensive loss, net of tax	(277)	(416)	(199)	(1,509)
Comprehensive income attributable to Humana	$ 555	$ 779	$ 2,831	$ 1,312

XML

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Millions	Total	Total Stockholders' Equity	Common Stock	Capital In Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive (Loss) income	Treasury Stock	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2021			198,649
Beginning balance at Dec. 31, 2021	$ 16,103	$ 16,080	$ 33	$ 3,082	$ 23,086	$ 42	$ (10,163)	$ 23
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	2,820	2,821			2,821			(1)
Distribution from (to) noncontrolling interest holders, net	(1)							(1)
Sale of Gentiva Hospice	(11)							(11)
Acquisition	53							53
Other comprehensive loss	(1,509)	(1,509)				(1,509)
Common stock repurchases	(1,032)	(1,032)					(1,032)
Dividends and dividend equivalents	(301)	(301)			(301)
Stock-based compensation	173	173		173
Restricted stock unit vesting (in shares)			18
Restricted stock unit vesting	0			(31)			31
Stock option exercises	22	22		10			12
Ending balance (in shares) at Sep. 30, 2022			198,667
Ending balance at Sep. 30, 2022	16,317	16,254	$ 33	3,234	25,606	(1,467)	(11,152)	63
Beginning balance (in shares) at Jun. 30, 2022			198,667
Beginning balance at Jun. 30, 2022	15,510	15,490	$ 33	3,153	24,511	(1,051)	(11,156)	20
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,193	1,195			1,195			(2)
Distribution from (to) noncontrolling interest holders, net	3							3
Sale of Gentiva Hospice	(11)							(11)
Acquisition	53							53
Other comprehensive loss	(416)	(416)				(416)
Common stock repurchases	(4)	(4)					(4)
Dividends and dividend equivalents	(100)	(100)			(100)
Stock-based compensation	80	80		80
Restricted stock unit vesting	0			(3)			3
Stock option exercises	9	9		4			5
Ending balance (in shares) at Sep. 30, 2022			198,667
Ending balance at Sep. 30, 2022	16,317	16,254	$ 33	3,234	25,606	(1,467)	(11,152)	63
Beginning balance (in shares) at Dec. 31, 2022			198,667
Beginning balance at Dec. 31, 2022	15,370	15,311	$ 33	3,246	25,492	(1,304)	(12,156)	59
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	3,024	3,030			3,030			(6)
Distribution from (to) noncontrolling interest holders, net	7							7
Acquisition	(5)							(5)
Other comprehensive loss	(199)	(199)				(199)
Common stock repurchases	(1,011)	(1,011)					(1,011)
Dividends and dividend equivalents	(331)	(331)			(331)
Stock-based compensation	142	142		142
Restricted stock unit vesting (in shares)			23
Restricted stock unit vesting	0			(30)			30
Stock option exercises	7	7		4			3
Ending balance (in shares) at Sep. 30, 2023			198,690
Ending balance at Sep. 30, 2023	17,004	16,949	$ 33	3,362	28,191	(1,503)	(13,134)	55
Beginning balance (in shares) at Jun. 30, 2023			198,690
Beginning balance at Jun. 30, 2023	16,891	16,834	$ 33	3,313	27,468	(1,226)	(12,754)	57
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	830	832			832			(2)
Other comprehensive loss	(277)	(277)				(277)
Common stock repurchases	(383)	(383)					(383)
Dividends and dividend equivalents	(109)	(109)			(109)
Stock-based compensation	53	53		53
Restricted stock unit vesting	0			(3)			3
Stock option exercises	(1)	(1)		(1)
Ending balance (in shares) at Sep. 30, 2023			198,690
Ending balance at Sep. 30, 2023	$ 17,004	$ 16,949	$ 33	$ 3,362	$ 28,191	$ (1,503)	$ (13,134)	$ 55

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Net income	$ 3,024	$ 2,820
Adjustments to reconcile net income to net cash provided by operating activities:
Gain on sale of Gentiva Hospice	0	(240)
Loss on investment securities, net	49	136
Equity in net losses (earnings)	39	(1)
Stock-based compensation	142	173
Depreciation	628	555
Amortization	51	73
Impairment of property and equipment	31	144
Deferred income taxes	0	(33)
Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:
Receivables	(126)	11
Other assets	(935)	(465)
Benefits payable	870	948
Other liabilities	39	(195)
Unearned revenues	7,250	5,758
Other	53	30
Net cash provided by operating activities	11,115	9,714
Cash flows from investing activities
Proceeds from sale of Gentiva Hospice, net	0	2,708
Acquisitions, net of cash and cash equivalents acquired	(223)	(293)
Purchases of property and equipment, net	(721)	(862)
Purchases of investment securities	(3,366)	(4,740)
Proceeds from maturities of investment securities	885	1,214
Proceeds from sales of investment securities	815	1,979
Net cash (used in) provided by investing activities	(2,610)	6
Cash flows from financing activities
Receipts from contract deposits, net	2,481	3,787
Proceeds from issuance of senior notes, net	1,215	744
Repayments of senior notes	(1,719)	0
Proceeds from issuance (repayments) of commercial paper, net	1,618	(660)
Repayment of term loan	(500)	(2,000)
Debt issue costs	(4)	(2)
Change in book overdraft	(52)	(89)
Common stock repurchases	(1,002)	(1,032)
Dividends paid	(320)	(291)
Other	(135)	(13)
Net cash provided by financing activities	1,582	444
Increase in cash and cash equivalents	10,087	10,164
Cash and cash equivalents at beginning of period	5,061	3,394
Cash and cash equivalents at end of period	15,148	13,558
Supplemental cash flow disclosures:
Interest payments	317	256
Income tax payments, net	957	751
Details of businesses acquired in purchase transactions:
Fair value of assets acquired, net of cash and cash equivalents acquired	454	411
Less: Fair value of liabilities assumed	(236)	(65)
Less: Noncontrolling interests acquired	5	(53)
Cash paid for acquired businesses, net of cash and cash equivalents acquired	$ 223	$ 293

XML

BASIS OF PRESENTATION AND SIGNIFICANT EVENTS

9 Months Ended

Sep. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION AND SIGNIFICANT EVENTS

BASIS OF PRESENTATION AND SIGNIFICANT EVENTS

The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2022, that was filed with the Securities and Exchange Commission, or the SEC, on February 16, 2023. We refer to this Form 10-K as the “2022 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.

The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.

Employer Group Commercial Medical Products Business Exit

In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.

Value Creation Initiatives

During 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities beginning in 2023, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, during the three and nine months ended September 30, 2022, we recorded charges of $82 million and $285 million, respectively. For the three and nine months ended September 30, 2022, these charges primarily relate to $4 million and $144 million, respectively, in asset impairments, including software and abandonment, and $44 million and $65 million, respectively, of severance charges in connection with workforce optimization. The remainder of the charges primarily relate to external consulting fees. During the three months ended September 30, 2023, we recorded charges of $52 million primarily in asset impairments relating to software and abandonment. In connection with these initiatives, we expect to incur additional charges through the end of 2024. These charges are recorded at the corporate level and not allocated to the segments.

COVID-19

The emergence and spread of the novel coronavirus, or COVID-19, beginning in the first quarter of 2020 has impacted our business. Initially during periods of increased incidences of COVID-19, a reduction in non-COVID-19 hospital admissions for non-emergent and elective medical care have resulted in lower overall healthcare system utilization. At the same time, COVID-19 treatment and testing costs increased utilization. During 2022, we experienced lower overall utilization of the healthcare system than anticipated, as the reduction in COVID-19 utilization following the increased incidence associated with the Omicron variant outpaced the increase in non-COVID-19 utilization. The significant disruption in utilization during 2020 also impacted our ability to implement clinical initiatives to manage health care costs and chronic conditions of our members, and appropriately document their risk profiles, and, as such, significantly affected our 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2021 as a result of the COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and shifting the timing of claim payments and provider capitation surplus payments, impacted our claim reserve development and operating cash flows for 2021.

The COVID-19 National Emergency declared in 2020 was terminated on April 10, 2023 and the Public Health Emergency expired on May 11, 2023.

Revenue Recognition

Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

At September 30, 2023, accounts receivable related to services were $322 million. For the three and nine months ended September 30, 2023, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the condensed consolidated balance sheet at September 30, 2023.

For the three and nine months ended September 30, 2023, services revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. Further, services revenue expected to be recognized in any future year related to remaining performance obligations was not material.

XML

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

9 Months Ended

Sep. 30, 2023

Accounting Standards Update and Change in Accounting Principle [Abstract]

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTSIn November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The new guidance relates to accounting for long-duration contracts of insurers which revises key elements of the measurement models and disclosure requirements for long-duration contracts issued by insurers, including the amortization of deferred contract acquisition costs and the measurement of liabilities for future policy benefits using current, rather than locked-in, assumptions. The new guidance, limited to our Medicare Supplement product which represents less than 1% of consolidated premiums and services revenue, became effective for us beginning January 1, 2023 and is to be applied to contracts in force on the basis of their

existing carrying value amounts at the beginning of the earliest period presented. The adoption of the new standard in 2023 did not have a material impact on our consolidated results of operations, financial position or cash flows.

There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.

XML

ACQUISITIONS AND DIVESTITURES

9 Months Ended

Sep. 30, 2023

Business Combination and Asset Acquisition [Abstract]

ACQUISITIONS AND DIVESTITURES

ACQUISITIONS AND DIVESTITURES

On August 11, 2022, we completed the sale of a 60% interest in Gentiva (formerly Kindred) Hospice to Clayton, Dubilier & Rice, or CD&R, for cash proceeds of approximately $2.7 billion, net of cash disposed, including debt repayments from Gentiva Hospice to Humana of $1.9 billion. In connection with the sale we recognized a pre-tax gain, net of transaction costs, of $240 million. For the three and nine months ended September 30, 2022, the accompanying condensed consolidated statement of income includes revenues related to Gentiva Hospice of $177 million and $958 million, respectively, and pretax earnings of $24 million and $150 million, respectively.

During 2023 and 2022, we acquired various health and wellness related businesses which, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows. The results of operations and financial condition of these businesses acquired in 2023 and 2022 have been included in our condensed consolidated statements of income and condensed consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in 2023 and 2022 were not material to our results of operations. For asset acquisitions, the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the year of acquisition, were not material for disclosure purposes.

XML

INVESTMENT SECURITIES

9 Months Ended

Sep. 30, 2023

Investments, Debt and Equity Securities [Abstract]

INVESTMENT SECURITIES

INVESTMENT SECURITIES

Investment securities classified as current and long-term were as follows at September 30, 2023 and December 31, 2022, respectively:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
	(in millions)
September 30, 2023
U.S. Treasury and other U.S. government     corporations and agencies:
U.S. Treasury and agency obligations	$	2,043	$	—	$	(105)	$	1,938
Mortgage-backed securities	3,890		—		(637)		3,253
Tax-exempt municipal securities	848		—		(50)		798
Mortgage-backed securities:
Residential	497		—		(85)		412
Commercial	1,475		—		(155)		1,320
Asset-backed securities	1,849		—		(65)		1,784
Corporate debt securities	6,864		14		(868)		6,010
Total debt securities	$	17,466	$	14	$	(1,965)	15,515
Common stock							—
Total investment securities							$	15,515
December 31, 2022
U.S. Treasury and other U.S. government     corporations and agencies:
U.S. Treasury and agency obligations	$	1,093	$	1	$	(55)	$	1,039
Mortgage-backed securities	3,697		4		(471)		3,230
Tax-exempt municipal securities	765		—		(37)		728
Mortgage-backed securities:
Residential	477		—		(76)		401
Commercial	1,554		—		(155)		1,399
Asset-backed securities	1,809		1		(79)		1,731
Corporate debt securities	6,551		3		(828)		5,726
Total debt securities	$	15,946	$	9	$	(1,701)	14,254
Common stock							7
Total investment securities							$	14,261

We held certain corporate debt securities of Gentiva Hospice at September 30, 2023 with amortized cost and fair value of approximately $281 million and $295 million, respectively.

Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at September 30, 2023 and December 31, 2022, respectively:

	Less than 12 months				12 months or more				Total
	Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses
	(in millions)
September 30, 2023
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	1,483	$	(51)	$	407	$	(54)	$	1,890	$	(105)
Mortgage-backed securities	1,084		(66)		2,169		(571)		3,253		(637)
Tax-exempt municipal securities	278		(6)		515		(44)		793		(50)
Mortgage-backed securities:
Residential	48		(1)		363		(84)		411		(85)
Commercial	15		—		1,304		(155)		1,319		(155)
Asset-backed securities	343		(6)		1,430		(59)		1,773		(65)
Corporate debt securities	961		(35)		4,648		(833)		5,609		(868)
Total debt securities	$	4,212	$	(165)	$	10,836	$	(1,800)	$	15,048	$	(1,965)
December 31, 2022
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	512	$	(5)	$	397	$	(50)	$	909	$	(55)
Mortgage-backed securities	1,231		(104)		1,683		(367)		2,914		(471)
Tax-exempt municipal securities	64		(2)		615		(36)		679		(38)
Mortgage-backed securities:
Residential	124		(16)		274		(60)		398		(76)
Commercial	243		(13)		1,157		(142)		1,400		(155)
Asset-backed securities	620		(32)		1,011		(46)		1,631		(78)
Corporate debt securities	1,625		(98)		3,825		(730)		5,450		(828)
Total debt securities	$	4,419	$	(270)	$	8,962	$	(1,431)	$	13,381	$	(1,701)

Approximately 98% of our debt securities were investment-grade quality, with a weighted average credit rating of AA by Standard & Poor's Rating Service, or S&P, at September 30, 2023. Most of the debt securities that were below investment-grade were rated BB-, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding approximately 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.

Our unrealized losses from all debt securities were generated from approximately 1,790 positions out of a total of approximately 2,070 positions at September 30, 2023. All issuers of debt securities we own that were trading at an unrealized loss at September 30, 2023 remain current on all contractual payments. After taking into account these

and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time these debt securities were purchased. At September 30, 2023, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position for the three and nine months ended September 30, 2023 or 2022.

The detail of gains (losses) related to investment securities and included within investment income was as follows for the three and nine months ended September 30, 2023 and 2022:

	Three months ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(in millions)				(in millions)
Gross gains on investment securities	$	—	$	2	$	15	$	41
Gross losses on investment securities	(4)		(52)		(65)		(58)
Gross gains on equity securities	—		51		1		51
Gross losses on equity securities	—		—		—		(170)
Net recognized (losses) gains on investment securities	$	(4)	$	1	$	(49)	$	(136)

The gains and losses related to equity securities for the three and nine months ended September 30, 2023 and 2022 was as follows:

	Three months ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(in millions)				(in millions)
Net gains (losses) recognized on equity securities during the period	$	—	$	51	$	1	$	(119)
Less: Net gains (losses) recognized on equity securities sold during the period	—		47		—		(105)
Unrealized gains (losses) recognized on equity securities still held at the end of the period	$	—	$	4	$	1	$	(14)

The contractual maturities of debt securities available for sale at September 30, 2023, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

	Amortized Cost		Fair Value
	(in millions)
Due within one year	$	659	$	654
Due after one year through five years	4,850		4,565
Due after five years through ten years	3,017		2,573
Due after ten years	1,229		954
Mortgage and asset-backed securities	7,711		6,769
Total debt securities	$	17,466	$	15,515

For additional information regarding our investment securities, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

XML

FAIR VALUE

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

FAIR VALUE

FAIR VALUE

Financial Assets

The following table summarizes our fair value measurements at September 30, 2023 and December 31, 2022, respectively, for financial assets measured at fair value on a recurring basis:

	Fair Value Measurements Using
	Fair Value		Quoted Prices in Active Markets (Level 1)		Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
	(in millions)
September 30, 2023
Cash equivalents	$	15,035	$	15,035	$	—	$	—
Debt securities:
U.S. Treasury and other U.S. government     corporations and agencies:
U.S. Treasury and agency obligations	1,938		—		1,938		—
Mortgage-backed securities	3,253		—		3,253		—
Tax-exempt municipal securities	798		—		798		—
Mortgage-backed securities:
Residential	412		—		412		—
Commercial	1,320		—		1,320		—
Asset-backed securities	1,784		—		1,784		—
Corporate debt securities	6,010		—		5,905		105
Total debt securities	15,515		—		15,410		105
Total invested assets	$	30,550	$	15,035	$	15,410	$	105
December 31, 2022
Cash equivalents	$	4,832	$	4,832	$	—	$	—
Debt securities:
U.S. Treasury and other U.S. government     corporations and agencies:
U.S. Treasury and agency obligations	1,039		—		1,039		—
Mortgage-backed securities	3,230		—		3,230		—
Tax-exempt municipal securities	728		—		728		—
Mortgage-backed securities:
Residential	401		—		401		—
Commercial	1,399		—		1,399		—
Asset-backed securities	1,731		—		1,731		—
Corporate debt securities	5,726		—		5,625		101
Total debt securities	14,254		—		14,153		101
Common stock	7		7		—		—
Total invested assets	$	19,093	$	4,839	$	14,153	$	101

Our Level 3 assets had a fair value of $105 million at September 30, 2023, or 0.3% of our total invested assets. During the nine months ended September 30, 2023 and 2022, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:

	For the nine months ended September 30, 2023		For the nine months ended September 30, 2022
	Private Placements
	(in millions)
Beginning balance at January 1	$	101	$	68
Total gains or losses:
Realized in earnings	—		—
Unrealized in other comprehensive income	(1)		—
Purchases	13		(12)
Sales	—		44
Maturities	(4)		—
Transfer out	(4)
Balance at September 30	$	105	$	100

Interest Rate Swaps

During the third quarter of 2023, we entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on our $750 million of 5.875% senior notes and our $750 million of 5.500% senior notes from fixed rates to variable rates to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities. Our swap agreements, which are considered derivative instruments, exchange the fixed interest rate under our 5.875% and 5.500% senior notes for a variable interest rate based on SOFR. Interest rate swaps with notional amounts of $650 million, maturing September 1, 2032, and $250 million, maturing March 15, 2033, were outstanding on our 5.875% and 5.500% senior notes, respectively, at September 30, 2023. These swap agreements were qualified and designated as a fair value hedge. The swap liability, included within other long-term liabilities on our condensed consolidated balance sheet, was not material at September 30, 2023. We include the gain or loss on the swap agreements in interest expense on our condensed consolidated income statement, the same line item as the offsetting loss or gain on the related senior notes. The gain or loss due to hedge ineffectiveness was not material for the three and nine months ended September 30, 2023.

Financial Liabilities

Our debt is recorded at carrying value in our consolidated balance sheets. The carrying value of our senior notes debt outstanding, net of unamortized debt issuance costs, was $9.5 billion at September 30, 2023 and $10.0 billion at December 31, 2022. The fair value of our senior notes debt was $8.7 billion at September 30, 2023 and $9.4 billion at December 31, 2022. The fair value of our senior notes debt is determined based on Level 2 inputs, including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities. Carrying value approximates fair value for our term loans and commercial paper borrowings. The commercial paper borrowings were $2.2 billion at September 30, 2023. The term loans and commercial paper borrowings were $1.1 billion at December 31, 2022.

Put and Call Options Measured at Fair Value

Our put and call options associated with our equity method investments are measured at fair value each period using a Monte Carlo simulation.

The put and call options fair values associated with our Primary Care Organization strategic partnership with Welsh, Carson, Anderson & Stowe, or WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte

Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $410 million and $12 million, respectively, at September 30, 2023. The put and call options fair values, derived from the Monte Carlo simulation, were $267 million and $10 million, respectively, at December 31, 2022. The put liability and call asset are included within other long-term liabilities and other long-term assets, respectively, within our condensed consolidated balance sheets.

The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, annualized volatility and credit spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term revenue, to measure underlying cash flows, weighted average cost of capital and long term growth rate. The table below presents the assumptions used for each reporting period.

	September 30, 2023		December 31, 2022
Annualized volatility	16.6% - 19.6%		16.7% - 20.8%
Credit spread	0.9% - 1.4%		1.3% - 1.5%
Revenue exit multiple	1.5x - 2.5x		1.5x - 2.5x
Weighted average cost of capital	12.0% - 13.0%		11.5% - 12.5%
Long term growth rate	3.0	%	3.0	%

The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.

Other Assets and Liabilities Measured at Fair Value

Certain assets and liabilities are measured at fair value on a non-recurring basis subject to fair value adjustment only in certain circumstances. As disclosed in Note 3, we acquired various health and wellness related businesses during 2023. The net assets acquired and resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs. The net tangible assets including receivables and accrued liabilities were recorded at their carrying value which approximated their fair value due to their short term nature. The fair value of goodwill and other intangible assets were internally estimated based primarily on the income approach. The income approach estimates fair value based on the present value of cash flow that the assets could be expected to generate in the future. We developed internal estimates for expected cash flows in the present value calculation using inputs and significant assumptions that include historical revenues and earnings, revenue growth rates, the amount and timing of future cash flows, discount rates, contributory asset charges and future tax rates, among others. The excess purchase price over the fair value of assets and liabilities acquired is recorded as goodwill.

As disclosed in Note 3, we completed the sale of Gentiva Hospice on August 11, 2022. The carrying value of the assets and liabilities of Gentiva Hospice disposed approximates fair value. The amount of goodwill included in the carrying value is based on the relative fair value of the Home Solutions reporting unit included within the CenterWell segment.

Other than the assets and liabilities acquired during 2023, there were no other material assets or liabilities measured at fair value on a recurring or nonrecurring basis during 2023.

For additional information regarding our fair value measurements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

XML

MEDICARE PART D

9 Months Ended

Sep. 30, 2023

Insurance [Abstract]

MEDICARE PART D

MEDICARE PART D

We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with the Centers for Medicare and Medicaid Services, or CMS. The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at September 30, 2023 and December 31, 2022. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

	September 30, 2023				December 31, 2022
	Risk Corridor Settlement		CMS Subsidies/ Discounts		Risk Corridor Settlement		CMS Subsidies/ Discounts
	(in millions)
Other current assets	$	131	$	517	$	240	$	696
Trade accounts payable and accrued expenses	(150)		(3,566)		(166)		(1,236)
Net current (liability) asset	(19)		(3,049)		74		(540)
Other long-term assets	235		—		19		—
Other long-term liabilities	(123)		—		(78)		—
Net long-term asset (liability)	112		—		(59)		—
Total net asset (liability)	$	93	$	(3,049)	$	15	$	(540)

XML

GOODWILL AND OTHER INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the carrying amount of goodwill for our reportable segments for the nine months ended September 30, 2023 were as follows:

	Insurance		CenterWell		Total
	(in millions)
Balance at January 1, 2023	$	2,472	$	6,670	$	9,142
Acquisitions	191		207		398
Balance at September 30, 2023	$	2,663	$	6,877	$	9,540

The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at September 30, 2023 and December 31, 2022:

		September 30, 2023						December 31, 2022
	Weighted Average Life	Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net
		($ in millions)
Other intangible assets:
Certificates of need	Indefinite	$	1,132	$	—	$	1,132	$	1,132	$	—	$	1,132
Medicare licenses	Indefinite	302		—		302		286		—		286
Customer contracts/     relationships	9.4 years	955		708		247		929		673		256
Trade names and     technology	6.7 years	139		106		33		142		107		35
Provider contracts	11.6 years	73		64		9		73		63		10
Noncompetes and     other	8.4 years	84		42		42		86		40		46
Total other intangible     assets	9.2 years	$	2,685	$	920	$	1,765	$	2,648	$	883	$	1,765

    For the three months ended September 30, 2023 and 2022, amortization expense for other intangible assets was approximately $17 million and $25 million, respectively. For the nine months ended September 30, 2023 and 2022, amortization expense for other intangible assets was approximately $51 million and $61 million, respectively. The following table presents our estimate of amortization expense remaining for 2023 and each of the next five succeeding years at September 30, 2023:

	(in millions)
For the years ending December 31,
2023	$	15
2024	60
2025	58
2026	44
2027	34
2028	29

For additional information regarding our goodwill and intangible assets, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

XML

BENEFITS PAYABLE

9 Months Ended

Sep. 30, 2023

Insurance [Abstract]

BENEFITS PAYABLE

BENEFITS PAYABLE

On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the nine months ended September 30, 2023 and 2022:

	For the nine months ended September 30,
	2023		2022
	(in millions)
Balances, beginning of period	$	9,264	$	8,289
Acquisitions	62		—
Incurred related to:
Current year	66,370		57,512
Prior years	(758)		(404)
Total incurred	65,612		57,108
Paid related to:
Current year	(56,700)		(48,835)
Prior years	(8,042)		(7,325)
Total paid	(64,742)		(56,160)
Balances, end of period	$	10,196	$	9,237

The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net incurred claims amounts. At September 30, 2023, benefits payable included IBNR of approximately $6.4 billion, primarily associated with claims incurred in 2023.

Amounts incurred related to prior periods vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development).

Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

XML

EARNINGS PER COMMON SHARE COMPUTATION

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

EARNINGS PER COMMON SHARE COMPUTATION

EARNINGS PER COMMON SHARE COMPUTATION

Detail supporting the computation of basic and diluted earnings per common share was as follows for the three and nine months ended September 30, 2023 and 2022:

	Three months ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders	$	832	$	1,195	$	3,030	$	2,821
Weighted average outstanding shares of common stock     used to compute basic earnings per common share	123,426		126,572		124,335		126,678
Dilutive effect of:
Employee stock options	26		61		31		50
Restricted stock	531		723		519		577
Shares used to compute diluted earnings per common share	123,983		127,356		124,885		127,305
Basic earnings per common share	$	6.74	$	9.45	$	24.37	$	22.27
Diluted earnings per common share	$	6.71	$	9.39	$	24.26	$	22.16
Number of antidilutive stock options and restricted stock     excluded from computation	137		78		251		267

For additional information regarding earnings per common share, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

XML

STOCKHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

STOCKHOLDERS' EQUITY

STOCKHOLDERS’ EQUITY

Dividends

The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2023 under our Board approved quarterly cash dividend policy:

Record Date	Payment Date	Amount per Share		Total Amount
				(in millions)
12/30/2022	1/27/2023	$	0.7875	$	98
03/31/2023	04/28/2023	$	0.8850	$	111
06/30/2023	07/28/2023	$	0.8850	$	110
9/29/2023	10/27/2023	$	0.8850	$	109

In October 2023, the Board declared a cash dividend of $0.885 per share payable on January 26, 2024 to stockholders of record as of the close of business on December 29, 2023. Declaration and payment of future quarterly dividends are at the discretion of our Board and may be adjusted as business needs or market conditions change.

Stock Repurchases

Our Board of Directors may authorize the purchase of our common stock shares. Under the share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as

amended, or in privately-negotiated transactions, including pursuant to accelerated share repurchase agreements with investment banks, subject to certain regulatory restrictions on volume, pricing, and timing.

On February 15, 2023, the Board of Directors replaced the previous share repurchase authorization of up to $3 billion (of which approximately $1 billion remained unused) with a new authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2026. During the nine months ended September 30, 2023, we repurchased 2.0 million shares in open market transactions for $980 million at an average price of $478.20 under the current share repurchase authorization. During the nine months ended September 30, 2022, we did not repurchase shares in open market transactions.

Our remaining repurchase authorization was $1.9 billion as of October 31, 2023.

In connection with employee stock plans, we acquired 0.06 million common shares for $31 million and 0.07 million common shares for $32 million during the nine months ended September 30, 2023 and 2022, respectively.

For additional information regarding our stockholders' equity, refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

XML

INCOME TAXES

9 Months Ended

Sep. 30, 2023

Income Tax Disclosure [Abstract]

INCOME TAXES

INCOME TAXES

The effective income tax rate was 23.5% and 23.1% for the three and nine months ended September 30, 2023, respectively, and 8.2% and 22.5% for the three and nine months ended September 30, 2022, respectively. The year-over-year increase in the effective income tax rate is primarily due to the August 2022 disposition of our 60% interest in Gentiva Hospice, which resulted in an increase to our tax basis in both the shares sold and the shares retained, thereby reducing the effective income tax rate for the three and nine months ended September 30, 2022.

For additional information regarding income taxes, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

XML

DEBT

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

DEBT

DEBT

The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(in millions)
Short-term debt:
Commercial paper	$	2,245	$	595
Senior notes:
$1.5 billion, 0.650% due August 3, 2023	—		1,497
Total senior notes	—		1,497
Total short-term debt	$	2,245	$	2,092
Long-term debt:
Senior notes:
$600 million, 3.850% due October 1, 2024	$	572	$	599
$600 million, 4.500% due April 1, 2025	598		597
$500 million, 5.700% due March 13, 2026	497		—
$750 million, 1.350% due February 3, 2027	688		745
$600 million, 3.950% due March 15, 2027	537		597
$500 million, 5.750% due March 1, 2028	495		494
$750 million, 3.700% due March 23, 2029	689		743
$500 million, 3.125% due August 15, 2029	458		496
$500 million, 4.875% due April 1, 2030	496		495
$750 million, 2.150% due February 3, 2032	743		743
$750 million, 5.875% due March 1, 2033	715		739
$250 million, 8.150% due June 15, 2038	261		261
$400 million, 4.625% due December 1, 2042	396		396
$750 million, 4.950% due October 1, 2044	740		740
$400 million, 4.800% due March 15, 2047	396		396
$500 million, 3.950% due August 15, 2049	493		493
$750 million, 5.500% due March 15, 2053	709		—
Total senior notes	9,483		8,534
Term loans:
Delayed draw term loan, due May 28, 2024	—		500
Total term loans	—		500
Total long-term debt	$	9,483	$	9,034

Senior Notes

In March 2023, we issued $500 million of 5.700% unsecured senior notes due March 13, 2026 and $750 million of 5.500% unsecured senior notes due March 15, 2053. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.2 billion. We used the net proceeds to repay outstanding amounts under our $500 million Delayed Draw Term Loan. The remaining net proceeds will be used for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.

In August 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $750 million aggregate principal amount of 1.350% senior notes maturing in February 2027, our $600 million aggregate principal amount of 3.950% senior notes maturing in March 2027, our $750 million aggregate principal amount of 3.700%

senior notes maturing in March 2029, and our $500 million aggregate principal amount of 3.125% senior notes maturing in August 2029 during the period beginning on August 7, 2023 and ending on November 15, 2023. For the three months ended September 30, 2023, we repurchased $213 million principal amount of these senior notes for approximately $196 million cash.

In March 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $1.5 billion aggregate principal amount of 0.650% senior notes maturing in August 2023 and our $600 million aggregate principal amount of 3.850% senior notes maturing in October 2024 during the period beginning on March 13, 2023 and ending on July 21, 2023. For the nine months ended September 30, 2023, we repurchased $361 million principal amount of these senior notes for approximately $358 million cash. In August 2023, we repaid the remaining $1.2 billion aggregate principal amount of our 0.650% senior notes due on their maturity date of August 3, 2023.

During the third quarter of 2023, we entered into interest rate swap agreements to exchange the fixed interest rate under our 5.875% and 5.500% senior notes for a variable interest rate based on SOFR, as further described in Note 5. As a result, the carrying value of these senior notes has been adjusted to reflect changes in value caused by an increase or decrease in interest rates. The cumulative, aggregate adjustment to the carrying value of the 5.875% and 5.500% senior notes was $26 million and $5 million, respectively, at September 30, 2023.

For additional information regarding our Senior Notes, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Revolving Credit Agreements

In June 2023, we entered into an amended and restated 5-year, $2.5 billion unsecured revolving credit agreement (replacing the 5-year, $2.5 billion unsecured revolving credit agreement entered in June 2021) and entered into a 364-day $1.5 billion unsecured revolving credit agreement (replacing the 364-day $1.5 billion unsecured revolving credit agreement entered in June 2022, which expired in accordance with its terms).

Under the credit agreements, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at Term SOFR or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based Term SOFR, at our option.

The SOFR spread, currently 103.5 basis points under the 5-year revolving credit agreement and 105.5 basis points under the 364-day revolving credit agreement, varies depending on our credit ratings ranging from 92.0 to 130.0 basis points under the 5-year revolving credit agreement and from 94.0 to 135.0 basis points under the 364-day revolving credit agreement. We also pay an annual facility fee regardless of utilization. This facility fee, currently 9.0 basis points, under the 5-year revolving credit agreement and 7.0 basis points under the 364-day revolving agreement, varies depending on our credit ratings ranging from 8.0 to 20.0 basis points under the 5-year revolving credit agreement and from 6.0 to 15.0 basis points under the 364-day revolving credit agreement.

Our credit agreements contain customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 60%, as well as customary events of default. We are in compliance with this financial covenant, with actual debt to capitalization of 41.1% as measured in accordance with the revolving credit agreements as of September 30, 2023.

At September 30, 2023, we had no borrowings and approximately $18 million of letters of credit outstanding under the revolving credit agreements. Accordingly, as of September 30, 2023, we had $2.482 billion of remaining borrowing capacity under the 5-year revolving credit agreement and $1.5 billion of remaining borrowing capacity under the 364-day revolving credit agreement (which excludes the uncommitted $750 million of incremental loan facilities), none of which would be restricted by our financial covenant compliance requirement.

For additional information regarding our Revolving Credit Agreements, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Commercial Paper

Under our commercial paper program we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any time. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the nine months ended September 30, 2023 was $2.3 billion, with $2.2 billion outstanding at September 30, 2023 compared to $0.6 billion outstanding at December 31, 2022. The outstanding commercial paper at September 30, 2023 had a weighted average annual interest rate of 5.58%.

For additional information regarding our Commercial Paper refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Other Short-term Borrowings

We are a member, through one subsidiary, of the Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At September 30, 2023 we had no outstanding short-term FHLB borrowings.

XML

COMMITMENTS, GUARANTEES AND CONTINGENCIES

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS, GUARANTEES AND CONTINGENCIES

COMMITMENTS, GUARANTEES AND CONTINGENCIES

Government Contracts

Our Medicare products, which accounted for approximately 83% of our total premiums and services revenue for the nine months ended September 30, 2023, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2023, and all of our product offerings filed with CMS for 2023 have been approved.

CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997, or BBA, and the Benefits Improvement and Protection Act of 2000, or BIPA, generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service, or FFS, program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS

as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model.

CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, perform audits of various companies’ risk adjustment diagnosis data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices that influence the calculation of health status-related premium payments to MA plans.

In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract’s entire health status-related risk adjusted premium amount for the year under audit. In doing so, CMS recognized “that the documentation standard used in RADV audits to determine a contract’s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).” To correct for this difference, CMS stated that it would apply a “Fee-for-Service Adjuster (FFS Adjuster)” as “an offset to the preliminary recovery amount.” This adjuster would be “calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.” CMS stated that this methodology would apply to audits beginning with PY 2011. Humana relied on CMS’s 2012 guidance in submitting MA bids to CMS. Humana also launched a “Self-Audits” program in 2013 that applied CMS’s 2012 RADV audit methodology and included an estimated FFS Adjuster. Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS.

In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit methodology, including elimination of the FFS Adjuster. CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011. On January 30, 2023, CMS published a final rule related to the RADV audit methodology (Final RADV Rule). The Final RADV Rule confirmed CMS’s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS’s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed. However, CMS’s Final RADV Rule does not adopt a specific sampling, extrapolation or audit methodology. CMS instead stated its general plan to rely on “any statistically valid method . . . that is determined to be well-suited to a particular audit.”

We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (“APA”). CMS failed to meet its legal obligations in the federal rulemaking process to give a reasoned justification for the rule or provide a meaningful opportunity for public comment. They also chose to apply the rule retroactively rather than prospectively, as required by law. Humana’s actuarially certified bids through PY 2023 preserved Humana’s position that CMS should apply an FFS Adjuster in any RADV audit that CMS intends to extrapolate. We expect CMS to apply the Final RADV Rule, including the first application of extrapolated audit results to determine audit settlements without a FFS Adjuster, to CMS and HHS-OIG RADV audits conducted for PY 2018 and subsequent years. The Final RADV Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.

In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows.

On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members. It is critical that MA plans

are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.

Our state-based Medicaid business, which accounted for approximately 7% of our total premiums and services revenue for the nine months ended September 30, 2023 primarily consisted of serving members enrolled in Medicaid, and in certain circumstances members who qualify for both Medicaid and Medicare, under contracts with various states.

At September 30, 2023, our Military business, which accounted for approximately 1% of our total premiums and services revenue for the nine months ended September 30, 2023, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract comprises 32 states and approximately 6 million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract, which was originally set to expire on December 31, 2022, was subsequently extended by the DoD and is currently scheduled to expire on December 31, 2023, unless further extended.

In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the TRICARE East Region by the Defense Health Agency of the DoD. The contract is expected to go into effect in 2024. Until then the T2017 contract remains in place. Under the terms of the award, our service area covers approximately 4.6 million beneficiaries in a region consisting of 24 states and Washington, D.C. The length of the contract is one base year with eight annual option periods, which, if all options are exercised, would result in a total contract length of nine years.

The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.

Legal Proceedings and Certain Regulatory Matters

As previously disclosed, the Civil Division of the United States Department of Justice provided us with an information request in December 2014, concerning our Medicare Part C risk adjustment practices. The request relates to our oversight and submission of risk adjustment data generated by providers in our Medicare Advantage network, as well as to our business and compliance practices related to risk adjustment data generated by our providers and by us, including medical record reviews conducted as part of our data and payment accuracy compliance efforts, the use of health and well-being assessments, and our fraud detection efforts. We believe that this request for information is in connection with a wider review of Medicare Risk Adjustment generally that includes a number of Medicare Advantage plans, providers and vendors. We cooperated with the Department of Justice, and we have not heard from the Department of Justice on this matter since 2020.

As previously disclosed, on January 19, 2016, an individual filed a qui tam suit captioned United States of America ex rel. Steven Scott v. Humana Inc., currently pending in United States District Court, Western District of Kentucky, Louisville division. The complaint alleges certain civil violations by us in connection with the actuarial equivalence of the plan benefits under Humana’s Basic PDP plan, a prescription drug plan offered by us under Medicare Part D. The action seeks damages and penalties on behalf of the United States under the False Claims Act. The court ordered the qui tam action unsealed on September 13, 2017, so that the relator could proceed, following notice from the U.S. Government that it was not intervening at that time. On March 31, 2022, the Court denied the parties' Motions for Summary Judgement. We take seriously our obligations to comply with applicable CMS requirements and actuarial standards of practice, and continue to vigorously defend against these allegations. As of September 30, 2023, we have accrued certain anticipated expenses in connection with this matter.

On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. There is no assurance that we will prevail in the lawsuit. See “Government Contracts” in this footnote to the unaudited Consolidated Financial Statements of this Form 10-Q for additional information regarding this matter.

Other Lawsuits and Regulatory Matters

Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider contracting, risk adjustment, competitive practices, commission payments, privacy issues, utilization management practices, pharmacy benefits, access to care, sales practices, and provision of care by our healthcare services businesses, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.

We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. Under state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do.

As a government contractor, we may also be subject to false claims litigation, such as qui tam lawsuits brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government or related overpayments from the government, including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of nonperformance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.

A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.

We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is

uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.

The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.

XML

SEGMENT INFORMATION

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

SEGMENT INFORMATION

SEGMENT INFORMATION

During December 2022, we realigned our businesses into two distinct segments: Insurance and CenterWell. The Insurance segment includes the businesses that were previously included in the Retail and Group and Specialty segments, as well as the Pharmacy Benefit Manager, or PBM, business which was previously included in the Healthcare Services segment. The CenterWell segment (formerly Healthcare Services) represents our payor-agnostic healthcare services offerings, including pharmacy dispensing services, primary care, and home services. In addition to the new segment classifications being utilized to assess performance and allocate resources, we believe this simpler structure will create greater collaboration across the Insurance and CenterWell businesses and will accelerate work that is underway to centralize and integrate operations within the organization. Prior period segment financial information has been recast to conform to the 2023 presentation.

Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources.

The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our Military business, primarily our T-2017 East Region contract, as well as the operations of our PBM business.

The CenterWell segment includes our pharmacy, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.

Our CenterWell intersegment revenues primarily relate to the operations of CenterWell Pharmacy (our mail- order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics.

In addition, our CenterWell intersegment revenues include revenues earned by certain owned providers derived from certain value-based arrangements with our health plans. Under these value-based arrangements, our owned providers enter into agreements with our health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our members. In exchange, the owned provider receives a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our members. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.

We present our condensed consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $5.7 billion and $5.4 billion for the three months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023 and 2022 these amounts were $14.7 billion and $14.2 billion, respectively. In addition, depreciation and amortization expense associated with certain businesses delivering benefits to our members, primarily associated with our primary care and pharmacy operations, are included with benefits expense. The amount of this expense was $35 million and $30 million for the three months ended September 30, 2023 and 2022, respectively, and $102 million and $89 million for the nine months ended September 30, 2023 and 2022, respectively.

Other than those described previously, the accounting policies of each segment are the same. For additional information regarding our accounting policies refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home services, to our Insurance segment customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below.

Our segment results were as follows for the three and nine months ended September 30, 2023 and 2022:

	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Three months ended September 30, 2023	(in millions)
External revenues
Premiums:
Individual Medicare Advantage	$	19,637	$	—	$	—	$	19,637
Group Medicare Advantage	1,695		—		—		1,695
Medicare stand-alone PDP	493		—		—		493
Total Medicare	21,825		—		—		21,825
Commercial fully-insured	842		—		—		842
Specialty benefits	252		—		—		252
Medicare Supplement	185		—		—		185
State-based contracts and other	1,995		—		—		1,995
Total premiums	25,099		—		—		25,099
Services revenue:
Home solutions	—		342		—		342
Primary care	—		214		—		214
Commercial ASO	55		—		—		55
Military and other	202		—		—		202
Pharmacy solutions	—		203		—		203
Total services revenue	257		759		—		1,016
Total external revenues	25,356		759		—		26,115
Intersegment revenues
Services	1		1,307		(1,308)		—
Products	—		2,594		(2,594)		—
Total intersegment revenues	1		3,901		(3,902)		—
Investment income	154		—		154		308
Total revenues	25,511		4,660		(3,748)		26,423
Operating expenses:
Benefits	21,976		—		(231)		21,745
Operating costs	2,634		4,207		(3,570)		3,271
Depreciation and amortization	179		53		(31)		201
Total operating expenses	24,789		4,260		(3,832)		25,217
Income from operations	722		400		84		1,206
Interest expense	—		1		113		114
Other income, net	—		—		(6)		(6)
Income (loss) before income taxes and equity in net earnings	722		399		(23)		1,098
Equity in net losses	—		(12)		—		(12)
Segment earnings (loss)	$	722	$	387	$	(23)	$	1,086
Net loss (income) attributable to noncontrolling interests	3		(1)		—		2
Segment earnings (loss) attributable to Humana	$	725	$	386	$	(23)	$	1,088

	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Three months ended September 30, 2022	(in millions)
External revenues
Premiums:
Individual Medicare Advantage	$	16,007	$	—	$	—	$	16,007
Group Medicare Advantage	1,792		—		—		1,792
Medicare stand-alone PDP	534		—		—		534
Total Medicare	18,333		—		—		18,333
Commercial fully-insured	1,075		—		—		1,075
Specialty benefits	262		—		—		262
Medicare Supplement	188		—		—		188
State-based contracts and other	1,610		—		—		1,610
Total premiums	21,468		—		—		21,468
Services revenue:
Home solutions	—		519		—		519
Primary care	—		159		—		159
Commercial ASO	73		—		—		73
Military and other	137		—		—		137
Pharmacy solutions	—		271		—		271
Total services revenue	210		949		—		1,159
Total external revenues	21,678		949		—		22,627
Intersegment revenues
Services	14		863		(877)		—
Products	—		2,459		(2,459)		—
Total intersegment revenues	14		3,322		(3,336)		—
Investment income	51		3		118		172
Total revenues	21,743		4,274		(3,218)		22,799
Operating expenses:
Benefits	18,413		—		(29)		18,384
Operating costs	2,294		3,929		(3,162)		3,061
Depreciation and amortization	163		45		(26)		182
Total operating expenses	20,870		3,974		(3,217)		21,627
Income (loss) from operations	873		300		(1)		1,172
Gain on sale of Gentiva Hospice	—		(240)		—		(240)
Interest expense	—		—		102		102
Other expense, net	—		—		13		13
Income (loss) before income taxes and equity in net earnings	873		540		(116)		1,297
Equity in net earnings (losses)	8		(5)		—		3
Segment earnings (loss)	$	881	$	535	$	(116)	$	1,300
Net loss attributable to noncontrolling interests	2		—		—		2
Segment earnings (loss) attributable to Humana	$	883	$	535	$	(116)	$	1,302

	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Nine months ended September 30, 2023	(in millions)
External revenues
Premiums:
Individual Medicare Advantage	$	59,195	$	—	$	—	$	59,195
Group Medicare Advantage	5,192		—		—		5,192
Medicare stand-alone PDP	1,677		—		—		1,677
Total Medicare	66,064		—		—		66,064
Commercial fully-insured	2,810		—		—		2,810
Specialty benefits	758		—		—		758
Medicare Supplement	546		—		—		546
State-based contracts and other	5,966		—		—		5,966
Total premiums	76,144		—		—		76,144
Services revenue:
Home solutions	—		997		—		997
Primary care	—		605		—		605
Commercial ASO	190		—		—		190
Military and other	540		—		—		540
Pharmacy solutions	—		661		—		661
Total services revenue	730		2,263		—		2,993
Total external revenues	76,874		2,263		—		79,137
Intersegment revenues
Services	30		3,584		(3,614)		—
Products	—		7,848		(7,848)		—
Total intersegment revenues	30		11,432		(11,462)		—
Investment income	385		—		390		775
Total revenues	77,289		13,695		(11,072)		79,912
Operating expenses:
Benefits	66,096		—		(484)		65,612
Operating costs	7,597		12,526		(10,762)		9,361
Depreciation and amortization	516		152		(90)		578
Total operating expenses	74,209		12,678		(11,336)		75,551
Income from operations	3,080		1,017		264		4,361
Interest expense	—		2		345		347
Other expense, net	—		—		40		40
Income (loss) before income taxes and equity in net losses	3,080		1,015		(121)		3,974
Equity in net losses	(2)		(37)		—		(39)
Segment earnings (loss)	$	3,078	$	978	$	(121)	$	3,935
Net loss (income) attributable to noncontrolling interests	7		(1)		—		6
Segment earnings (loss) attributable to Humana	$	3,085	$	977	$	(121)	$	3,941

	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Nine months ended September 30, 2022	(in millions)
External Revenues
Premiums:
Individual Medicare Advantage	$	49,751	$	—	$	—	$	49,751
Group Medicare Advantage	5,524		—		—		5,524
Medicare stand-alone PDP	1,779		—		—		1,779
Total Medicare	57,054		—		—		57,054
Commercial fully-insured	3,324		—		—		3,324
Specialty benefits	784		—		—		784
Medicare Supplement	555		—		—		555
State-based contracts and other	4,720		—		—		4,720
Total premiums	66,437		—		—		66,437
Services revenue:
Home solutions	—		1,997		—		1,997
Primary care	—		409		—		409
Commercial ASO	225		—		—		225
Military and other	395		—		—		395
Pharmacy solutions	—		746		—		746
Total services revenue	620		3,152		—		3,772
Total external revenues	67,057		3,152		—		70,209
Intersegment revenues
Services	42		2,614		(2,656)		—
Products	—		7,394		(7,394)		—
Total intersegment revenues	42		10,008		(10,050)		—
Investment income	143		6		73		222
Total revenues	67,242		13,166		(9,977)		70,431
Operating expenses:
Benefits	57,311		—		(203)		57,108
Operating costs	6,486		12,002		(9,368)		9,120
Depreciation and amortization	469		136		(78)		527
Total operating expenses	64,266		12,138		(9,649)		66,755
Income (loss) from operations	2,976		1,028		(328)		3,676
Gain on sale of Gentiva Hospice	—		(240)		—		(240)
Interest expense	—		—		293		293
Other income, net	—		—		(16)		(16)
Income (loss) before income taxes and equity in net losses	2,976		1,268		(605)		3,639
Equity in net earnings (losses)	16		(15)		—		1
Segment earnings (loss)	$	2,992	$	1,253	$	(605)	$	3,640
Net loss (income) attributable to noncontrolling interests	2		(1)		—		1
Segment earnings (loss) attributable to Humana	$	2,994	$	1,252	$	(605)	$	3,641

XML

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net income attributable to Humana	$ 832	$ 1,195	$ 3,030	$ 2,821

XML

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML

BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies)

9 Months Ended

Sep. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2022, that was filed with the Securities and Exchange Commission, or the SEC, on February 16, 2023. We refer to this Form 10-K as the “2022 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.

The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.

Employer Group Commercial Medical Products Business Exit

In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.

Value Creation Initiatives

During 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities beginning in 2023, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, during the three and nine months ended September 30, 2022, we recorded charges of $82 million and $285 million, respectively. For the three and nine months ended September 30, 2022, these charges primarily relate to $4 million and $144 million, respectively, in asset impairments, including software and abandonment, and $44 million and $65 million, respectively, of severance charges in connection with workforce optimization. The remainder of the charges primarily relate to external consulting fees. During the three months ended September 30, 2023, we recorded charges of $52 million primarily in asset impairments relating to software and abandonment. In connection with these initiatives, we expect to incur additional charges through the end of 2024. These charges are recorded at the corporate level and not allocated to the segments.

Revenue Recognition

Revenue Recognition

Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

Recently Issued Accounting Pronouncements

In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The new guidance relates to accounting for long-duration contracts of insurers which revises key elements of the measurement models and disclosure requirements for long-duration contracts issued by insurers, including the amortization of deferred contract acquisition costs and the measurement of liabilities for future policy benefits using current, rather than locked-in, assumptions. The new guidance, limited to our Medicare Supplement product which represents less than 1% of consolidated premiums and services revenue, became effective for us beginning January 1, 2023 and is to be applied to contracts in force on the basis of their

existing carrying value amounts at the beginning of the earliest period presented. The adoption of the new standard in 2023 did not have a material impact on our consolidated results of operations, financial position or cash flows.

There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.

XML

INVESTMENT SECURITIES (Tables)

9 Months Ended

Sep. 30, 2023

Investments, Debt and Equity Securities [Abstract]

Schedule of Investment Securities Classified as Current and Long-Term

Investment securities classified as current and long-term were as follows at September 30, 2023 and December 31, 2022, respectively:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
	(in millions)
September 30, 2023
U.S. Treasury and other U.S. government     corporations and agencies:
U.S. Treasury and agency obligations	$	2,043	$	—	$	(105)	$	1,938
Mortgage-backed securities	3,890		—		(637)		3,253
Tax-exempt municipal securities	848		—		(50)		798
Mortgage-backed securities:
Residential	497		—		(85)		412
Commercial	1,475		—		(155)		1,320
Asset-backed securities	1,849		—		(65)		1,784
Corporate debt securities	6,864		14		(868)		6,010
Total debt securities	$	17,466	$	14	$	(1,965)	15,515
Common stock							—
Total investment securities							$	15,515
December 31, 2022
U.S. Treasury and other U.S. government     corporations and agencies:
U.S. Treasury and agency obligations	$	1,093	$	1	$	(55)	$	1,039
Mortgage-backed securities	3,697		4		(471)		3,230
Tax-exempt municipal securities	765		—		(37)		728
Mortgage-backed securities:
Residential	477		—		(76)		401
Commercial	1,554		—		(155)		1,399
Asset-backed securities	1,809		1		(79)		1,731
Corporate debt securities	6,551		3		(828)		5,726
Total debt securities	$	15,946	$	9	$	(1,701)	14,254
Common stock							7
Total investment securities							$	14,261

Schedule of Gross Unrealized Losses and Fair Value of Securities

Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at September 30, 2023 and December 31, 2022, respectively:

	Less than 12 months				12 months or more				Total
	Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses
	(in millions)
September 30, 2023
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	1,483	$	(51)	$	407	$	(54)	$	1,890	$	(105)
Mortgage-backed securities	1,084		(66)		2,169		(571)		3,253		(637)
Tax-exempt municipal securities	278		(6)		515		(44)		793		(50)
Mortgage-backed securities:
Residential	48		(1)		363		(84)		411		(85)
Commercial	15		—		1,304		(155)		1,319		(155)
Asset-backed securities	343		(6)		1,430		(59)		1,773		(65)
Corporate debt securities	961		(35)		4,648		(833)		5,609		(868)
Total debt securities	$	4,212	$	(165)	$	10,836	$	(1,800)	$	15,048	$	(1,965)
December 31, 2022
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	512	$	(5)	$	397	$	(50)	$	909	$	(55)
Mortgage-backed securities	1,231		(104)		1,683		(367)		2,914		(471)
Tax-exempt municipal securities	64		(2)		615		(36)		679		(38)
Mortgage-backed securities:
Residential	124		(16)		274		(60)		398		(76)
Commercial	243		(13)		1,157		(142)		1,400		(155)
Asset-backed securities	620		(32)		1,011		(46)		1,631		(78)
Corporate debt securities	1,625		(98)		3,825		(730)		5,450		(828)
Total debt securities	$	4,419	$	(270)	$	8,962	$	(1,431)	$	13,381	$	(1,701)

Schedule of Realized Gains (Losses) Related to Investment Securities Included Within Investment Income

The detail of gains (losses) related to investment securities and included within investment income was as follows for the three and nine months ended September 30, 2023 and 2022:

	Three months ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(in millions)				(in millions)
Gross gains on investment securities	$	—	$	2	$	15	$	41
Gross losses on investment securities	(4)		(52)		(65)		(58)
Gross gains on equity securities	—		51		1		51
Gross losses on equity securities	—		—		—		(170)
Net recognized (losses) gains on investment securities	$	(4)	$	1	$	(49)	$	(136)

Schedule of Gain (Loss) on Equity Securities

The gains and losses related to equity securities for the three and nine months ended September 30, 2023 and 2022 was as follows:

	Three months ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(in millions)				(in millions)
Net gains (losses) recognized on equity securities during the period	$	—	$	51	$	1	$	(119)
Less: Net gains (losses) recognized on equity securities sold during the period	—		47		—		(105)
Unrealized gains (losses) recognized on equity securities still held at the end of the period	$	—	$	4	$	1	$	(14)

Schedule of Contractual Maturity of Debt Securities Available for Sale

The contractual maturities of debt securities available for sale at September 30, 2023, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

	Amortized Cost		Fair Value
	(in millions)
Due within one year	$	659	$	654
Due after one year through five years	4,850		4,565
Due after five years through ten years	3,017		2,573
Due after ten years	1,229		954
Mortgage and asset-backed securities	7,711		6,769
Total debt securities	$	17,466	$	15,515

XML

FAIR VALUE (Tables)

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Schedule of Financial Assets Measured at Fair Value on Recurring Basis

The following table summarizes our fair value measurements at September 30, 2023 and December 31, 2022, respectively, for financial assets measured at fair value on a recurring basis:

	Fair Value Measurements Using
	Fair Value		Quoted Prices in Active Markets (Level 1)		Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
	(in millions)
September 30, 2023
Cash equivalents	$	15,035	$	15,035	$	—	$	—
Debt securities:
U.S. Treasury and other U.S. government     corporations and agencies:
U.S. Treasury and agency obligations	1,938		—		1,938		—
Mortgage-backed securities	3,253		—		3,253		—
Tax-exempt municipal securities	798		—		798		—
Mortgage-backed securities:
Residential	412		—		412		—
Commercial	1,320		—		1,320		—
Asset-backed securities	1,784		—		1,784		—
Corporate debt securities	6,010		—		5,905		105
Total debt securities	15,515		—		15,410		105
Total invested assets	$	30,550	$	15,035	$	15,410	$	105
December 31, 2022
Cash equivalents	$	4,832	$	4,832	$	—	$	—
Debt securities:
U.S. Treasury and other U.S. government     corporations and agencies:
U.S. Treasury and agency obligations	1,039		—		1,039		—
Mortgage-backed securities	3,230		—		3,230		—
Tax-exempt municipal securities	728		—		728		—
Mortgage-backed securities:
Residential	401		—		401		—
Commercial	1,399		—		1,399		—
Asset-backed securities	1,731		—		1,731		—
Corporate debt securities	5,726		—		5,625		101
Total debt securities	14,254		—		14,153		101
Common stock	7		7		—		—
Total invested assets	$	19,093	$	4,839	$	14,153	$	101

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

During the nine months ended September 30, 2023 and 2022, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:

	For the nine months ended September 30, 2023		For the nine months ended September 30, 2022
	Private Placements
	(in millions)
Beginning balance at January 1	$	101	$	68
Total gains or losses:
Realized in earnings	—		—
Unrealized in other comprehensive income	(1)		—
Purchases	13		(12)
Sales	—		44
Maturities	(4)		—
Transfer out	(4)
Balance at September 30	$	105	$	100

Schedule of Assumptions Used For Inputs In Fair Value Measurement

The table below presents the assumptions used for each reporting period.

	September 30, 2023		December 31, 2022
Annualized volatility	16.6% - 19.6%		16.7% - 20.8%
Credit spread	0.9% - 1.4%		1.3% - 1.5%
Revenue exit multiple	1.5x - 2.5x		1.5x - 2.5x
Weighted average cost of capital	12.0% - 13.0%		11.5% - 12.5%
Long term growth rate	3.0	%	3.0	%

XML

MEDICARE PART D (Tables)

9 Months Ended

Sep. 30, 2023

Insurance [Abstract]

Schedule of Balance Sheet Amounts Associated With Medicare Part D

The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at September 30, 2023 and December 31, 2022. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

	September 30, 2023				December 31, 2022
	Risk Corridor Settlement		CMS Subsidies/ Discounts		Risk Corridor Settlement		CMS Subsidies/ Discounts
	(in millions)
Other current assets	$	131	$	517	$	240	$	696
Trade accounts payable and accrued expenses	(150)		(3,566)		(166)		(1,236)
Net current (liability) asset	(19)		(3,049)		74		(540)
Other long-term assets	235		—		19		—
Other long-term liabilities	(123)		—		(78)		—
Net long-term asset (liability)	112		—		(59)		—
Total net asset (liability)	$	93	$	(3,049)	$	15	$	(540)

XML

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes in Carrying Amount of Goodwill By Reportable Segments

Changes in the carrying amount of goodwill for our reportable segments for the nine months ended September 30, 2023 were as follows:

	Insurance		CenterWell		Total
	(in millions)
Balance at January 1, 2023	$	2,472	$	6,670	$	9,142
Acquisitions	191		207		398
Balance at September 30, 2023	$	2,663	$	6,877	$	9,540

Schedule of Other Intangible Assets, Indefinite-Lived

The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at September 30, 2023 and December 31, 2022:

		September 30, 2023						December 31, 2022
	Weighted Average Life	Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net
		($ in millions)
Other intangible assets:
Certificates of need	Indefinite	$	1,132	$	—	$	1,132	$	1,132	$	—	$	1,132
Medicare licenses	Indefinite	302		—		302		286		—		286
Customer contracts/     relationships	9.4 years	955		708		247		929		673		256
Trade names and     technology	6.7 years	139		106		33		142		107		35
Provider contracts	11.6 years	73		64		9		73		63		10
Noncompetes and     other	8.4 years	84		42		42		86		40		46
Total other intangible     assets	9.2 years	$	2,685	$	920	$	1,765	$	2,648	$	883	$	1,765

Schedule of Other Intangible Assets, Amortizable

The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at September 30, 2023 and December 31, 2022:

		September 30, 2023						December 31, 2022
	Weighted Average Life	Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net
		($ in millions)
Other intangible assets:
Certificates of need	Indefinite	$	1,132	$	—	$	1,132	$	1,132	$	—	$	1,132
Medicare licenses	Indefinite	302		—		302		286		—		286
Customer contracts/     relationships	9.4 years	955		708		247		929		673		256
Trade names and     technology	6.7 years	139		106		33		142		107		35
Provider contracts	11.6 years	73		64		9		73		63		10
Noncompetes and     other	8.4 years	84		42		42		86		40		46
Total other intangible     assets	9.2 years	$	2,685	$	920	$	1,765	$	2,648	$	883	$	1,765

Schedule of Estimated Amortization Expense

The following table presents our estimate of amortization expense remaining for 2023 and each of the next five succeeding years at September 30, 2023:

	(in millions)
For the years ending December 31,
2023	$	15
2024	60
2025	58
2026	44
2027	34
2028	29

XML

BENEFITS PAYABLE (Tables)

9 Months Ended

Sep. 30, 2023

Insurance [Abstract]

Schedule of Activity in Benefits Payable

On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the nine months ended September 30, 2023 and 2022:

	For the nine months ended September 30,
	2023		2022
	(in millions)
Balances, beginning of period	$	9,264	$	8,289
Acquisitions	62		—
Incurred related to:
Current year	66,370		57,512
Prior years	(758)		(404)
Total incurred	65,612		57,108
Paid related to:
Current year	(56,700)		(48,835)
Prior years	(8,042)		(7,325)
Total paid	(64,742)		(56,160)
Balances, end of period	$	10,196	$	9,237

XML

EARNINGS PER COMMON SHARE COMPUTATION (Tables)

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Schedule of Details Supporting Computation of Earnings Per Share

Detail supporting the computation of basic and diluted earnings per common share was as follows for the three and nine months ended September 30, 2023 and 2022:

	Three months ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders	$	832	$	1,195	$	3,030	$	2,821
Weighted average outstanding shares of common stock     used to compute basic earnings per common share	123,426		126,572		124,335		126,678
Dilutive effect of:
Employee stock options	26		61		31		50
Restricted stock	531		723		519		577
Shares used to compute diluted earnings per common share	123,983		127,356		124,885		127,305
Basic earnings per common share	$	6.74	$	9.45	$	24.37	$	22.27
Diluted earnings per common share	$	6.71	$	9.39	$	24.26	$	22.16
Number of antidilutive stock options and restricted stock     excluded from computation	137		78		251		267

XML

STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

Schedule of Details of Dividend Payments

The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2023 under our Board approved quarterly cash dividend policy:

Record Date	Payment Date	Amount per Share		Total Amount
				(in millions)
12/30/2022	1/27/2023	$	0.7875	$	98
03/31/2023	04/28/2023	$	0.8850	$	111
06/30/2023	07/28/2023	$	0.8850	$	110
9/29/2023	10/27/2023	$	0.8850	$	109

XML

DEBT (Tables)

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Schedule of Carrying Value of Debt Outstanding

The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(in millions)
Short-term debt:
Commercial paper	$	2,245	$	595
Senior notes:
$1.5 billion, 0.650% due August 3, 2023	—		1,497
Total senior notes	—		1,497
Total short-term debt	$	2,245	$	2,092
Long-term debt:
Senior notes:
$600 million, 3.850% due October 1, 2024	$	572	$	599
$600 million, 4.500% due April 1, 2025	598		597
$500 million, 5.700% due March 13, 2026	497		—
$750 million, 1.350% due February 3, 2027	688		745
$600 million, 3.950% due March 15, 2027	537		597
$500 million, 5.750% due March 1, 2028	495		494
$750 million, 3.700% due March 23, 2029	689		743
$500 million, 3.125% due August 15, 2029	458		496
$500 million, 4.875% due April 1, 2030	496		495
$750 million, 2.150% due February 3, 2032	743		743
$750 million, 5.875% due March 1, 2033	715		739
$250 million, 8.150% due June 15, 2038	261		261
$400 million, 4.625% due December 1, 2042	396		396
$750 million, 4.950% due October 1, 2044	740		740
$400 million, 4.800% due March 15, 2047	396		396
$500 million, 3.950% due August 15, 2049	493		493
$750 million, 5.500% due March 15, 2053	709		—
Total senior notes	9,483		8,534
Term loans:
Delayed draw term loan, due May 28, 2024	—		500
Total term loans	—		500
Total long-term debt	$	9,483	$	9,034

XML

SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Schedule of Segment Results

Our segment results were as follows for the three and nine months ended September 30, 2023 and 2022:

	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Three months ended September 30, 2023	(in millions)
External revenues
Premiums:
Individual Medicare Advantage	$	19,637	$	—	$	—	$	19,637
Group Medicare Advantage	1,695		—		—		1,695
Medicare stand-alone PDP	493		—		—		493
Total Medicare	21,825		—		—		21,825
Commercial fully-insured	842		—		—		842
Specialty benefits	252		—		—		252
Medicare Supplement	185		—		—		185
State-based contracts and other	1,995		—		—		1,995
Total premiums	25,099		—		—		25,099
Services revenue:
Home solutions	—		342		—		342
Primary care	—		214		—		214
Commercial ASO	55		—		—		55
Military and other	202		—		—		202
Pharmacy solutions	—		203		—		203
Total services revenue	257		759		—		1,016
Total external revenues	25,356		759		—		26,115
Intersegment revenues
Services	1		1,307		(1,308)		—
Products	—		2,594		(2,594)		—
Total intersegment revenues	1		3,901		(3,902)		—
Investment income	154		—		154		308
Total revenues	25,511		4,660		(3,748)		26,423
Operating expenses:
Benefits	21,976		—		(231)		21,745
Operating costs	2,634		4,207		(3,570)		3,271
Depreciation and amortization	179		53		(31)		201
Total operating expenses	24,789		4,260		(3,832)		25,217
Income from operations	722		400		84		1,206
Interest expense	—		1		113		114
Other income, net	—		—		(6)		(6)
Income (loss) before income taxes and equity in net earnings	722		399		(23)		1,098
Equity in net losses	—		(12)		—		(12)
Segment earnings (loss)	$	722	$	387	$	(23)	$	1,086
Net loss (income) attributable to noncontrolling interests	3		(1)		—		2
Segment earnings (loss) attributable to Humana	$	725	$	386	$	(23)	$	1,088

	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Three months ended September 30, 2022	(in millions)
External revenues
Premiums:
Individual Medicare Advantage	$	16,007	$	—	$	—	$	16,007
Group Medicare Advantage	1,792		—		—		1,792
Medicare stand-alone PDP	534		—		—		534
Total Medicare	18,333		—		—		18,333
Commercial fully-insured	1,075		—		—		1,075
Specialty benefits	262		—		—		262
Medicare Supplement	188		—		—		188
State-based contracts and other	1,610		—		—		1,610
Total premiums	21,468		—		—		21,468
Services revenue:
Home solutions	—		519		—		519
Primary care	—		159		—		159
Commercial ASO	73		—		—		73
Military and other	137		—		—		137
Pharmacy solutions	—		271		—		271
Total services revenue	210		949		—		1,159
Total external revenues	21,678		949		—		22,627
Intersegment revenues
Services	14		863		(877)		—
Products	—		2,459		(2,459)		—
Total intersegment revenues	14		3,322		(3,336)		—
Investment income	51		3		118		172
Total revenues	21,743		4,274		(3,218)		22,799
Operating expenses:
Benefits	18,413		—		(29)		18,384
Operating costs	2,294		3,929		(3,162)		3,061
Depreciation and amortization	163		45		(26)		182
Total operating expenses	20,870		3,974		(3,217)		21,627
Income (loss) from operations	873		300		(1)		1,172
Gain on sale of Gentiva Hospice	—		(240)		—		(240)
Interest expense	—		—		102		102
Other expense, net	—		—		13		13
Income (loss) before income taxes and equity in net earnings	873		540		(116)		1,297
Equity in net earnings (losses)	8		(5)		—		3
Segment earnings (loss)	$	881	$	535	$	(116)	$	1,300
Net loss attributable to noncontrolling interests	2		—		—		2
Segment earnings (loss) attributable to Humana	$	883	$	535	$	(116)	$	1,302

	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Nine months ended September 30, 2023	(in millions)
External revenues
Premiums:
Individual Medicare Advantage	$	59,195	$	—	$	—	$	59,195
Group Medicare Advantage	5,192		—		—		5,192
Medicare stand-alone PDP	1,677		—		—		1,677
Total Medicare	66,064		—		—		66,064
Commercial fully-insured	2,810		—		—		2,810
Specialty benefits	758		—		—		758
Medicare Supplement	546		—		—		546
State-based contracts and other	5,966		—		—		5,966
Total premiums	76,144		—		—		76,144
Services revenue:
Home solutions	—		997		—		997
Primary care	—		605		—		605
Commercial ASO	190		—		—		190
Military and other	540		—		—		540
Pharmacy solutions	—		661		—		661
Total services revenue	730		2,263		—		2,993
Total external revenues	76,874		2,263		—		79,137
Intersegment revenues
Services	30		3,584		(3,614)		—
Products	—		7,848		(7,848)		—
Total intersegment revenues	30		11,432		(11,462)		—
Investment income	385		—		390		775
Total revenues	77,289		13,695		(11,072)		79,912
Operating expenses:
Benefits	66,096		—		(484)		65,612
Operating costs	7,597		12,526		(10,762)		9,361
Depreciation and amortization	516		152		(90)		578
Total operating expenses	74,209		12,678		(11,336)		75,551
Income from operations	3,080		1,017		264		4,361
Interest expense	—		2		345		347
Other expense, net	—		—		40		40
Income (loss) before income taxes and equity in net losses	3,080		1,015		(121)		3,974
Equity in net losses	(2)		(37)		—		(39)
Segment earnings (loss)	$	3,078	$	978	$	(121)	$	3,935
Net loss (income) attributable to noncontrolling interests	7		(1)		—		6
Segment earnings (loss) attributable to Humana	$	3,085	$	977	$	(121)	$	3,941

	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Nine months ended September 30, 2022	(in millions)
External Revenues
Premiums:
Individual Medicare Advantage	$	49,751	$	—	$	—	$	49,751
Group Medicare Advantage	5,524		—		—		5,524
Medicare stand-alone PDP	1,779		—		—		1,779
Total Medicare	57,054		—		—		57,054
Commercial fully-insured	3,324		—		—		3,324
Specialty benefits	784		—		—		784
Medicare Supplement	555		—		—		555
State-based contracts and other	4,720		—		—		4,720
Total premiums	66,437		—		—		66,437
Services revenue:
Home solutions	—		1,997		—		1,997
Primary care	—		409		—		409
Commercial ASO	225		—		—		225
Military and other	395		—		—		395
Pharmacy solutions	—		746		—		746
Total services revenue	620		3,152		—		3,772
Total external revenues	67,057		3,152		—		70,209
Intersegment revenues
Services	42		2,614		(2,656)		—
Products	—		7,394		(7,394)		—
Total intersegment revenues	42		10,008		(10,050)		—
Investment income	143		6		73		222
Total revenues	67,242		13,166		(9,977)		70,431
Operating expenses:
Benefits	57,311		—		(203)		57,108
Operating costs	6,486		12,002		(9,368)		9,120
Depreciation and amortization	469		136		(78)		527
Total operating expenses	64,266		12,138		(9,649)		66,755
Income (loss) from operations	2,976		1,028		(328)		3,676
Gain on sale of Gentiva Hospice	—		(240)		—		(240)
Interest expense	—		—		293		293
Other income, net	—		—		(16)		(16)
Income (loss) before income taxes and equity in net losses	2,976		1,268		(605)		3,639
Equity in net earnings (losses)	16		(15)		—		1
Segment earnings (loss)	$	2,992	$	1,253	$	(605)	$	3,640
Net loss (income) attributable to noncontrolling interests	2		(1)		—		1
Segment earnings (loss) attributable to Humana	$	2,994	$	1,252	$	(605)	$	3,641

XML

BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2022
Services
Receivables and Other [Line Items]
Accounts receivable	$ 322
Value Creation Initiatives
Receivables and Other [Line Items]
Restructuring and impairment charge		$ 82	$ 285
Assets held for abandonment	$ 52	4	144
Severance costs		$ 44	$ 65

XML

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details)	9 Months Ended
	Sep. 30, 2023
Product Concentration Risk | Revenue Benchmark | Medicare Supplement
Concentration Risk [Line Items]
Concentration risk, less than (percent)	1.00%

XML

ACQUISITIONS AND DIVESTITURES (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Gentiva Hospice - USD ($) $ in Millions		3 Months Ended	9 Months Ended
	Aug. 11, 2022	Sep. 30, 2022	Sep. 30, 2022
Business Acquisition [Line Items]
Equity interest sold	60.00%
Consideration to be received	$ 2,700
Pre-tax gain, net of transaction costs	240
Revenue		$ 177	$ 958
Pretax earnings		$ 24	$ 150
Term Loan Due October 2023 | Term Loan
Business Acquisition [Line Items]
Repayment of debt	$ 1,900

XML

INVESTMENT SECURITIES - Securities Classified as Current and Long-Term (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	$ 17,466	$ 15,946
Gross Unrealized Gains	14	9
Gross Unrealized Losses	(1,965)	(1,701)
Fair Value	15,515	14,254
Common stock	0	7
Total investment securities	15,515	14,261
U.S. Treasury and agency obligations
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	2,043	1,093
Gross Unrealized Gains	0	1
Gross Unrealized Losses	(105)	(55)
Fair Value	1,938	1,039
Mortgage-backed securities
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	3,890	3,697
Gross Unrealized Gains	0	4
Gross Unrealized Losses	(637)	(471)
Fair Value	3,253	3,230
Tax-exempt municipal securities
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	848	765
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(50)	(37)
Fair Value	798	728
Residential
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	497	477
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(85)	(76)
Fair Value	412	401
Commercial
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	1,475	1,554
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(155)	(155)
Fair Value	1,320	1,399
Asset-backed securities
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	1,849	1,809
Gross Unrealized Gains	0	1
Gross Unrealized Losses	(65)	(79)
Fair Value	1,784	1,731
Corporate debt securities
Investment Securities, Available-for-sale Amortized Cost to Fair Value
Amortized Cost	6,864	6,551
Gross Unrealized Gains	14	3
Gross Unrealized Losses	(868)	(828)
Fair Value	$ 6,010	$ 5,726

XML

INVESTMENT SECURITIES - Narrative (Details) $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($) position	Dec. 31, 2022 USD ($)
Financing Receivable, Credit Quality Indicator [Line Items]
Book value	$ 17,466	$ 15,946
Fair value	$ 15,515	$ 14,254
Maximum individual state general bond obligation as a percentage of total debt securities (percent)	1.00%
Securities in unrealized loss positions, number of positions | position	1,790
Securities, number of positions | position	2,070
Standard & Poor's, AA Rating
Financing Receivable, Credit Quality Indicator [Line Items]
Percentage of debt securities considered to be of investment-grade (percent)	98.00%
Dispositions | Gentiva Hospice
Financing Receivable, Credit Quality Indicator [Line Items]
Book value	$ 281
Fair value	$ 295

XML

INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Fair Value
Less than 12 months	$ 4,212	$ 4,419
12 months or more	10,836	8,962
Total	15,048	13,381
Gross Unrealized Losses
Less than 12 months	(165)	(270)
12 months or more	(1,800)	(1,431)
Total	(1,965)	(1,701)
U.S. Treasury and agency obligations
Fair Value
Less than 12 months	1,483	512
12 months or more	407	397
Total	1,890	909
Gross Unrealized Losses
Less than 12 months	(51)	(5)
12 months or more	(54)	(50)
Total	(105)	(55)
Mortgage-backed securities
Fair Value
Less than 12 months	1,084	1,231
12 months or more	2,169	1,683
Total	3,253	2,914
Gross Unrealized Losses
Less than 12 months	(66)	(104)
12 months or more	(571)	(367)
Total	(637)	(471)
Tax-exempt municipal securities
Fair Value
Less than 12 months	278	64
12 months or more	515	615
Total	793	679
Gross Unrealized Losses
Less than 12 months	(6)	(2)
12 months or more	(44)	(36)
Total	(50)	(38)
Residential
Fair Value
Less than 12 months	48	124
12 months or more	363	274
Total	411	398
Gross Unrealized Losses
Less than 12 months	(1)	(16)
12 months or more	(84)	(60)
Total	(85)	(76)
Commercial
Fair Value
Less than 12 months	15	243
12 months or more	1,304	1,157
Total	1,319	1,400
Gross Unrealized Losses
Less than 12 months	0	(13)
12 months or more	(155)	(142)
Total	(155)	(155)
Asset-backed securities
Fair Value
Less than 12 months	343	620
12 months or more	1,430	1,011
Total	1,773	1,631
Gross Unrealized Losses
Less than 12 months	(6)	(32)
12 months or more	(59)	(46)
Total	(65)	(78)
Corporate debt securities
Fair Value
Less than 12 months	961	1,625
12 months or more	4,648	3,825
Total	5,609	5,450
Gross Unrealized Losses
Less than 12 months	(35)	(98)
12 months or more	(833)	(730)
Total	$ (868)	$ (828)

XML

INVESTMENT SECURITIES - Gains (Losses) Within Investment Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Gross gains on investment securities	$ 0	$ 2	$ 15	$ 41
Gross losses on investment securities	(4)	(52)	(65)	(58)
Gross gains on equity securities	0	51	1	51
Gross losses on equity securities	0	0	0	(170)
Net recognized (losses) gains on investment securities	$ (4)	$ 1	$ (49)	$ (136)

XML

INVESTMENT SECURITIES - Gains and Losses Related to Equity Securities (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Net gains (losses) recognized on equity securities during the period	$ 0	$ 51	$ 1	$ (119)
Less: Net gains (losses) recognized on equity securities sold during the period	0	47	0	(105)
Unrealized gains (losses) recognized on equity securities still held at the end of the period	$ 0	$ 4	$ 1	$ (14)

XML

INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Amortized Cost
Due within one year	$ 659
Due after one year through five years	4,850
Due after five years through ten years	3,017
Due after ten years	1,229
Mortgage and asset-backed securities	7,711
Amortized Cost	17,466	$ 15,946
Fair Value
Due within one year	654
Due after one year through five years	4,565
Due after five years through ten years	2,573
Due after ten years	954
Mortgage and asset-backed securities	6,769
Fair Value	$ 15,515	$ 14,254

XML

FAIR VALUE - Financial Assets Measured on Recurring Basis (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	$ 15,515	$ 14,254
Common stock	0	7
U.S. Treasury and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	1,938	1,039
Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	3,253	3,230
Tax-exempt municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	798	728
Residential
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	412	401
Commercial
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	1,320	1,399
Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	1,784	1,731
Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	6,010	5,726
Recurring Basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	15,035	4,832
Total debt securities	15,515	14,254
Common stock		7
Total invested assets	30,550	19,093
Recurring Basis | U.S. Treasury and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	1,938	1,039
Recurring Basis | Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	3,253	3,230
Recurring Basis | Tax-exempt municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	798	728
Recurring Basis | Residential
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	412	401
Recurring Basis | Commercial
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	1,320	1,399
Recurring Basis | Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	1,784	1,731
Recurring Basis | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	6,010	5,726
Recurring Basis | Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	15,035	4,832
Total debt securities	0	0
Common stock		7
Total invested assets	15,035	4,839
Recurring Basis | Quoted Prices in Active Markets (Level 1) | U.S. Treasury and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Tax-exempt municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Residential
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Commercial
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Recurring Basis | Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Total debt securities	15,410	14,153
Common stock		0
Total invested assets	15,410	14,153
Recurring Basis | Other Observable Inputs (Level 2) | U.S. Treasury and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	1,938	1,039
Recurring Basis | Other Observable Inputs (Level 2) | Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	3,253	3,230
Recurring Basis | Other Observable Inputs (Level 2) | Tax-exempt municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	798	728
Recurring Basis | Other Observable Inputs (Level 2) | Residential
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	412	401
Recurring Basis | Other Observable Inputs (Level 2) | Commercial
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	1,320	1,399
Recurring Basis | Other Observable Inputs (Level 2) | Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	1,784	1,731
Recurring Basis | Other Observable Inputs (Level 2) | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	5,905	5,625
Recurring Basis | Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Total debt securities	105	101
Common stock		0
Total invested assets	105	101
Recurring Basis | Unobservable Inputs (Level 3) | U.S. Treasury and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Recurring Basis | Unobservable Inputs (Level 3) | Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Recurring Basis | Unobservable Inputs (Level 3) | Tax-exempt municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Recurring Basis | Unobservable Inputs (Level 3) | Residential
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Recurring Basis | Unobservable Inputs (Level 3) | Commercial
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Recurring Basis | Unobservable Inputs (Level 3) | Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	0	0
Recurring Basis | Unobservable Inputs (Level 3) | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total debt securities	$ 105	$ 101

XML

FAIR VALUE - Narrative (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value	$ 105,000,000		$ 101,000,000	$ 100,000,000	$ 68,000,000
Put option
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial liability	410,000,000		267,000,000
Call option
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of financial asset	12,000,000		10,000,000
Term Loan And Commercial Paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term debt	2,200,000,000		1,100,000,000
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt outstanding	9,500,000,000		10,000,000,000
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt outstanding	8,700,000,000		$ 9,400,000,000
Interest Rate Swap Maturing 2032 | Interest rate swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, Notional Amount	650,000,000
Interest Rate Swap Maturing 2033 | Interest rate swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, Notional Amount	250,000,000
5.88 Percent Senior Notes Due 2023 | Senior notes:
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Aggregate principal	$ 750,000,000
Stated interest rate (percent)	5.875%
$750 million, 5.500% due March 15, 2053 | Senior notes:
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Aggregate principal	$ 750,000,000	$ 750,000,000
Stated interest rate (percent)	5.50%	5.50%
$750 million, 5.500% due March 15, 2053 | Senior notes: | SOFR
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stated interest rate (percent)	5.50%
Unobservable Inputs (Level 3) | Investments | Fair Value Risk
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Concentration risk (percent)	0.30%

XML

FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance at January 1	$ 101	$ 68
Total gains or losses:
Realized in earnings	0	0
Unrealized in other comprehensive income	(1)	0
Purchases	13	(12)
Sales	0	44
Maturities	(4)	0
Transfer out	(4)
Balance at September 30	$ 105	$ 100

XML

FAIR VALUE - Put and Call Options Measured at Fair Value (Details) - Options - Level 3 fair value measurement	Sep. 30, 2023	Dec. 31, 2022
Annualized volatility | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	0.166	0.167
Annualized volatility | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	0.196	0.208
Credit spread | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	0.009	0.013
Credit spread | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	0.014	0.015
Revenue exit multiple | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	1.5	1.5
Revenue exit multiple | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	2.5	2.5
Weighted average cost of capital | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	0.120	0.115
Weighted average cost of capital | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	0.130	0.125
Long term growth rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable inputs	0.030	0.030

XML

MEDICARE PART D (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Other current assets	$ 6,136	$ 5,567
Trade accounts payable and accrued expenses	(7,600)	(5,238)
Other long-term assets	3,638	3,380
Other long-term liabilities	(1,595)	(1,473)
Risk Corridor Settlement
Segment Reporting Information [Line Items]
Other current assets	131	240
Trade accounts payable and accrued expenses	(150)	(166)
Net current (liability) asset	(19)	74
Other long-term assets	235	19
Other long-term liabilities	(123)	(78)
Net long-term asset (liability)	112	(59)
Total net asset (liability)	93	15
CMS Subsidies/ Discounts
Segment Reporting Information [Line Items]
Other current assets	517	696
Trade accounts payable and accrued expenses	(3,566)	(1,236)
Net current (liability) asset	(3,049)	(540)
Other long-term assets	0	0
Other long-term liabilities	0	0
Net long-term asset (liability)	0	0
Total net asset (liability)	$ (3,049)	$ (540)

XML

GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill by Segments (Details) $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($)
Goodwill
Goodwill, beginning balance	$ 9,142
Acquisitions	398
Goodwill, ending balance	9,540
Insurance
Goodwill
Goodwill, beginning balance	2,472
Acquisitions	191
Goodwill, ending balance	2,663
CenterWell
Goodwill
Goodwill, beginning balance	6,670
Acquisitions	207
Goodwill, ending balance	$ 6,877

XML

GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Other intangible assets:
Weighted average life (in years)	9 years 2 months 12 days
Total other intangible assets, cost	$ 2,685	$ 2,648
Amortizable intangible assets, accumulated amortization	920	883
Total other intangible assets, net	1,765	1,765
Certificates of need
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	1,132	1,132
Medicare licenses
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	$ 302	286
Customer contracts/ relationships
Other intangible assets:
Weighted average life (in years)	9 years 4 months 24 days
Amortizable intangible assets, cost	$ 955	929
Amortizable intangible assets, accumulated amortization	708	673
Amortizable intangible assets, net	$ 247	256
Trade names and technology
Other intangible assets:
Weighted average life (in years)	6 years 8 months 12 days
Amortizable intangible assets, cost	$ 139	142
Amortizable intangible assets, accumulated amortization	106	107
Amortizable intangible assets, net	$ 33	35
Provider contracts
Other intangible assets:
Weighted average life (in years)	11 years 7 months 6 days
Amortizable intangible assets, cost	$ 73	73
Amortizable intangible assets, accumulated amortization	64	63
Amortizable intangible assets, net	$ 9	10
Noncompetes and other
Other intangible assets:
Weighted average life (in years)	8 years 4 months 24 days
Amortizable intangible assets, cost	$ 84	86
Amortizable intangible assets, accumulated amortization	42	40
Amortizable intangible assets, net	$ 42	$ 46

XML

GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization	$ 17	$ 25	$ 51	$ 61

XML

GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization and Estimated Future Amortization Expense (Details) $ in Millions	Sep. 30, 2023 USD ($)
For the years ending December 31,
2023	$ 15
2024	60
2025	58
2026	44
2027	34
2028	$ 29

XML

BENEFITS PAYABLE - Activity in Benefits Payable (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Balances, beginning of period	$ 9,264	$ 8,289
Acquisitions	62	0
Incurred related to:
Current year	66,370	57,512
Prior years	(758)	(404)
Total incurred	65,612	57,108
Paid related to:
Current year	(56,700)	(48,835)
Prior years	(8,042)	(7,325)
Total paid	(64,742)	(56,160)
Balances, end of period	10,196	$ 9,237
Total IBNR included in benefits payable	$ 6,400

XML

EARNINGS PER COMMON SHARE COMPUTATION (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net income available for common stockholders	$ 832	$ 1,195	$ 3,030	$ 2,821
Weighted average outstanding shares of common stock used to compute basic earnings per common share (in shares)	123,426	126,572	124,335	126,678
Shares used to compute diluted earnings per common share (in shares)	123,983	127,356	124,885	127,305
Basic earnings per common share (in dollars per share)	$ 6.74	$ 9.45	$ 24.37	$ 22.27
Diluted earnings per common share (in dollars per share)	$ 6.71	$ 9.39	$ 24.26	$ 22.16
Number of antidilutive stock options and restricted stock excluded from computation (in shares)	137	78	251	267
Employee stock options
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Dilutive effect of employee stock options and restricted stock (in shares)	26	61	31	50
Restricted stock
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Dilutive effect of employee stock options and restricted stock (in shares)	531	723	519	577

XML

STOCKHOLDERS' EQUITY - Dividends (Details) - USD ($) $ / shares in Units, $ in Millions	Oct. 27, 2023	Jul. 28, 2023	Apr. 28, 2023	Jan. 27, 2023
Equity, Class of Treasury Stock [Line Items]
Amount per Share (in dollars per share)		$ 0.8850	$ 0.8850	$ 0.7875
Total Amount		$ 110	$ 111	$ 98
Subsequent Event
Equity, Class of Treasury Stock [Line Items]
Amount per Share (in dollars per share)	$ 0.8850
Total Amount	$ 109

XML

STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Feb. 15, 2023
Equity, Class of Treasury Stock [Line Items]
Stock repurchases (in shares)					0
Stock repurchases		$ 383,000,000	$ 4,000,000	$ 1,011,000,000	$ 1,032,000,000
Common shares acquired in connection with employee stock plans (in shares)				60,000.00	70,000.00
Common shares acquired in connection with employee stock plans, amount				$ 31,000,000	$ 32,000,000
Subsequent Event
Equity, Class of Treasury Stock [Line Items]
Dividends declared (in dollars per share)	$ 0.885
Remaining authorized amount	$ 1,900,000,000
2021 Share Repurchase Authorization
Equity, Class of Treasury Stock [Line Items]
Share repurchase authorization						$ 3,000,000,000
Remaining authorized amount						1,000,000,000
2023 Share Repurchase Authorization
Equity, Class of Treasury Stock [Line Items]
Share repurchase authorization						$ 3,000,000,000
Stock repurchases (in shares)				2,000,000
Stock repurchases				$ 980,000,000
Stock repurchase average price (in dollars per share)				$ 478.20

XML

INCOME TAXES (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Aug. 11, 2022
Income Tax Examination [Line Items]
Effective income tax rate (percent)	23.50%	8.20%	23.10%	22.50%
Dispositions | Gentiva Hospice
Income Tax Examination [Line Items]
Equity interest sold					60.00%

XML

DEBT - Debt Outstanding (Details) - USD ($)	Sep. 30, 2023	Aug. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Total short-term debt	$ 2,245,000,000			$ 2,092,000,000
Total long-term debt	9,483,000,000			9,034,000,000
Senior Notes
Debt Instrument [Line Items]
Total senior notes	0			1,497,000,000
Total long-term debt	9,483,000,000			8,534,000,000
Senior Notes | $1.5 billion, 0.650% due August 3, 2023
Debt Instrument [Line Items]
Aggregate principal	$ 1,500,000,000		$ 1,500,000,000
Stated interest rate (percent)	0.65%		0.65%
Total senior notes	$ 0			1,497,000,000
Senior Notes | $600 million, 3.850% due October 1, 2024
Debt Instrument [Line Items]
Aggregate principal	$ 600,000,000		$ 600,000,000
Stated interest rate (percent)	3.85%		3.85%
Total long-term debt	$ 572,000,000			599,000,000
Senior Notes | $600 million, 4.500% due April 1, 2025
Debt Instrument [Line Items]
Aggregate principal	$ 600,000,000
Stated interest rate (percent)	4.50%
Total long-term debt	$ 598,000,000			597,000,000
Senior Notes | $500 million, 5.700% due March 13, 2026
Debt Instrument [Line Items]
Aggregate principal	$ 500,000,000		$ 500,000,000
Stated interest rate (percent)	5.70%		5.70%
Total long-term debt	$ 497,000,000			0
Senior Notes | $750 million, 1.350% due February 3, 2027
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000	$ 750,000,000
Stated interest rate (percent)	1.35%	1.35%
Total long-term debt	$ 688,000,000			745,000,000
Senior Notes | $600 million, 3.950% due March 15, 2027
Debt Instrument [Line Items]
Aggregate principal	$ 600,000,000	$ 600,000,000
Stated interest rate (percent)	3.95%	3.95%
Total long-term debt	$ 537,000,000			597,000,000
Senior Notes | $500 million, 5.750% due March 1, 2028
Debt Instrument [Line Items]
Aggregate principal	$ 500,000,000
Stated interest rate (percent)	5.75%
Total long-term debt	$ 495,000,000			494,000,000
Senior Notes | $750 million, 3.700% due March 23, 2029
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000	$ 750,000,000
Stated interest rate (percent)	3.70%	3.70%
Total long-term debt	$ 689,000,000			743,000,000
Senior Notes | $500 million, 3.125% due August 15, 2029
Debt Instrument [Line Items]
Aggregate principal	$ 500,000,000	$ 500,000,000
Stated interest rate (percent)	3.125%	3.125%
Total long-term debt	$ 458,000,000			496,000,000
Senior Notes | $500 million, 4.875% due April 1, 2030
Debt Instrument [Line Items]
Aggregate principal	$ 500,000,000
Stated interest rate (percent)	4.875%
Total long-term debt	$ 496,000,000			495,000,000
Senior Notes | $750 million, 2.150% due February 3, 2032
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000
Stated interest rate (percent)	2.15%
Total long-term debt	$ 743,000,000			743,000,000
Senior Notes | $750 million, 5.875% due March 1, 2033
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000
Stated interest rate (percent)	5.875%
Total long-term debt	$ 715,000,000			739,000,000
Senior Notes | $250 million, 8.150% due June 15, 2038
Debt Instrument [Line Items]
Aggregate principal	$ 250,000,000
Stated interest rate (percent)	8.15%
Total long-term debt	$ 261,000,000			261,000,000
Senior Notes | $400 million, 4.625% due December 1, 2042
Debt Instrument [Line Items]
Aggregate principal	$ 400,000,000
Stated interest rate (percent)	4.625%
Total long-term debt	$ 396,000,000			396,000,000
Senior Notes | $750 million, 4.950% due October 1, 2044
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000
Stated interest rate (percent)	4.95%
Total long-term debt	$ 740,000,000			740,000,000
Senior Notes | $400 million, 4.800% due March 15, 2047
Debt Instrument [Line Items]
Aggregate principal	$ 400,000,000
Stated interest rate (percent)	4.80%
Total long-term debt	$ 396,000,000			396,000,000
Senior Notes | $500 million, 3.950% due August 15, 2049
Debt Instrument [Line Items]
Aggregate principal	$ 500,000,000
Stated interest rate (percent)	3.95%
Total long-term debt	$ 493,000,000			493,000,000
Senior Notes | $750 million, 5.500% due March 15, 2053
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000		$ 750,000,000
Stated interest rate (percent)	5.50%		5.50%
Total long-term debt	$ 709,000,000			0
Term Loan
Debt Instrument [Line Items]
Total long-term debt	0			500,000,000
Term Loan | Delayed draw term loan, due May 28, 2024
Debt Instrument [Line Items]
Total long-term debt	0			500,000,000
Commercial paper
Debt Instrument [Line Items]
Short-term debt	$ 2,245,000,000			$ 595,000,000

XML

DEBT - Senior Notes (Details) - USD ($)	1 Months Ended		9 Months Ended
	Aug. 31, 2023	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Debt Instrument [Line Items]
Proceeds from issuance of senior notes, net			$ 1,215,000,000	$ 744,000,000
5.70 Percent Senior Notes Due March 2026 and 5.50 Percent Senior Notes Due March 2053 | Senior Notes
Debt Instrument [Line Items]
Proceeds from issuance of senior notes, net		$ 1,200,000,000
$500 million, 5.700% due March 13, 2026 | Senior Notes
Debt Instrument [Line Items]
Aggregate principal		$ 500,000,000	$ 500,000,000
Stated interest rate (percent)		5.70%	5.70%
$750 million, 5.500% due March 15, 2053 | Senior Notes
Debt Instrument [Line Items]
Aggregate principal		$ 750,000,000	$ 750,000,000
Stated interest rate (percent)		5.50%	5.50%
Aggregate carrying value adjustment			$ 5,000,000
Delayed Draw Term Loan | Term Loan
Debt Instrument [Line Items]
Aggregate principal		$ 500,000,000
Repurchase Plan, August 2023 | Senior Notes
Debt Instrument [Line Items]
Debt instrument, repurchased face amount			213,000,000
Debt instrument, repurchase amount			196,000,000
$750 million, 1.350% due February 3, 2027 | Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000		$ 750,000,000
Stated interest rate (percent)	1.35%		1.35%
$600 million, 3.950% due March 15, 2027 | Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 600,000,000		$ 600,000,000
Stated interest rate (percent)	3.95%		3.95%
$750 million, 3.700% due March 23, 2029 | Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 750,000,000		$ 750,000,000
Stated interest rate (percent)	3.70%		3.70%
$500 million, 3.125% due August 15, 2029 | Senior Notes
Debt Instrument [Line Items]
Aggregate principal	$ 500,000,000		$ 500,000,000
Stated interest rate (percent)	3.125%		3.125%
Repurchase Plan, March 2023 | Senior Notes
Debt Instrument [Line Items]
Debt instrument, repurchased face amount			$ 361,000,000
Debt instrument, repurchase amount			358,000,000
$1.5 billion, 0.650% due August 3, 2023 | Senior Notes
Debt Instrument [Line Items]
Aggregate principal		$ 1,500,000,000	$ 1,500,000,000
Stated interest rate (percent)		0.65%	0.65%
Repayment of remaining principal	$ 1,200,000,000
$600 million, 3.850% due October 1, 2024 | Senior Notes
Debt Instrument [Line Items]
Aggregate principal		$ 600,000,000	$ 600,000,000
Stated interest rate (percent)		3.85%	3.85%
5.88 Percent Senior Notes Due 2023 | Senior Notes
Debt Instrument [Line Items]
Aggregate principal			$ 750,000,000
Stated interest rate (percent)			5.875%
Aggregate carrying value adjustment			$ 26,000,000

XML

DEBT - Revolving Credit Agreements (Details) - USD ($)	1 Months Ended			9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2023
Term Loan
Line of Credit Facility [Line Items]
Actual debt to capitalization percentage				41.10%
Revolving credit facility
Line of Credit Facility [Line Items]
Debt to capitalization percentage, maximum				60.00%
Outstanding borrowings				$ 0
Uncommitted incremental loan facility				$ 750,000,000
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023
Line of Credit Facility [Line Items]
Debt instrument term (in years)	5 years			5 years
Maximum borrowing capacity	$ 2,500,000,000
Facility fee (percent)				0.09%
Remaining borrowing capacity				$ 2,482,000,000
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023 | Minimum
Line of Credit Facility [Line Items]
Facility fee (percent)				0.08%
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023 | Maximum
Line of Credit Facility [Line Items]
Facility fee (percent)				0.20%
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023 | SOFR
Line of Credit Facility [Line Items]
Basis points spread on variable rate (percent)				1.035%
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023 | SOFR | Minimum
Line of Credit Facility [Line Items]
Basis points spread on variable rate (percent)				0.92%
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023 | SOFR | Maximum
Line of Credit Facility [Line Items]
Basis points spread on variable rate (percent)				1.30%
Revolving credit facility | 5-year unsecured revolving credit agreement June 2021
Line of Credit Facility [Line Items]
Debt instrument term (in years)			5 years
Maximum borrowing capacity			$ 2,500,000,000
Revolving credit facility | 364-day unsecured revolving credit agreement June 2023
Line of Credit Facility [Line Items]
Debt instrument term (in years)	364 days			364 days
Maximum borrowing capacity	$ 1,500,000,000
Facility fee (percent)				0.07%
Remaining borrowing capacity				$ 1,500,000,000
Revolving credit facility | 364-day unsecured revolving credit agreement June 2023 | Minimum
Line of Credit Facility [Line Items]
Facility fee (percent)				0.06%
Revolving credit facility | 364-day unsecured revolving credit agreement June 2023 | Maximum
Line of Credit Facility [Line Items]
Facility fee (percent)				0.15%
Revolving credit facility | 364-day unsecured revolving credit agreement June 2023 | SOFR
Line of Credit Facility [Line Items]
Basis points spread on variable rate (percent)				1.055%
Revolving credit facility | 364-day unsecured revolving credit agreement June 2023 | SOFR | Minimum
Line of Credit Facility [Line Items]
Basis points spread on variable rate (percent)				0.94%
Revolving credit facility | 364-day unsecured revolving credit agreement June 2023 | SOFR | Maximum
Line of Credit Facility [Line Items]
Basis points spread on variable rate (percent)				1.35%
Revolving credit facility | 364-day unsecured revolving credit agreement June 2022
Line of Credit Facility [Line Items]
Debt instrument term (in years)		364 days
Maximum borrowing capacity		$ 1,500,000,000
Letter of credit
Line of Credit Facility [Line Items]
Outstanding borrowings				$ 18,000,000

XML

DEBT - Commercial Paper and Other Short-term Borrowings (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Commercial paper
Short-term Debt [Line Items]
Maximum amount outstanding during period	$ 2,300,000,000
Short-term debt outstanding	$ 2,245,000,000	$ 595,000,000
Weighted average annual interest rate (percent)	5.58%
FHLB borrowings
Short-term Debt [Line Items]
Short-term debt outstanding	$ 0

XML

COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details)	1 Months Ended	9 Months Ended
	Dec. 31, 2022 state option_period beneficiary	Sep. 30, 2023 beneficiary state
T2017 East Region
Loss Contingencies [Line Items]
Number of states comprising TRICARE beneficiaries | state		32
Number of TRICARE beneficiaries | beneficiary		6,000,000
T-5, Effective 2024
Loss Contingencies [Line Items]
Number of TRICARE managed care support contract beneficiaries | beneficiary	4,600,000
Number of states comprising of TRICARE managed care support contract beneficiaries | state	24
Contract base term	1 year
Annual option periods | option_period	8
Contract term with exercises	9 years
Medicare
Loss Contingencies [Line Items]
Percentage of premiums and services revenue		83.00%
Medicaid
Loss Contingencies [Line Items]
Percentage of premiums and services revenue		7.00%
Military services | T2017 East Region
Loss Contingencies [Line Items]
Percentage of premiums and services revenue		1.00%

XML

SEGMENT INFORMATION - Narrative (Details) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Dec. 31, 2022 segment	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) segment	Sep. 30, 2022 USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment	2			2
Member co-share amounts and government subsidies		$ 5,700	$ 5,400	$ 14,700	$ 14,200
Depreciation and amortization classified as benefit expense		$ 35	$ 30	$ 102	$ 89

XML

SEGMENT INFORMATION - Segment Results (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Premiums	$ 25,099	$ 21,468	$ 76,144	$ 66,437
Services revenue	1,016	1,159	2,993	3,772
Total revenues	26,423	22,799	79,912	70,431
Investment income	308	172	775	222
Benefits	21,745	18,384	65,612	57,108
Operating costs	3,271	3,061	9,361	9,120
Depreciation and amortization	201	182	578	527
Total operating expenses	25,217	21,627	75,551	66,755
Income (loss) from operations	1,206	1,172	4,361	3,676
Gain on sale of Gentiva Hospice	0	(240)	0	(240)
Interest expense	114	102	347	293
Other expense (income), net	(6)	13	40	(16)
Income (loss) before income taxes and equity in net losses	1,098	1,297	3,974	3,639
Equity in net earnings (losses)	(12)	3	(39)	1
Segment earnings (loss)	1,086	1,300	3,935	3,640
Net loss (income) attributable to noncontrolling interests	2	2	6	1
Segment earnings (loss) attributable to Humana	1,088	1,302	3,941	3,641
Products
Segment Reporting Information [Line Items]
Premiums	25,099	21,468	76,144	66,437
Products | Total Medicare
Segment Reporting Information [Line Items]
Premiums	21,825	18,333	66,064	57,054
Products | Individual Medicare Advantage
Segment Reporting Information [Line Items]
Premiums	19,637	16,007	59,195	49,751
Products | Group Medicare Advantage
Segment Reporting Information [Line Items]
Premiums	1,695	1,792	5,192	5,524
Products | Medicare stand-alone PDP
Segment Reporting Information [Line Items]
Premiums	493	534	1,677	1,779
Products | Commercial fully-insured
Segment Reporting Information [Line Items]
Premiums	842	1,075	2,810	3,324
Products | Specialty benefits
Segment Reporting Information [Line Items]
Premiums	252	262	758	784
Products | Medicare Supplement
Segment Reporting Information [Line Items]
Premiums	185	188	546	555
Products | State-based contracts and other
Segment Reporting Information [Line Items]
Premiums	1,995	1,610	5,966	4,720
Services
Segment Reporting Information [Line Items]
Services revenue	1,016	1,159	2,993	3,772
Services | Home solutions
Segment Reporting Information [Line Items]
Services revenue	342	519	997	1,997
Services | Primary care
Segment Reporting Information [Line Items]
Services revenue	214	159	605	409
Services | Commercial ASO
Segment Reporting Information [Line Items]
Services revenue	55	73	190	225
Services | Military and other
Segment Reporting Information [Line Items]
Services revenue	202	137	540	395
Services | Pharmacy solutions
Segment Reporting Information [Line Items]
Services revenue	203	271	661	746
Total external revenues
Segment Reporting Information [Line Items]
Total revenues	26,115	22,627	79,137	70,209
Operating segments | Insurance
Segment Reporting Information [Line Items]
Total revenues	25,511	21,743	77,289	67,242
Investment income	154	51	385	143
Benefits	21,976	18,413	66,096	57,311
Operating costs	2,634	2,294	7,597	6,486
Depreciation and amortization	179	163	516	469
Total operating expenses	24,789	20,870	74,209	64,266
Income (loss) from operations	722	873	3,080	2,976
Gain on sale of Gentiva Hospice		0		0
Interest expense	0	0	0	0
Other expense (income), net	0	0	0	0
Income (loss) before income taxes and equity in net losses	722	873	3,080	2,976
Equity in net earnings (losses)	0	8	(2)	16
Segment earnings (loss)	722	881	3,078	2,992
Net loss (income) attributable to noncontrolling interests	3	2	7	2
Segment earnings (loss) attributable to Humana	725	883	3,085	2,994
Operating segments | Insurance | Products
Segment Reporting Information [Line Items]
Premiums	25,099	21,468	76,144	66,437
Operating segments | Insurance | Products | Total Medicare
Segment Reporting Information [Line Items]
Premiums	21,825	18,333	66,064	57,054
Operating segments | Insurance | Products | Individual Medicare Advantage
Segment Reporting Information [Line Items]
Premiums	19,637	16,007	59,195	49,751
Operating segments | Insurance | Products | Group Medicare Advantage
Segment Reporting Information [Line Items]
Premiums	1,695	1,792	5,192	5,524
Operating segments | Insurance | Products | Medicare stand-alone PDP
Segment Reporting Information [Line Items]
Premiums	493	534	1,677	1,779
Operating segments | Insurance | Products | Commercial fully-insured
Segment Reporting Information [Line Items]
Premiums	842	1,075	2,810	3,324
Operating segments | Insurance | Products | Specialty benefits
Segment Reporting Information [Line Items]
Premiums	252	262	758	784
Operating segments | Insurance | Products | Medicare Supplement
Segment Reporting Information [Line Items]
Premiums	185	188	546	555
Operating segments | Insurance | Products | State-based contracts and other
Segment Reporting Information [Line Items]
Premiums	1,995	1,610	5,966	4,720
Operating segments | Insurance | Services
Segment Reporting Information [Line Items]
Services revenue	257	210	730	620
Operating segments | Insurance | Services | Home solutions
Segment Reporting Information [Line Items]
Services revenue	0	0	0	0
Operating segments | Insurance | Services | Primary care
Segment Reporting Information [Line Items]
Services revenue	0	0	0	0
Operating segments | Insurance | Services | Commercial ASO
Segment Reporting Information [Line Items]
Services revenue	55	73	190	225
Operating segments | Insurance | Services | Military and other
Segment Reporting Information [Line Items]
Services revenue	202	137	540	395
Operating segments | Insurance | Services | Pharmacy solutions
Segment Reporting Information [Line Items]
Services revenue	0	0	0	0
Operating segments | Insurance | Total external revenues
Segment Reporting Information [Line Items]
Total revenues	25,356	21,678	76,874	67,057
Operating segments | CenterWell
Segment Reporting Information [Line Items]
Total revenues	4,660	4,274	13,695	13,166
Investment income	0	3	0	6
Benefits	0	0	0	0
Operating costs	4,207	3,929	12,526	12,002
Depreciation and amortization	53	45	152	136
Total operating expenses	4,260	3,974	12,678	12,138
Income (loss) from operations	400	300	1,017	1,028
Gain on sale of Gentiva Hospice		(240)		(240)
Interest expense	1	0	2	0
Other expense (income), net	0	0	0	0
Income (loss) before income taxes and equity in net losses	399	540	1,015	1,268
Equity in net earnings (losses)	(12)	(5)	(37)	(15)
Segment earnings (loss)	387	535	978	1,253
Net loss (income) attributable to noncontrolling interests	(1)	0	(1)	(1)
Segment earnings (loss) attributable to Humana	386	535	977	1,252
Operating segments | CenterWell | Products
Segment Reporting Information [Line Items]
Premiums	0	0	0	0
Operating segments | CenterWell | Products | Total Medicare
Segment Reporting Information [Line Items]
Premiums	0	0	0	0
Operating segments | CenterWell | Products | Individual Medicare Advantage
Segment Reporting Information [Line Items]
Premiums	0	0	0	0
Operating segments | CenterWell | Products | Group Medicare Advantage
Segment Reporting Information [Line Items]
Premiums	0	0	0	0
Operating segments | CenterWell | Products | Medicare stand-alone PDP
Segment Reporting Information [Line Items]
Premiums	0	0	0	0
Operating segments | CenterWell | Products | Commercial fully-insured
Segment Reporting Information [Line Items]
Premiums	0	0	0	0
Operating segments | CenterWell | Products | Specialty benefits
Segment Reporting Information [Line Items]
Premiums	0	0	0	0
Operating segments | CenterWell | Products | Medicare Supplement
Segment Reporting Information [Line Items]
Premiums	0	0	0	0
Operating segments | CenterWell | Products | State-based contracts and other
Segment Reporting Information [Line Items]
Premiums	0	0	0	0
Operating segments | CenterWell | Services
Segment Reporting Information [Line Items]
Services revenue	759	949	2,263	3,152
Operating segments | CenterWell | Services | Home solutions
Segment Reporting Information [Line Items]
Services revenue	342	519	997	1,997
Operating segments | CenterWell | Services | Primary care
Segment Reporting Information [Line Items]
Services revenue	214	159	605	409
Operating segments | CenterWell | Services | Commercial ASO
Segment Reporting Information [Line Items]
Services revenue	0	0	0	0
Operating segments | CenterWell | Services | Military and other
Segment Reporting Information [Line Items]
Services revenue	0	0	0	0
Operating segments | CenterWell | Services | Pharmacy solutions
Segment Reporting Information [Line Items]
Services revenue	203	271	661	746
Operating segments | CenterWell | Total external revenues
Segment Reporting Information [Line Items]
Total revenues	759	949	2,263	3,152
Eliminations/ Corporate
Segment Reporting Information [Line Items]
Total revenues	(3,748)	(3,218)	(11,072)	(9,977)
Investment income	154	118	390	73
Benefits	(231)	(29)	(484)	(203)
Operating costs	(3,570)	(3,162)	(10,762)	(9,368)
Depreciation and amortization	(31)	(26)	(90)	(78)
Total operating expenses	(3,832)	(3,217)	(11,336)	(9,649)
Income (loss) from operations	84	(1)	264	(328)
Gain on sale of Gentiva Hospice		0		0
Interest expense	113	102	345	293
Other expense (income), net	(6)	13	40	(16)
Income (loss) before income taxes and equity in net losses	(23)	(116)	(121)	(605)
Equity in net earnings (losses)	0	0	0	0
Segment earnings (loss)	(23)	(116)	(121)	(605)
Net loss (income) attributable to noncontrolling interests	0	0	0	0
Segment earnings (loss) attributable to Humana	(23)	(116)	(121)	(605)
Eliminations/ Corporate | Insurance
Segment Reporting Information [Line Items]
Total revenues	1	14	30	42
Eliminations/ Corporate | Insurance | Products
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Eliminations/ Corporate | Insurance | Services
Segment Reporting Information [Line Items]
Total revenues	1	14	30	42
Eliminations/ Corporate | CenterWell
Segment Reporting Information [Line Items]
Total revenues	3,901	3,322	11,432	10,008
Eliminations/ Corporate | CenterWell | Products
Segment Reporting Information [Line Items]
Total revenues	2,594	2,459	7,848	7,394
Eliminations/ Corporate | CenterWell | Services
Segment Reporting Information [Line Items]
Total revenues	1,307	863	3,584	2,614
Intersegment Eliminations
Segment Reporting Information [Line Items]
Total revenues	(3,902)	(3,336)	(11,462)	(10,050)
Intersegment Eliminations | Products
Segment Reporting Information [Line Items]
Total revenues	(2,594)	(2,459)	(7,848)	(7,394)
Intersegment Eliminations | Services
Segment Reporting Information [Line Items]
Total revenues	$ (1,308)	$ (877)	$ (3,614)	$ (2,656)